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" J .( 1 * . H t ,FOREWORD
The Arctic explorer, Peter Freuchen once described how while being trapped in a
blizzard in Greenland, he built himself an igloo to protect himself from the elements only to
discover that with every breath he took the walls of the igloo were closing in on him because
of the condensation of his breath (Paul Auster, Groimdworifc). Writing a PhD very often felt
like this and there are many that I am indebted to for their help in this accomplishment.
*' My primary debt is to my supervisors, Luc Soete and Thomas Ziesemer without whose
support this endeavour would not even have been attempted. Thomas's painstaking reading
and re-reading of earlier drafts especially, have made a major contribution to this document.
The thesis began as a result of research at the Science Policy Research Unit (SPRU) and at
the International Federation of Institutes for Advanced Study (IFIAS) on biotechnology and
the international implications of this new technology. At the time, Frank Rijsberman,
Calestous Juma and Norman Clark played a major part in encouraging me to begin a PhD by
combining newly gained experience in biotechnology with my previous background in
economics and international economics. I am grateful to them for encouraging me in this
effort.
The many people at MERIT and at the Economics Faculty who have taken time to talk
to me about issues directly and indirectly related to research, cannot all be individually
mentioned, but I thank them all. There are however a few who have gone out of their way
to help me. At MERIT, I thank Bart Verspagen for allowing me access to his computing
acumen, Theon van Dijk for helping me to use patent data from the European Patent Office,
Wilma Coenegrachts for all her help and encouragement over the years, Corien Gijsbers for
translating the summary into Dutch, Mieke Donders, Lori Mees, JoAnn van Rooijen, Silvana
de Sanctis and Ellen Boulanger.
Outside MERIT and Maastricht, there is also a long list of persons who have contributed
to this thesis, especially government officials and researchers in India, China, Taiwan, South
Korea, Thailand and the Philippines, whom I have had the opportunity of meeting over the
years. I would especially like to mention Dr Padolina, Undersecretary at the Department of
Science and Technology in the Philippines, Dr Yuthavong, Director of the National Centre for
Genetic Engineering and Biotechnology, in Thailand, Professor Hong-Ik Chung at Seoul
National University and Dr Jang Liu, Director and Dr Han, former Executive Director at the
Genetic Engineering Research Institute (GERI) in South Korea, Professor Jei-Fu Shaw at the
Institute of Botany, Academia Sinica and Dr Leah Lo at the Development Centre for
Biotechnology in Taiwan, Dr N.K. Jain at the Department of Biotechnology and Dr
Chandrasekhar, Director of BCIL in India and Dr Yonghui Liu, Director of the China National
Centre for Biotechnology Development (CNCBD) in the Peoples Republic of China.
Furthermore, comments received from participants at various conferences on topics ranging
from the economics of technological change to the conservation of biological diversity have
also greatly enriched the contents of this thesis. In addition, Martin Fransman's comments
were extremely useful in helping me to focus on my thesis topic. Lynn Mytelka has enabled
me to continue doing research in this field.
It was also my privilege to receive financial and academic support for my work over the
years. I especially thank Charles Cooper for giving me the opportunity of working atUNU/Intech as a visiting PhD student and all INTECH-ites, both past and present, for
providing a challenging environment, both social and academic, the NWO, for their financial
assistance which enabled me to carry out much of my field work in India, to the Faculty of
Economics for providing me with a research grant to support that initial work and finally, I
would like to thank the Finnish Development Agency (FINNIDA), for their financial
contribution to a project on biotechnology capabilities to the African Centre for Technology
Studies (ACTS), which made part of my own research possible.
Finally, I would also like to thank the members of the Examining Commission, for
carefully reading this document. The thesis is a lot richer and more coherent as a result of
their comments.
On a more personal note, I would like to thank all those I have known, in and outside
the Trait d'Union, from Maastricht and from places further afield, who have supported me in
this endeavour. -
To my parents I owe this thesis in its entirety, especially Chapter 4, for which I would
not have obtained enough data had it not been for their constant visits to the Department of
Biotechnology. To my sisters, the environmental economist and the chemist, thank you for
putting your faith in me. David and Jeanette, you probably understand me better than most
and your presence was sorely missed. Finally, to MB, for showing me that it is the little
things in life that matter. Merci pour tous! I know my french isn't quite up to standard, but
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"Once upon a rime am/ a very good rime if way"...7. Joyce
Introduction
When James Watson, a young 23 year old who upon completing his PhD went to join Francis
Crick at the Cavendish Laboratories at Cambridge, little did he realize that the discovery
which they were to make would earn them the Nobel Prize a few years later, and would be
the beginning of a chain of innovations which would revolutionize the field of biotechnology.
Even if he did recognize the importance of mapping the structure of deoxyribonucleic acid
(DNA), (see Watson, 1968), he could not possibly have imagined that by the late 1980s and
early 1990s he would first head the multi-national genome project, which set itself the task
of mapping the human gene, or that he would be resigning from that position over a
controversy over intellectual property rights.
In a little over four decades since that discovery, biotechnology today claims that it
is one of the fastest growing new technologies in the world. It boasts radical changes not just
in one sector, but across sectors as well. The potential of developing vaccines or cures for
diseases which are as yet incurable, as well as the ability to increase food output in many
developing countries has provided new hope to scientists across the world. However,
biotechnology has also brought with it many controversies. Intellectual property rights and
the trend toward granting process and product patents for a new generation of plants and
animal species has led to conflicts, especially between the industrialized and the developing
countries, or the innovators and the technological followers in this case. The granting of a
patent for transgenic cotton to the biotechnology company Agracetus for example, implies that
all future research on this plant will be closely controlled by Agracetus'. A growing
technology gap is thus compounded by the innovator's control not only over the innovation,
but future generations of new products. The developing country loses not only its traditional
product which is displaced by the innovation, in this instance, transgenic cotton, but its access
to the new product is also considerably lessened by the patent.
The exploitation of the world's biological diversity, a trend started by the previous
generation of chemical technologies, such as those used during the green revolution,
similarly, it is argued is being compounded by biotechnology. New generations of genetically
engineered agricultural products will, it is argued by some (see for example Shiva, 1991),
replace the rich species diversity found in many parts of the world with the new super strains,
' See for example the articles by Mestel (1994) and Kidd and Dvorak (1994), the latter arguing
that the patent may not be as controversial as it is being made out to be. iSstS if.and in many cases, create new disasters as genetically altered products are released into the
environment.
This study aims to examine the potential impact of biotechnology on international
growth and trade, looking specifically at the impact of innovation and consumer preferences
on product variety. In this chapter, the aims and outline of the thesis are presented.
1.1. Biotechnology: A Brief History i." 'V
Biotechnology, or bioengineering, as its name suggests, straddles a number of scientific
disciplines, including molecular biology and chemistry*, and involves the engineering of
biological material to produce a new product with completely different characteristics. The
discovery of the structure of DNA by Watson and Crick in Cambridge, England in 1953,
began a race to develop new products and processes based on this important discovery. A
series of successes, led eventually to the insertion of a foreign gene in between two ends of
DNA, and recombinant DNA (rDNA) or genetic engineering, discovered in 1973, has since
formed the basis for modern biotechnology research. Since then, the "new" biotechnology
which is the name commonly used for the generation of techniques which followed the gene
splicing technique demonstrated by Cohen and Boyer, has enabled radical new changes in
both processes and products, within established sectors, both in industrialized and in
developing countries.
The success of basic research and discoveries made during the 1950s-1970s, were
matched in the 1970s and 1980s by attempts to commercialize new products based on these
important discoveries. The first country to make its mark in this endeavour was the USA,
where a number of small companies built solely around genetic manipulation technologies and
products, were established in the 1970s and 1980s. The 1980s were characterized by heavy
investment in biotechnology, as a number of these companies built up cash reserves for their
initial investments. This was achieved through a number of methods, beginning with short
term investment capital provided by venture capital and then later through public offerings.
By the late 1980s however, recession coupled with low levels of product development, led
to fewer successes than anticipated. This period also saw the beginning of takeovers and
mergers between small biotech companies and the large pharmaceutical and chemical giants
(US OTA, 1991). The first and largest of these companies, established solely for
biotechnology research, Genentech, became one of the earlier examples of this in a much
a-ti
* In fact the Nobel prize for Chemistry in 1993 was awarded to two Chemists for their work on
the genetic modification of DNA. K. Mullis developed the technique of Polymerase Chain Reaction
(PCR) which has subsequently been used in gene sequencing and gene cloning research while M.
Smith's work on changing the structure of an amino acid is being used by biotechnologists working
on human diseases to insert altered genes into organisms (Economic Times (N. Delhi), 30 October
1993. Similarly, the work done by Watson and Crick in the early 1950s was done at the Department
of Physics at Cambridge. s . •-.<• ,» . :,.-, .-,-. -> <;• i..>.y,.i: .-,•.• -.apublicised merger with Hoffman LaRoche, the pharmaceutical giant in 1990'. Two reasons
are usually given for this rise in alliances between small, specialized companies and the large
multinationals: first, the large companies had by now come to recognize the potential of
biotechnology R&D in medical technologies and second, the small companies came to realize
that their skills really lay in research and that they could not compete with the extensive
product development and marketing networks of the large multinational companies. Thus,
the mergers and takeovers were the result of both groups of companies realizing and
exploiting each others' complementary skills in biotechnology (US OTA 1991).
Elsewhere, especially in Europe and Japan, the 1980s saw the beginnings of strong
pressure from governments to encourage both basic research as well as applied research,
especially through public-private collaboration. In Europe, Germany quickly established itself
as the strongest in biotechnology, while in Asia, Japan lagged only slightly behind. This is
evident from patent statistics, used as a proxy measure for innovation and which are discussed
below in Chapter 3*. Developing countries, with the exception of the NICs in east Asia were
less successful, struggling not only with the technology gap that had developed, but also with
imperfect or no capital markets and low levels of government funding (the experiences of the
NICs and of other developing countries are discussed in more detail in Chapter 4 below). A
severe shortage of trained personnel who would lead the new biotechnology sectors was
another problem and much government effort has gone into funding for basic training and
research. The private sector in developing countries however, is now responding to the
economic incentives which most developing country governments provide, and is investing
in biotechnology research and development of varying degrees of sophistication.
A chronology of events is given in table 1.1. below which provides the reader with
a quick overview of the major developments in biotechnology during the last two decades.
As is evident, it has not been an easy process, slow at times, with a spurt of growth and a
flurry of activities coming in the 1980s. This was largely due to the excitement generated
by the first new biotechnology patent, and the granting of the Cohen-Boyer process patent for
their genetic engineering technique. These major landmarks, not only gave the green light
to biotechnology companies, but also encouraged governments in industrialized and in
developing countries to establish policy guidelines, both to encourage investment and R&D
in biotechnology, and also to regulate its environmental and economic effects.
The table also shows that activities in biotechnology appeared to have slowed down
considerably since the late 1980s, especially in industrialized countries, where a realization
of the long time lag between investment in R&D and profits from commercialization, has
slowed investment in biotechnology firms. This last point is better demonstrated in table 1.2
below, where the figures on R&D investment and net income show that biotechnology
companies are still making a net loss despite increasing sales because their investment in
R&D is still higher. This is despite the fact that product sales rose 20% in 1992, implying
' Although fears were initially expressed about the disappearance of these small companies, it is
evident, as discussed later, that this has not been as disadvantageous for the small company as earlier
predicted.
'.. * See also Sharp (1985) for details on the German programme.that sales have to rise by a great deal more in order for companies to recover their initial and
annual investment in R&D.
Table 1.1. Landmarks in the development of Biotechnology
, 1953 Watson and Crick discover the double helix structure of DNA
1963 Nirenberg and Khorana decipher the genetic code
1971 Founding of Cetus
1972 General Electric apply for the Chakrabarty patent (see 1980 below)
1973 Cohen and Boyer demonstrate the splicing of rDNA
1975 Kohler and Millstein produce monoclonal antibodies using hybridoma
technology **af
1976 First firm to exploit rDNA technology, Genentech, formed in the US
1980 Diamond vs Chakrabarty. First micro-organism patent granted in the
US. Cohen-Boyer process patent granted. Spinks Report published in
the UK. Germany's Biotechnology Plan (Leistungsplan) published.
Genentech goes public.
.1981 First monoclonal antibody (MABs) diagnostic kits approved in the US.
MITI in Japan declares 1981 to be "The Year of Biotechnology".
Cetus goes public. Celltech established in the UK.
1982 First rDNA animal vaccine (for colibacillosis) approved in Europe and
* first rDNA pharmaceutical product (human insulin) approved in US
and UK. Taiwan declares biotechnology one of eight priority areas.
1983 First time a plant gene is inserted in a plant of a different species.
Thailand establishes the National Centre for Genetic Engineering and
Biotechnology within the Ministry of Science and Technology.
1984 Genetic Engineering Bill passed in South Korea. Malaysian
Government forms National Biotechnology Committee
1985 Korea establishes the Genetic Engineering Centre.
^mt;'i«f W India forms the Department of Biotechnology within the Department
of Science and Technology to introduce new biotechnology in India.
• - - • China also launches its biotechnology programme.
1988 ' US NIH establishes the Human Genome Programme. First US patent
granted for a living animal, a transgenic mouse.Table 1.1. contd.
1989 Bioremediation used in the Exxon Valdez oil spill. First US
biotechnology firm (Gen-Probe) bought by a foreign company
(Chugai Pharmaceuticals of Japan). Kenya makes life forms
patentable under its Industrial Property Act provided they do not
compromise principles of environmental conservation.
1990 FDA approves first bioengineered food additive (renin used to
produce cheese). Federal Republic of Germany introduces Gene
Law to regulate biotechnology. Hoffman LaRoche declares its
majority holding intent in Genentech.
1991 The Philippines establishes a programme on Biotechnology. A
Kenyan outline for a a National Biotechnology Programme is
drafted. India establishes the Biotech Consortium India Limited
(BCIL), a cooperative venture between the government and
private sector to stimulate cooperative research and development.
Mexico passes its new patent law which some argue is even
stronger than the US law and allows patenting of genetically
engineered plants and animals. UPOV is altered, removing the
"breeders exemption" clause. Merck signs agreement with the
Instituto Nacional de Biodiversidad (INBio) in Costa Rica to
obtain 1000 biological samples from Costa Rica in return for a
promise of a share of the royalties from any patent granted to a
product based on any of those samples provided by Costa Rica.
1992 The US refuses to sign the Biodiversity Convention in the
UNCED meeting in Rio de Janeiro on the grounds that it would
restrict US companies from doing their research. James Watson
resigns as head of the Human Genome Project over a
controversy regarding patent applications for DNA fragments
identified by the project. FDA announces that henceforth no new
testing will be required of genetically engineered foods. A
; Bioservice Unit set up to stimulate private sector activity in
Thailand. The EPO patents the first genetically engineered
mouse in Europe'.
1993 US Biopharmaceutical firms record a slump in sales. Only 14
Biopharmaceutical companies make profits despite the recovery
in the US economy.
' Although genetically engineered plant and animal varieties are not patentable according to the
EPO's rules, in this case, the mice were granted a patent because "the benefits to mankind outweighed
the suffering of the mice" (van Wijk et.al. (1994), p 5).Table 1.1. contd.
1994 The NIH withdraws all patent applications for DNA identified by
the genome project. Agrecetus is granted a patent which will
; henceforth give it rights over all future improvements made to the
cotton plant. Hoffman LaRoche takeover of Syntex, a a
biotechnology company based in the USA. The use of Bovine
"" Somatotropin (BST), a growth hormone, is approved for use on _,..^
;•••;• dairy cattle to increase yields in the USA. Genetically engineered '
food goes on sale in UK supermarket, the first in a European
country. The US approves Calgene's genetically engineered tomato.
US companies pick up again as the public's confidence grows in
/. them, boosted by an increase in strategic alliances especially with ,'-vf
large firms. The GATT accord on intellectual property rights
agrees that countries should extend patent protection to a number of
biotechnology related sectors and that the period of protection
.nj^r should be increased to 20 years. Some exceptions are provided for
developing countries, especially those which are least developed.
Taiwan changes its patent law to comply with this ruling in
December.
Source: Compiled from Orsenigo 1989, US OTA 1991, Various issues of the Biotechnology
and Development Monitor, Bio/Technology and own research (see Acharya and Mugabe
(1995a), Acharya, (1993a) and also Chapter 4 below).
















Source: Taken from Ernst and Young (1994), pp VIE and Ernst and Young (1993).
Governments are also facing a period of extensive debate, especially with respect to
changing intellectual property environments and the need for achieving that fine balance
which is required to enable the biotechnology industries to develop new products, without
causing extensive damage to the environment through genetic testing.
It has been argued in various issues of Bio/Technology, during 1994, (see also the
industry surveys by Ernst and Young (1993 and 1994)), that the 1990s, after an initial slump,
will gradually see the stabilizing of biotechnology activities especially in the private sector.
This is based on an increasing number of products entering the market, which will enableinnovators to recover some of their initial investments, as well as a growing number of
companies which are recording annual profits, rather than the losses of the previous decades,
although the industry average was still negative as table 1.2. shows.
Rather than the extreme swings characterized by the 1980s, a recognition of the very
real problems and prospects associated with biotechnology, coupled with consumers who are
better informed about the dangers and potentials of genetically engineered products appears
to bode a period of consolidation and greater stability in biotechnology based sectors. Again,
from table 1.1. one gets an idea that industrialized and to some extent developing countries
are seeing a realisation of some of their research investment, as is evident from activities of
the early 1990s which are related to commercialization rather than policy, perhaps a signal
that the technology appears to be slowly coming of age.
Indeed, recent surveys of biotechnology, especially in industrialized countries (Ernst
and Young, (1993) and (1994) for example), show that a number of changes have taken place
since the 1970s and 1980s. While the 1970s were an exciting time for researchers in
biotechnology with a number of new and key discoveries being made, the 1980s were
turbulent times for the new companies which had to survive in the face of heavy investments
and low returns. In the 1990s in contrast, an increasing number of strategic alliances
especially arrangements between small biotech companies and large pharmaceutical and
chemical multinationals for product development and marketing, have lent some stability to
the industry. It has ensured the survival of the small companies, and especially with an
increasing number of products being approved and being released on to the market, they now
have an opportunity to recover their initial investments. Thus just as the 1970s were a period
of new discoveries in biotechnology and the 1980s of the small biotechnology firm, the 1990s
appear to be a period of consolidation for the small biotechnology companies and also for the
large companies. The period has been marked by an increasing number of strategic alliances,
for R&D, product development and marketing. A recent survey of small and large companies
estimates that the cost of production in the smaller companies is still much lower (Ernst and
Young, 1994), providing an advantage to the specialized biotechnology companies. However,
the advantage of size and scale of operations (see appendix I below for a comparison of
annual sales figures for small biotech companies and the multinationals), still gives the large
company an edge in developing and distributing the final product. Thus, both groups of firms
have come to rely on one another and the strategic alliances are an indication of the
increasing interdependency between the small, specialized firm and the large, well-established
multinational company.
This therefore, is the record of biotechnology thus far. There have been many
problems on the way, and considerable obstacles still remain. For developing countries, the
shortage of skilled labour, capital and a tendency for the public and private sectors to not talk
to one another is hampering the further development of this technology. In industrialized
countries, although these problems are not as severe, regulation, especially with respect to
new agricultural products, is becoming a problem. The advanced nature of their capabilities
has enabled companies in industrialized countries to produce genetically engineered products,
which have to be tested before they can be released for public consumption. The testing
however, has to be carried out under controlled conditions, so as to ensure public and
environmental safety. For agricultural products, which have to be tested in the field, this is
especially difficult and countries such as Germany have strict restrictions on this type oftesting. Regulation will therefore be the next hurdle for industrialized countries and there are
some indications that the EC is considering a loosening of restrictions, especially as many
more agricultural products are developed, and competition from other regions, notably North
America, increases.
What is it about biotechnology that has prompted such a quick response from
governments and later from private companies? Why have huge sums of money been
invested in a technology, where the results at present are small? Evidence shows that as early
as 1983, when there were only about 600 firms in existence, by going public over US $ 500
million was raised in the US public market alone*. By the early 1990s the size of money
raised publicly in the US had gone up to more than US $ 4 billion while the number of
companies had increased to 1,231 (Ernst and Young, 1993). This is despite the fact that the
first drug produced from recombinant technologies, only became available in 1982 and there
was to be a long gap before the next product was approved by the USDA in 1985'. Yet
another question which arises is the potential impact of biotechnology on consumer and
international welfare.
In this study, we look at the implications that biotechnology may have for economic
growth, both in industrialized and developing countries. Its science based nature, presents
enormous potentials for a wide range of countries, with different levels of technological
capabilities. Not only does this new technology present the prospect of higher quality
products, such as vaccines to prevent the occurrence of life-threatening diseases and drugs to
treat widespread diseases such as cancer and AIDS, but it may potentially improve consumer
welfare by increasing both the total quantity and the variety of products available. Such
implications for increasing quality and increasing and decreasing variety of products form a
major theme of this thesis and additionally the rationale for the structure of the model
developed below.
In the next section, these questions of changing quality and variety of products
produced and chosen by consumers are examined in more detail. First we look at debate on
older technologies relating to agriculture, such as plant breeding and the green revolution
technologies, and the literature on risk spreading by farmers and the impact on product
variety; the second way in which the new biotechnologies can be related to increasing or
declining variety is in the argument that the exploitation of genetic material by
biotechnologists has a negative impact on the variety of biological diversity; finally, we look
specifically at consumer preferences in biotechnology and their implications for the quality
and variety of products preferred by consumers in different sectors.
Based on this analysis, section 1.3 presents methodologies, examining more closely
such linkages between quantity, quality and variety especially as they relate to innovation in
biotechnology. Two basic questions form the background to the methodological section: One
is whether there is any evidence that modern biotechnology techniques and innovations are,
or will, by increasing quality, also increase the total variety of products (old and new
together), available to consumers. The second issue is that of the treatment of technological
* US OTA (1991), p. 4. .,,.,.•;,„, ,,o
' The table on page 77 of US OTA (1991) furthermore, shows that most of the 15 or so drugs that
became available by 1991, were only approved in the late 1980s and early 1990s.
8change in the theoretical literature, especially in its treatment of issues of product
development. Each will be examined in turn in section 1.2, which as mentioned above
presents the arguments, and 1.3 below which develops methodologies based on these
arguments.
1.2. Quality and Variety: Three Problems
The question we are ultimately interested in examining, is that of consumer welfare and the
improvements that new technologies, in this case biotechnology, can bring to consumer choice
and to their consumption bundle. It was argued above that biotechnology introduces both
quality improvements as well as differentiated products of the same quality into the market.
However, the impact on consumer welfare is not immediately apparent because we do not
know whether consumers will prefer a greater variety of products, or if a preference for
higher quality products will always drive older qualities out of the market. In the literature
on economic growth, there are a number of ways in which innovation and the impact on
consumer preferences and welfare has been modelled. In this section, we discuss the manner
in which the issue of consumer preferences and consumer choice are modelled and how this
relates to the emerging relationships between quality and variety in biotechnology based
innovations.
One way to model increasing variety or quality, as a number of the new growth and
trade models have done, is through consumer preferences. Before the new growth models,
consumer utility was modelled in such a way that consumers maximized their utility by
consuming the maximum amount of a particular good or goods, given a budget constraint.
Thus the larger the number of goods consumed, the higher is the consumer's utility. In the
new variety based models, consumer utility (as modelled in the Spence-Dixit-Stiglitz manner),
is maximized by consuming a maximum of differentiated products. Consumer choice, the
way in which it is modelled here, ensures that the new varieties produced will always be
added to the consumer bundle and will not replace other varieties (see for example, Grossman
and Helpman 199Id). Consumers will therefore choose to buy all varieties, rather than
preferring larger quantities of one variety over another. Thus, at all times, there are a number
of differentiated products being supplied and demanded in the economy. In contrast, in the
quality based models, consumer utility is maximized by consuming the highest price adjusted
quality. Preference for the highest quality good, rather than a variety of goods, ensures that
the consumer will choose the highest quality good as soon as it is produced and becomes
available to the consumer. Demand in these quality models therefore immediately shifts to
the new product, resulting only in the highest quality remaining in the market (see Aghion
and Howitt, 1992, Grossman and Helpman 1991a, b and c). Older goods, i.e., those which
are of a lower quality are immediately rejected and dropped from the consumer choice bundle.
The Flam and Helpman (1987), and Young (1991, 1993) models include income
distribution to show that different budget constraints can lead to a number of different
qualities being demanded at the same time. Here, rather than higher quality pushing out older
products, or the production of horizontally differentiated goods simply adding to total variety,
variety can either remain constant as in Flam and Helpman (1987) where higher quality goods
always replace the same range of older products, as is also the case in Young (1993), or theproduction of higher quality goods results in an increasing range of varieties chosen by
consumers as in Young (1991).
In biotechnology, the availability of higher qualities has resulted in an increase in
demand for these products. In agriculture, the forerunner of biotechnology, the green
revolution in the 1960s and 1970s, was successful largely because of farmers' choices with
respect to high yielding varieties. Similarly, in pharmaceuticals, consumer utility will be
maximized with higher quality medical products. This is already evident from a number of
new products such as Tissue Plasminogen Activator (tPA), which is being used with great
success to dissolve blood clots in heart attack patients. Another example is a vaccine for
hepatitis B and C which afflict millions around the world and drugs to treat Acquired Immune
Deficiency Syndrome (AIDS) related illnesses. Thus both the quality of goods as well as the
variety of goods available to the consumer is increasing as a result of biotechnology.
In the next section, we examine the manner by which biotechnology has an impact on
quality and variety, by looking at three specific problems, which also explain the impact of
biotechnology on quality and variety in general. As the crux of the problem is how
innovation in the form of higher quality and variety affects consumer welfare, the emphasis
in each section will lie on consumer preferences and consumer choice for either higher quality
and/or greater variety.
7.2.7. Afon Gener/caWy /fugi/ieered Biotec/i/ioto^ies and
The use of biotechnology to introduce improved qualities of plants and animals into the
environment has led to a controversial debate on the impact on the variety of products chosen
by farmers. While the green revolution, at the time, created revolutionary new high yielding
varieties, their introduction by farmers, led to the displacement of many traditional varieties.
In some cases these were preserved in gene banks, but many were lost. The farmer's choice
of higher quality products is often tempered by a number of other factors associated with
agriculture, most notably risk. Agriculture, because it is subject to the vagaries of the weather
is usually risk prone. The farmer, if he/she is risk averse will tend not to choose and plant
only one variety, in this case the highest quality available, but will prefer to spread risk by
planting a variety of different qualities. The risk loving farmer on the other hand, will choose
the highest quality and his/her preference for variety will be low. In this way, the farmer's
choice behaviour drives the displacement of older varieties, displacement occurring or not
occurring depending upon the degree of risk averseness of the farmer as well as a number of
other issues such as access to capital.
The theoretical literature (Ziesemer 1987, Ch.8, Newberry 1975, Bardhan, 1977 among
others; for a further debate on the impact of adoption of new technologies on different groups
of farmers, the reader is referred to Bhaduri, 1973, Ghosh and Saith, 1976, Newberry 1975
and more recently, Hayami and Ruttan, 1991) describes four types of agricultural systems
which are generally used to classify agricultural activities and societies in the literature:
sharecropping, fixed rental tenancy, wage labour and the independent family farm. In the
latter case, under the assumption off decreasing absolute and increasing relative risk aversion,
each type of fanner faces different degrees of climatic risk and moral hazard. With the
introduction of technologies which increase the variance of output and the expected value of
10that output, a smaller portion of land is used for the new product, the greater the size of the
farm. In addition, with credit restrictions, the closer the farmer is to the subsistence
minimum, the greater his/her risk aversion and the less likely he/she will be to apply a new
technique if it may reduce standards of living further. In fact, in the extreme, a high degree
of risk aversion combined with credit restrictions may prevent technical change from leading
to economic growth because the capital market fails to offer perfect insurance against a bad
harvest.
Empirical analysis (Shiva, 1991, Juma, 1989), shows that different rates of adoption,
although they occur, are not as extreme as shown to be possible in the theoretical literature.
The introduction of high-response varieties during the green revolution did achieve their aim
of increasing per capita agricultural output in a number of developing countries, but at the
expense of variety. It has also been argued that the need of these varieties for fertilizer
reduced variety in the crops grown. The introduction of high response varieties of wheat and
rice displaced traditional varieties, creating vast areas of monoculture in many countries. This
tendency toward monoculture they argue, is being aggravated by the introduction of
biotechnologically developed crops which largely ignore locally adapted strains or the
advantages of local planting techniques which are partial to maintaining diversity rather than
increasing productivity*.
It is however, not clear from the studies which have been done about the impact of
the green revolution, what the dominant tenancy system is in the regions being studied. As
discussed above, this is an important determining factor in the relative and absolute risks
depending upon farm size and therefore an important determining factor, according to the
theoretical literature, of the impact on variety. This is discussed further in Chapter 5 below.
The tradeoff between variety and quality is also evident from discussions on traditional
and modern agricultural systems. It has been estimated that local communities maintain a
much higher degree of genetic variety in the crops they cultivate, than commercial agriculture,
which relies on a much narrower genetic base, utilising only a few modern varieties' with
an infrastructure of seed companies and transport that have larger "reserve" variety. The
isolation of characteristics which are beneficial, such as disease and pest resistance, response
to climate and higher productivity, although ultimately beneficial for international consumer
welfare, is the further cause of reduced genetic variety. There are several examples of entire
species being lost as a result of monoculture in planting as well as the uniform characteristics
of the plants replacing them'". The result is a loss of biological species and diversity, and
although there is an international effort to preserve older species ex situ, in gene banks, there
is some evidence to show that this is not proving to be sufficient. Another problem is a lack
of sufficient documentation of wild varieties, especially those found in developing countries.
The funds to support this effort are lacking and more funding is being provided now to
accelerate this documentation process through activities such as biodiversity prospecting (see
the section 1.2.2. below), it is not at all clear that the effort will be sufficient to match the
pace of the loss of biodiversity. ,,-
* UNEP (1990), p 6. '''
' Grain (1990), p 3.
"° Juma, C. (1989), pp 100-103. t
'7.2.2. Biofec/zno/o&y and Biodivcrj/'O'-' TTic JLOJJ o/Ztesource Vdriefy "
Another area where the link between improved quality through biotechnology and decreased
variety is becoming increasingly apparent, is in the impact of biotechnology on biological
diversity. Biological diversity is defined as "the totality of genes, species and ecosystem in
a region'*. Biodiversity is usually divided into a hierarchical structure, comprising three
parts: Genef/c d/veryirv, which includes variations of genes within one particular species; the
second level consists of species diversify, which refers to the variety of species contained in
a particular region. This is what is usually referred to in discussions about monoculture
reducing variety, as older varieties die out, or are replaced by the new varieties; finally,
ecosystem diversify, refers to a region or community which is contained within a particular
ecosystem". Farmers and plant breeders have relied for centuries on local varieties found
in the wild to develop and cultivate domestic varieties that are consumed today. Similarly,
in Pharmaceuticals, it is estimated that over 5,000 species form the basis of Chinese
traditional medicine, and 2,000 species have been used by Amazonian populations for
medicinal purposes, while in modern medicine, more than 3,000 antibiotics alone, including
penicillin and tetracycline, are derived from microorganisms'".
Thus biotechnology can actually increase the world's biological diversity by creating
new species of plants and animals. The tradeoff for farmers between expected value of the
high quality and the risk of losing the entire crop and investment, will determine whether they
will choose for greater variety in their fields or for higher quality.
With respect to centres of biodiversity, or those areas which are rich in a wide variety
of species, such as the tropical forests, however, a misuse of biological resources and
environmental pollution has resulted in the destruction of large numbers of ecosystems. The
signing of the biodiversity convention in 1992 by over 150 countries signalled an international
recognition of this problem.
The convention accepts that genetic resources are rapidly being depleted (UNEP,
1992). Some of this is caused by growing human populations, as has been observed in the
Amazon region in recent years, where the clearing of tropical forests for mining and farming
have been a major cause of destruction. However, a much larger cause is the increasing
degree of Biodiversify Prospecfi/i^, which is the search for previously unknown plant species
" This section uses material from: Acharya, R. (1992a), "Intellectual Property, Biotechnology and
Trade: The Impact of the Uruguay Round on Biodiversity" Bio/?o/icy /nrernariona/, No. 4 (Nairobi:
ACTS Press); Acharya, R. (1991), "Patenting of Biotechnology: GATT and the Erosion of the World's
Biodiversity" Jouma/ o/Wor/d Trade Vol. 25, No. 6, pp 71-88 and Acharya, R. (1994c), "Biodiversity
Prospecting: Prospects for Private Sector Participation in the Asia-Pacific", paper presented to the
flegiona/ Con/erence on Biodiversity Conservation, organized by the Asian Development Bank in
Manila, June 6-8 1994.
" WR1, IUCN and UNEP (1992), p.2.
" Ibid, p. 2.
'* Ibid, p. 4.
12in areas of rich genetic diversity for biotechnology research. Increasing interest in this
activity is evident from the number of bioprospecting agreements and companies which have
been formed in the last decade or so". Except in those cases, where systematic
documentation and preservation of these species is carried out, the possible result of
prospecting activities is the loss of genetic and species diversity in the long run. Until now,
prospecting has largely been carried out by a small number of multinationals, who are
involved in new drug discovery related research. Their requirements in terms of the total
volume of raw material is therefore relatively limited. Given that these activities have been
carried out for many decades both by private companies as well as by public institutions such
as Kew Gardens and other public sector research institutions, the magnitude of collection does
not appear to have significantly harmed biological diversity thus far. However, if new interest
in prospecting activity results in a race to extract more from available varieties, then these
activities will pose a real danger to species diversity. There are two ways in which this could
occur: first, as discussed above, if extraction and the collection of samples exceeds the rate
of regeneration of wild varieties, resulting in a smaller base from which to regenerate
vareities; and second, if the race to discover new drugs results in private deals being made
between local institutions and multinationals, guaranteeing the private company some degree
of exclusive access to the resources and the information collected, such as that between Merck
and InBio, discussed in greater detail below, which may increasingly result in a privatization
of knowledge based on these resources, and also a privatization of these resources themselves.
Biotechnology thus may find itself in the peculiar position of being both beneficiary and
potential destroyer of these resources.
Whether biotechnology increases or decreases the world's biological diversity depends
upon two factors:
1. The first relates to access to biological resources and the ongoing debate on the
privatization of the global commons. Genetic resources, it has been argued, form part of a
common heritage and therefore, all nations and peoples should have access to these natural
resources. Developing countries, where most of the centres of biodiversity are located, have
argued, that unless they receive compensation for the use of their natural resources, these
resources will no longer be available for biotechnologists or plant and animal breeders. Some
countries have tried to halt the outflow of germplasm by making the export of some of these
resources illegal (Reid etal., 1993). However, the cost of monitoring their outflow has been
much higher than the immediate benefits and many countries are unable to enforce their
regulations. Thus biotechnology based industries may, in the long run, be destroying their
research base if the rate of destruction of biological diversity continues at its present rate.
The eventual losers may be the biotechnology research sector and all production sectors
affected by it, which in turn will eventually affect consumers, whose potential move to a
higher utility curve from consuming higher qualities and larger variety, will be halted in the
long run. In the extreme case, it could be conceivable that improved quality will reduce
variety which in turn will reduce quality. Unless gene banks are able to compensate for this
loss, the end result will be a loss in both quality and in variety in the long run.
" See Reid et.al. (1993) and Acharya (1994c) for more details on these agreements.
132. The viability of ex situ conservation for example gene banks. The expansion of
biotechnology research is increasing demand for biological materials. Some of this material
has been preserved e* i/r« in gene banks around the world. However, the viability of the
"banked" material and hence the method itself, is being questioned. In 1991, representatives
of 13 national germplasm banks in Latin America reported losses of between 5 and 100
percent in batches of maize seed collected between 1940 and 1980 is no longer usable". If
this indicates a long term trend in maize seed banks, rates closer to the 100 percent level
especially would imply catastrophic consequences for variety in species of maize.
There are normally three types of collections held by gene banks: worftng co/Zecrions,
which are normally kept in airconditioned surroundings for a period of one year, and are used
primarily for annual breeding purposes. The merfiwwi term co//ecrio/w, can be kept between
0 degrees Celsius and -5 degrees Celsius and are normally dried first. The low temperatures
ensure viability of the genetic material for a period of 10 - 20 years usually. Finally, the fowe
coWecrio/tr are dried and stored in aluminium foil in temperatures between -10 and -20
degrees Celsius. Viability tests have to be carried out every so often to ensure that the genetic
information is still intact. The tests which basically involve germination of a sample of the
accession, require that for viability, at least 85 percent of the sample tested should germinate.
Otherwise, there is a danger of genetic information being lost".
While gene banks, if they can be made viable, may provide the answer in the long run,
resources in the world are dwindling as they are being removed from their natural habitats
faster than they are able to replenish themselves. The estimated increase is even greater,
despite attempts of late to reduce this rate. In areas of rich biodiversity such as the tropical
forests, it has been estimated that between 5 and 10 percent of species native to these
ecosystems may disappear within the next 30 years. Furthermore, scientists have estimated
that almost one fourth of the world's plant species will become extinct in the next three
decades unless the rate of deforestation declines considerably'*.
While the first has a potential to reduce biological and genetic variety if they are
depleted through excessive use by biotechnologists, the second, if some of the problems
highlighted above can be avoided or reduced, can contribute to ensuring that genetic diversity
does not decline.
Biotechnology can actually help in increasing variety both in sita as well as e* s/to:
1. Conservation". Biotechnology has the potential to increase rates of regeneration of forest
and biomass cover. In light of the recent concerns which have arisen over climate change and
environmental damage, this is an important resource and there are also a number of private
companies doing R&D in this area.
" WRI, IUCN and UNEP (1992), p 11.
" Mugabe, J. (1994), p 198.
" Ibid, p 7.
" For an analysis of the international effort to increase conservation, please refer to Mugabe
(1994), which also presents an analysis of institutional capability in Kenya to preserve both its animal
and plant species, many of which are in immediate danger of extinction.
142. Biodiversity Prospecting as briefly described above, is the actions of researchers or
scientists who go into areas of biological diversity specifically seeking out species which may
be useful for the development of biotechnology based products and processes, or for future
scientific research. While developing countries have recently begun to make a record of their
resources, the real impetus has come from private sector investment. The formation of INBio
(Instituto Nacional de Biodiversidad) in Costa Rica*°, which is being funded in part by the
pharmaceutical giant Merck, is an example of the above. INBio has used its funding from
Merck to hire researchers and maintain a sophisticated data base on information on local
species collected by its researchers. In return for the information provided by INBio to Merck
on the properties of Costa Rica's natural resources, and its freedom to use those resources for
biotechnology research, Merck guarantees INBio a share of all future royalties (which can be
viewed as compensation for the privatization of public resources), from any patents granted
on products which use resources provided by INBio. In this way, a privatization of natural
resources, or a privatization of the global commons, in some ways reminiscent of the
enclosure laws in industrial revolution England, may be the only way in which private
interests to develop new products based on biological resources, may coincide with global
interests to conserve natural resources.
7.2.5. Consumer i>re/erence.s /or Qwa/iTy and Vane/)'
When discussing the impact of biotechnology on product variety, we turn to evidence from
the two most important sectors where biotechnology has had an impact in most countries,
namely the agricultural and pharmaceutical sectors.
In agriculture, the different preferences of two kinds of players may lead to somewhat
different implications for variety. Firstly, for farmers as discussed above, the demand for new
varieties depends on their ability to spread risk. If the fears of conservationists become
reality, then the tendency towards monoculture, as they accuse the green revolution of having
caused, will be worsened because of biotechnology. On the other hand, if farmers are risk
averse, genetic diversity will not necessarily decline and the production of biotechnology
based higher qualities will only add to the varieties available to farmers. The crucial issue
here is whether or not traditional varieties will be supplied by large seed companies, even
though newer varieties are available. If the latter is the case, and old varieties are no longer
supplied, and with the additional problem of little or no access to capital markets, the risk
averse farmer will be driven out of the market altogether. The reality is probably somewhere
in between these two extremes and empirical evidence appears to support this*'.
A second case, which may result in increasing variety, is that of the development of
biotechnology based substitutes which specifically replace traditional agricultural products.
New products, produced either through more sophisticated technologies such as genetic
engineering, or through using industrial biotechnologies, have the capacity to displace
20 Reid, W. et al. (1993).
" Hayami and Ruttan (1991), Juma (1989b). This point is also reiterated and discussed below in
the main body of the thesis.
15homogenous products with a larger variety of new products. Thus in this case, a greater
number of varieties are produced, and society has a preference for greater variety.
In the pharmaceutical industry, biotechnology is being used to improve the quality of
a number of vaccines and diagnostics, among other medical products. The resulting benefit
to consumers is higher utility from higher quality products. The structure of demand and
supply in Pharmaceuticals however is somewhat different from a number of other sectors.
A number of reasons peculiar to the pharmaceutical sector can be attributed to this:
1. Medicines are never bought directly by the consumer or the patient from the producer or
the manufacturer. Instead, they are usually sold to doctors, or hospitals or retailers such as
chemists". Demand for pharmaceuticals can therefore be expected to combine quality and
variety, as hospitals have to maintain a supply of all major drugs which can be supplied to
patients, even those with a lower quality. In fact, both horizontal variety, as in brand names
and like products, as well as vertical quality improvements, may increase in the long run.
2. Another argument for a preference for increasing variety is the variety of illnesses or
different strains of the same illness which prevail among patients. In many cases, a
combination of different medicines are prescribed for the same illness to different patients
because of differences such as allergic reactions to particular medicines.
For these reasons therefore, a social planner or a doctor will always ensure that a
sufficient variety of medicines or treatments are available for use. Preferences will therefore
always be for increasing variety in this case.
This may however not be the case with the entire pharmaceutical sector. Unlike the
demand for drugs, rDNA based products such as Somatotropin may have the effect of
reducing variety in the same way as in agriculture. Bovine somatotropin (BST) is a growth
hormone which has been developed through genetic engineering and is being used in animals,
mostly cattle, to increase milk yields. Growth hormones are also being developed to increase
the production of meat, especially the proportion of leaner meat One step beyond this is to
genetically alter the animal so that it produces higher levels of the hormone rather than having
it administered artificially. The transgenic animals thus produced through the endogenous
supply of the growth hormone will result in species which are larger than the original species.
The method is also being used to experiment on fish and shellfish. The US OTA (1991),
estimates that it will be the end of the century before this method becomes widespread
enough to use transgenic livestock as food. As the development stage, where the gene is
developed and adapted to individual species, is the most expensive and time consuming, once
this hurdle is overcome, the cost of production declines substantially, implying that the use
of genetic engineering to develop animals which are larger and leaner will become more
widespread. It is likely that farmers, given the substantially higher yielding varieties of
animals produced in this way, will switch production from the wider range of older species,
to the one species which is higher yielding, in this case, the genetically engineered one.
Although this is a somewhat dire prediction, it may not be so unrealistic, given the particular
circumstances we face in the long run. In this way, even in pharmaceuticals, the development
of genetic engineering may improve quality but may in the process also reduce the total
amount of variety available in the world.
US OTA (1991), p 83.
16Thus, in general, biotechnology innovations increase productivity or improve quality.
Consumer preferences, especially in Pharmaceuticals, indicate in general, a demand for
increasing variety. In agriculture, the degree of risk averseness of farmers plays an important
role in determining demand for variety. As discussed above, this is due to a range of factors
including farm size and access to credit markets, as well as risk spreading. We have used in
the model developed below in Chapters 8 and 9, the example of the pharmaceutical sector,
where the social utility function indicates a preference for increasing variety even though
higher quality products continue to be available. This is discussed in greater detail along with
the results which have a variety of implications for variety.
To summarize therefore, there are three diverging directions of research or issues
which have emerged from the discussion above.
(i) The first, discusses the ways in which risk aversion and moral hazard have played a role
in determining farmers' use of higher quality products as opposed to maintaining greater
variety.
(ii) the second deals with the impact of biotechnology upon the depletion of natural resources.
The latter, is concerned largely with issues of depletion and regulation of resource depletion.
The literature on this", deals with the problems of regulation and enforcement of regulation,
as it relates to monopolistic and oligopolistic market structures. Although the problem is an
interesting one and certainly relevant to the international debate on biotechnology, it is beyond
the scope of this thesis, which concentrates more on new growth and trade theories and the
impact of technical change on economic growth and technology gaps.
(iii) Finally, we looked at consumer preferences and the role played by these in choosing
variety over quality or vice versa. Evidence from Pharmaceuticals especially, points to a
preference for variety and for quality, implying therefore that increasing quality will just add
to the total variety of products, rather than replacing it. This last point will form the
background to the thesis. The question especially of how increasing quality may increase or
decrease total variety, depending upon consumer preferences will be put with respect to
biotechnology R&D in industrialized and developing countries, and the theoretical literature
on growth and trade, and will form the basis of the formal models developed in later chapters
below.
We now turn to a discussion of methods upon which the framework of the thesis is
based, and which can be used to examine the issues identified in this section, with respect to
this thesis.
" See for example the textbook by Laffont and Tirole (1993) for a survey of this literature as well
as a theoretical discussion of the problems related to the regulation of natural oligopolies in light of
imperfections in incentive structures. Mugabe (1994) provides a more empirical discussion of the
regulatory problems associated with the conservation of natural resources, especially in developing
countries.
1713. Some Methodological Notes
In the previous sections we have briefly described some of the developments in biotechnology
and the degree of participation by both private and public sectors in developing and
industrialized countries in biotechnology R&D. While biotechnology's major achievement
is in raising productivity and quality, thereby increasing utility from the same or new
products, considerable controversy exists regarding the impact of biotechnology on the variety
of products available to consumers. This was discussed in section 1.2 above. In this section
we briefly define the main approach of this study and present reasons for this particular
approach.
As already mentioned, biotechnology, whether in the pharmaceutical industry or in
agriculture and chemicals, has demonstrated its ability to improve international consumer
welfare. This it does either through improving products, increasing the productivity of
existing products, such as in agriculture, or by creating new products for previously
unbeatable diseases and ailments. Another impact is increasing quantity. The production of
enzymes such as Bovine somatotrophin (BST), for example, which was recently approved in
the USA, can increase the yield of milk, lead to both leaner cows producing more beef per
animal and larger fish. The production of recombinant human insulin in the early 1980s
resulted in a considerable increase in the total supply of insulin, thereby fulfilling the
requirements of insulin users. The insertion of similar high yielding genes in plants has
resulted in an increase in productivity, as well as an improvement in other characteristics such
as disease and climatic resistance.
However, there is some controversy with regard to the impact of biotechnology on
variety. A number of researchers have argued that while biotechnology improves quality, it
has a tendency to introduce a certain uniformity into these improved products (Mooney 1979,
Shiva 1991). The uniformity in turn results in a declining variety or diversity. This point has
been made most vehemently with regard to agriculture, where it is argued that a preference
for the newest or highest quality will result in farmers planting and harvesting genetically
uniform fields, reducing variety in the area.
7.5.2. CMflfrfy fl"^ Viariefy: A Frameworik /or
The central issue in this study is the impact of technical change on consumer utility and
welfare, looking specifically at the question of whether technical change and consumer
preferences, cause the quality as well as the variety of products to increase rather than
decrease, within a dynamic framework.
There are a number of ways in which quality or variety enhancing innovation is
modelled in new growth and trade models. Since the main theme of this thesis is the impact
of new technologies on consumer welfare and economic growth, examining specifically, the
way in which biotechnology improves consumer welfare, in what follows we look at those
methods which relate directly to the features we have noted above about biotechnology and
its impact on quality and variety and consumer welfare.
181. Technical change is usually modelled as a shift parameter in the production function, as
in the Solow aggregate production function model, or as a quality or variety increasing
innovation often modelled as learning, human capital, or as investment in R&D in a sector
devoted to R&D and knowledge accumulation, as in the new growth models. The source of
this technological change in this latter group of models, is presented variously as
improvements in the quality of human capital as in Lucas (1988), an increase in R&D
intensity as in Grossman and Helpman (for example, 1991c), or as a result of learning by
doing as in Arrow (1962), or Young (1991).
2. Preferences, where some models include a consumer preference function which indicates
a preference for the highest quality product at all times, while others model a utility function
which indicate that consumers always prefer the largest variety of products, that is, old and
new products, they can afford, given their budget constraints. In the former group of models
thus, consumers will always prefer higher quality, whereas in the variety functions, consumers
will prefer all the varieties available. The love of variety group of models in growth theory
for example (Helpman and Krugman, 1985, Ch. 6.2) suggest that utility is increased by the
consumption of a greater variety of products. In the quality models of Aghion and Howitt
(1992), Grossman and Helpman (1991b and c) and Flam and Helpman (1987) on the other
hand, consumer utility is maximized by consuming the highest quality or approaching the
ideal variety (Helpman and Krugman, 1985, Ch. 6.3). Thus, as in the Grossman and Helpman
models, once a higher quality product is produced, consumer preferences ensure that the old
variant is immediately dropped from the demand function. In a slightly different approach,
in the Flam and Helpman (1987) model, income distribution ensures that consumers with
different incomes demand a different quality, which in turn results in a range of qualities
being demanded at each particular time, in contrast to the Grossman and Helpman case.
3. The introduction of endogenous technological change and product differentiation has shifted
the emphasis from perfectly competitive market structures to imperfect competition. The
introduction of imperfect competition (Helpman and Krugman 1985, for example), changes
the traditional results based on perfectly competitive markets considerably. Factor
endowments together with the assumption of perfect competition in factor and product
markets ensured the existence of a pareto optimal equilibrium based on those initial
endowments. The introduction of monopoly profits from innovation, can provide an incentive
for R&D investment, leading to previous varieties being driven out of the market because of
creative destruction as in the Aghion and Howitt (1992) model, which is developed further
in Grossman and Helpman (1991b and c). By monopolizing the new innovation, perhaps
through the granting of a patent, each previous innovator is driven out of the market because
his or her monopoly profits are driven down by the new monopoly product. Thus, the
expectation of monopoly profits as well as the driving out of previous monopolists, at least
until the next innovation is developed, provides the incentive to innovate. The presence of
monopolistic markets and the problem of property rights implies that pareto-optimal market
equilibrium is no longer guaranteed and policy becomes relevant.
How does biotechnology relate to these arguments?
19With respect to the first, innovation, especially the use of the tools of molecular
biology and genetic engineering, will result in the production of goods with a higher quality,
or goods which are horizontally differentiated, presenting consumers with a larger range of
varieties. Productivity increases in agriculture, will also raise output or quantity, consequently
raising consumer utility through the availability of a larger basket of goods, or lower prices.
Due to its close dependence on scientific research and training, especially the biological
sciences, biotechnology places considerable demands on the skilled labour force in the
country. A number of countries have recognized this demand, and more funding is being
channelled through to universities and research institutes, both for training and also for
specific research projects. R&D funding for biotechnology research, both private and public
has also increased (US OTA, 1991) over the last two decades. In the US especially, the
participation of the private sector has been most apparent and the "biotechnology firm" has
contributed in a large way to applied biotechnology research. Developing countries have
emphasized the need for technology transfer and reverse engineering to learn by doing or by
emulation.
In agriculture, developing countries are using techniques which to them are relatively
superior, such as ri«we cn/fure and in some cases, r&yrncrionyragmercf /engf/i po/vmorp/iwmj
(RFLP) mapping, to select hardier plant varieties and to reproduce them, thereby increasing
yield levels of the farmer significantly. Research on biopesticides and biofertilizers is also
contributing significantly to soil fertility and agricultural yield increases in developing
countries.
Agricultural biotechnology in industrialized countries is also a rapidly growing sector.
Geneticists and molecular biologists have been successful in recent years in applying genetic
engineering methods to develop plants with improved characteristics such as higher yield or
adapted to specific climatic requirements, such as ice minus bacteria which are being used
to develop plants which are resistant to frost. This method has already been demonstrated
successfully in the tobacco plant which grows in the southern United States but has suffered
from outbreaks of frost in the last decades which has severely damaged the annual harvest
(US OTA, 1991). Thus technological change in the form of biological techniques have
created products which are of a higher quality, in the sense of having characteristics which
can produce higher quality substitutes and also give the consumer a variety of products to
choose from. Both the appearance of higher quality products of this kind as well as having
a greater variety of products to choose from, implies higher utility for the consumer. Thus,
it is quite evident that technological change in this case will increase productivity, through
the production function approach and will also increase quality and possibly variety. We
examine these last two aspects in more detail below.
The second category discussed above was preferences, and from the evidence with
respect to biotechnology, it is unclear whether increasing quality will have a positive or a
negative impact on variety. We therefore look at the sector where the indications are most
clear. In industrialized countries, the sector where biotechnology has made its main impact
thus far, is the pharmaceutical and medical biotechnology sector. The breakthrough made in
the 1950's, when the use of monoclonal antibodies (MABs), was demonstrated, has made
major contributions to the detection of diseases and the development of diagnostic kits which
are now widely marketed. Genetic engineering or rDNA technology has enabled scientists
to produce a number of high quality drugs and vaccines, a number of which are beingcommercially produced, especially in industrialized countries. It appears that in this sector,
consumers, in this case doctors, will prefer higher quality products over lower quality ones.
However, as discussed above in this chapter, the nature of demand and supply in this sector
indicates a consumer preference for higher quality products, but also for variety.
This impact of preferences and technological change on product selection and on
variety will be demonstrated in the growth and trade model of Chapters 8 and 9 below in a
manner that contains the love of variety (Krugman 1979, Judd 1985, Romer 1990) and highest
quality choice (Grossman and Helpman 1991b and c) as special cases, appearing under
different circumstances with respect to learning and R&D cost.
Finally, with respect to imperfect markets, there are two indications that this is
becoming increasingly relevant to biotechnology:
(i) Economies of Scale: As any new technology becomes better established, biotechnology
being no exception, especially in the pharmaceutical sector in industrialized countries,
economies of scale and size of investment capital become more important. It has been
pointed out that as technologies become mature, the importance of economies of scale become
more important (Nelson and Winter, 1977). With biotechnology, the size of the initial
investment and the length of the lag between the initial investment and innovation, has led
to the downfall of many a biotechnology company (US OTA, 1991, Bio/Technology, 1994).
Initial public offerings of biotechnology companies resulted in significant stock price
increases. However, once it became clear that the potential returns were not going to be
immediate, this source of funding dried up for many companies. This is also true in the
1990s where public funds have become greatly reduced, and in order to overcome this, a
number of new private sources of funding have appeared, perhaps prompting the formation
of a number of new small companies, although many of them tied up with the larger
biotechnology companies**.
Thus economies of scale and imperfect competition may have become more important
for the development of biotechnology, especially in industrialized countries. Only in the USA
has the dedicated biotechnology company managed to survive, largely because of imaginative
investment options by the private sector, but significantly only the large ones are able to
access capital on a regular basis. The number of companies in the US alone numbers around
1300 today. However, most of these are small, recent startupts, with signficant tie-ups to
large established companies or to the larger biotechnology companies (Ernst and Young,
1994). A series of takeovers and mergers between these dedicated biotechnology companies
and large established multinationals, again especially in the pharmaceutical sector during the
1980s and 1990s has further demonstrated the degree of consolidation that appears to be
taking place in biotechnology. However, as pointed out above, it is not clear whether there
is a clear trend toward increasing size. An increasing number of strategic alliances, between
" Some of the more creative ventures include Stock warrant, off-balance sheet, R&D financings
(SWORDS), which spin off a technology into a new company, which has no employees and Asset and
risk deployment option with warrants (ARROW): the company Alza for example, recently contributed
$250 million to the new company TDC to apply Alza's drug delivery technology to several drugs. By
doing this, Alza has transferred all potential risks associated with R&D expenditure to the new
company while maintaining control over its technology and the potential benefits from its application
(Ernst and Young, 1994).
21small and large as well as between small firms have also characterised the development of
biotechnology in recent years, and although these companies have faced an uphill battle
during the late 1980s and early 1990s, there is some evidence that this may be changing".
Thus, there appear to be no clear statistical evidence relating scale to profitability or
to rates of innovation. This issue will be examined in greater detail below.
(ii) A second issue is that of an increasing use of patents to earn monopoly profits. Here,
the changing role of intellectual property rights are important, both in biotechnology, and also
in the new trade and growth literature. The USA was the first country to include
biotechnology products and processes within its intellectual property rights regime. Patent
protection is not as strong in most other countries but due to a number of recent changes
especially in the World Intellectual Property Rights Organization (WIPO) and the General
Agreement on Tariffs and Trade (GATT) and a number of agreements relating to
biotechnology, as well as pressure from the US, the trend appears to be toward increasing
strictness in intellectual property rights applied in bilateral trade relations. Patent protection
as modelled in a number of the new growth and trade models, grants monopoly rights to the
innovator, provides an incentive for innovation, and leads to Schumpeterian "creative gales
of destruction" in the economy. In the north-south models however (Krugman, 1979,
Grossman and Helpman (1991b), in general, a lack of enforcement enables southern countries
to imitate. Although, to some degree, this is still relevant to many developing countries, who
do not recognize biotechnology patents, this is changing rapidly, as we discuss below. Thus
stricter IPRs internationally, imply an increasing degree of monopoly in biotechnology,
although an increasing rate of innovation as a result of monopoly protection, would imply
increasing entry by firms, thus reducing monopoly.
In the growth and trade model developed in Chapters 8 and 9 below and based on
evidence gathered in Chapters 3, 4 and 5, instead of assuming away international patents
which allows imitation or pirating, we assume that patents are enforced internationally, and
that countries have to license technologies in order to make use of them.
Thus to summarise, technological change through the use of biotechnology will have
the following tendencies: - ?».t. :;!••-•• .>•-•,.• -J-> ^, • / ^-*.-*.-:-;^. ../,, .-? •..-,-.
(i) Quality improvements in the form of appearance of new products of a higher quality in
the market. "•^ ft'^JwtpKw- ^iO^ruf-rKfe:,:. ,«^: .•:«•*;; ?=? .;.,•;>%**?#;-; ^M-?;'^,- • -•? %<
(ii) Preferences for variety, especially from the pharmaceutical and medical sectors, indicate
increasing variety and quality of products.
" Recent articles on the state of the private sector in the US and UK, for example argue that
despite the setbacks of the last decade, an increasing number of Biotechnology companies are making
public offerings in the US in 1994, while in the UK small biotechnology companies are becoming more
successful, especially as strategic alliances enable them to reach a wider range of markets
(Biotechnology, various issues 1994). Similarly, in the US, although public finance has largely dried
up and investors have become more discriminating, private sector finance has increased, prompting the
formation of a number of small companies. In 1993 for example, approximately three times as many
companies were formed as in the previous year (Ernst and Young, 1994).
22 <(iii) Increasing patenting of biotechnology products and processes implies privatization, as
resources are redistributed from public to private property, often at the cost of developing
countries.
(iv) Patenting also implies monopoly profits, also strengthening the previous point of
increasing privatization of resources.
In the next section, we describe the manner in which these issues will be addressed
in the main part of the thesis.
1.4 Methodology and Outline of the Thesis
In the previous section we have presented the main approach and rationale of this study:
namely examining the issue of quality and variety. Descriptive analyses of biotechnology,
some based on older features of technical change (for example the tendency of the green
revolution to introduce monoculture in large parts of the third world, thereby reducing the
variety of species available), have argued that there is a tendency for modern biotechnology,
especially genetic engineering, through its ability to create new species of a higher quality",
to cause variety to decline in the longer run. On the other hand, it will become quite clear
from the chapters which follow, that biotechnology has the potential to make major
contributions to increasing variety and quality. The production of new species for example
will add to the genetic diversity of the planet. The use of biotechnology to preserve
biological diversity, either in J//M or e* sim has also been recognized and a number of
techniques such as tissue culture and in vitro methods are being used to improve the quality
of material which is conserved. These methods may be able to overcome some of the
deficiencies of traditional conservation methods which have been used, with varying success,
in the world's gene banks. Thus biotechnology, depending upon its applications may either
increase quality and variety by technological means, or, by increasing quality destroying
variety for economic reasons. In the later chapter where we develop a model of growth and
trade, the tradeoffs between quality and variety will be discussed more explicitly.
The structure of the thesis itself is based on the conclusions we make from the
discussion of quality and variety. The main body of the thesis is divided into three broad
sections, each examining innovation within the framework of increasing quality and variety.
Part I contains four chapters. Chapter 2 which follows, presents a general overview
of biotechnology and development patterns observed during the 1960s, through to the 1990s.
A sectoral analysis shows the sectors in which biotechnology has made its mark thus far and
sectors which are expected to benefit in the future. ; •-•-'•'•" -• ";' •=-•"•"'" ^ •''•••• •"•
The third and fourth chapters look in greater detail at the development of
biotechnology, first in industrialized and then in developing countries. We argue that both
the government and the private sector have played important, if different roles, in this
development. A closer examination of this nature reveals characteristics that may have been
The term quality used in this instance is a broad term which may also include other kinds of
technological improvements such as productivity improvements which are cost reducing etc.
23instrumental for the early establishment and successes of biotechnology, for example, the
much talked about phenomenon of private-public cooperation, or the emergence of the small,
specialised biotechnology firm in the USA. In developing countries on the other hand, the
government was crucial in encouraging public sector scientific research of a pre-competitive
nature at a relatively early stage. The lack of an environment which would encourage private
sector investment in this risky technology, has probably meant that the role of the government
was much more instrumental in developing than in industrialized countries.
The objective of Part I, is however, also to examine the nature of innovation in the
different environments of developing and industrialized countries. An analysis of patent
statistics granted in the US and the European Patent Office, for a number of industrialized
countries, provides a preliminary analysis of the rates of invention in biotechnology and the
implications for sectoral development. In developing countries, patent statistics are not as
relevant, as many developing countries do not grant or recognize patents for biotechnology
inventions. In this case, productivity increases especially in agriculture, are the only currently
available measure of biotechnology innovations. Recent field testing data on an agricultural
crop in India was used as a proxy to calculate time trends and productivity increases in this
particular crop.
Chapter 5, the concluding chapter in Part One, discusses the impact of biotechnology
based quality and productivity improving innovations on older qualities and varieties. In
specific, we ask whether innovations, either based on higher quality or on productivity,
increase or decrease the total variety of products (old and new together) in the economy.
Part II examines the theoretical literature on economic growth and international trade.
Once again, the theme of quality and variety is used to examine the implications of innovation
on economic growth. We look at the new growth and trade models with respect to this
analysis. The literature reveals preferences of three kinds which are relevant to our
framework: the traditional utility function in which consumer utility is maximized through the
consumption of a larger quantity of goods, in contrast to the more recent models, known as
the "new" growth and trade models, which are characterized by consumer preferences where
utility is increased through the consumption of a greater variety of products (or love-of-variety
functions)(Romer 1990, Grossman and Helpman 1990b, 1989a) or by increased quality (or
ideal variety functions)(Grossman and Helpman, 1991b and c, Flam and Helpman 1987,
Aghion and Howitt, 1992). In Chapter 6, we examine each in turn, and their implications for
quality and variety, which we relate to the economic growth and trade model which follows
in Part III. Chapter 7 looks more explicitly at the issues of quality and variety in
biotechnology, expanding upon some of the issues discussed in section 1.2.3. of this chapter.
Part III contains three Chapters, drawing together the structure of biotechnology R&D
and the treatment of quality and variety in the theoretical literature, first in a closed economy
growth model which is discussed in Chapters 8 and subsequently in an open economy trade
model presented in Chapter 9. The model itself is an economic growth and trade model,
which is very much in the tradition of Judd (1985), Romer (1990) and Grossman and
Helpman (see 1991c among others) in that invention takes place first in a R&D sector and
the patented product is then licensed to the differentiated good producer. Observations about
consumer preferences in biotechnology are used to justify the use of a "love of variety" utility
function combined with the ideal variety approach where the Spence-Dixit-Stiglitz quantity
24function receives quality weights of the Flam and Helpman (1987) type. Consumers therefore
prefer greater variety, given the appearance of higher quality innovations in the economy.
Unlike the Grossman and Helpman models and perhaps more in the tradition of recent
papers by Ram and Helpman (1987) and Young (1991 and 1993), the appearance of new
qualities does not automatically mean the destruction of older varieties. Destruction of all
older varieties such as in Grossman and Helpman (1991c) or pure love of variety after
reappearance of varieties that had already been selected away are the results of simulations,
as special cases after some time periods. In the absence of learning, variety vanishes. In the
presence of learning, variety may increase if R&D is not too expensive. Thus, some of the
forces which determine the (non) vanishing of variety are identified by the model-theoretic
formulation of the third problem discussed in section 1.2. above, i.e., whether increasing
quality adds to or drives out older varieties from the market.
Thus the model adds to the literature in two ways: firstly by including both love of
variety and quality improvements, we move closer to empirical observations with regard to
consumer choice, and secondly by presenting a range of qualities available for the consumer
to choose from at each point in time and where the appearance of new innovations does not
immediately result in older varieties disappearing from the market. The difference between
this model and the Ram and Helpman (1987) model, is that while in Flam and Helpman the
analysis is static and the range of qualities remains the same with the number of old varieties
which drop out of the market being equal to the number of new varieties entering the market,
in this model we show in a dynamic analysis that the range of varieties present in the market
initially remains constant or diverges, but converges in time for some cases.
Finally, the last chapter of Part III and the dissertation, summarizes and discusses the
results of the model, making conclusions for biotechnology and growth and draws policy
conclusions.
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2.1. Biotechnology: Definitions and Difficulties
Biotechnology is a melange of scientific techniques which can be applied to alter the
composition or genetic structure of an organism. These techniques have been in use for
centuries in simple forms such as fermentation to produce cheese, wine and other alcohol and
also to preserve foods in many eastern countries. Since the 1970s however, a number of
important scientific breakthroughs have been made, beginning with the development of
rec<?m£/na/tf DNA technology, when Stanley Cohen of Stanford University and Herbert Boyer
of the University of California successfully spliced a foreign gene between the ends of
bacterial DNA, ushering in the era of new biotechnology based largely on genetic information
and techniques.
New biotechnology has been defined as "the industrial use of recombinant DNA, cell
fusion and novel bioprocessing techniques"". Broader definitions which are used
predominantly by developing countries are also available, describing biotechnology as, "the
application of scientific and engineering principles to the processing of materials by biological
agents to provide goods and services"*® and as "any technique that uses living organisms
(or parts of organisms) to make or modify products, to improve plants or animals, or to
develop micro-organisms for specific uses"". In many cases, these broader definitions cover
both new and old biotechnologies and are used by developing countries to describe
biotechnology in general. In industrialized countries, where the use of advanced genetic
engineering techniques is more predominant, the definition of biotechnology tends to be the
narrower one. Thus there are often misunderstandings between scientists and policymakers
when discussing biotechnology, depending on which definition is used. For our purposes, we
shall be using the broader definitions, as these are the ones more relevant to and more
widespread in developing countries.
US OTA (1991), p 5.
OECD (1982), p 21.
US OTA (1991), p 5.
29Another difficulty lies in analysing and measuring the impact of biotechnology on
economic growth and also the factors that contribute to the growth of biotechnology. The two
main indicators that have been used in the past, are R&D funding, frequently referred to as
an "input" indicator and patents which are known as "output" indicators'". Attempts to use
such measures for analyzing the growth of biotechnology in industrialized countries have also
been made". However, there are also a number of problems with using such input and
output data to measure rates of innovation.
Using R&D as an input measure can often result in an underestimation of the size of
biotechnology activity because data on the amount of R&D funding devoted specifically to
biotechnology is usually unavailable. Even at the level of the firm, disaggregated data on
biotechnology funding is often unavailable. Reasons for this include secrecy, but more
importantly, biotechnology is highly interdisciplinary and, because it is not a sector or an
industry per 5e, spending on biotechnology can occur in many sectors and thus is not
identified in the national accounts as spending on biotechnology'*. In the same way, a
number of the companies doing biotechnology research today have moved into this technology
partly as a result of their previous expertise in a sector where biotechnology has resulted in
radical changes. Companies in these sectors, such as those producing Pharmaceuticals and
products based on fermentation technologies, to give just two examples, do not separate R&D
spending on traditional research from that on biotechnology research. Their R&D figures
therefore, often do not reflect a division between old research and new biotechnology
research. Care should therefore be taken in accepting R&D figures at face value, especially
in an interdisciplinary technology such as biotechnology.
Given this difficulty in measuring technological innovation through the use of R&D
data, many researchers have turned to another measure, namely patents. Patents are granted
for inventions for a period ranging from 8 to 17 years in developing and industrialized
countries respectively". They are regarded as a measure of the output of innovation activity,
as opposed to R&D statistics which measure the input into innovative activity. Patents, since
*° Soete (1980, 1987) and Patel and Pavitt (1987), provide a thorough discussion of the major
disadvantages and advantages of the various innovation indicators which can be used.
" Wheale and McNally (1986) for example, use US patent data both for second generation
biotechnologies as well as genetic engineering to examine trends in biotechnology innovations. They
also project the number of biotechnology products which would be commercialized by the year 2000
based on market data for a number of research areas. Orsenigo (1989) uses both US patent data to
project trends, as well as publications of articles in biotechnology and genetic engineering journals in
OECD countries.
'* Sharp (1985) among others have used government spending on R&D in biotechnology in the
OECD, and especially in the US as an estimate of the size of biotechnology research, however,
because of the reasons discussed above, this cannot usually be used as an indicator of the size of
biotechnology R&D in individual countries.
" The recently concluded Uruguay Round of Multilateral Trade Negotiations in the GATT has
however extended the period to 20 years for all member countries, developing and industrialized
although many of the former have been given a buffer period during which they can slowly phase in
the new period of 20 years.they are granted for new inventions often are used as proxy measures for new innovations and
therefore measure the rate of technological change in the particular technology or sector.
The need to find a proxy measure for technological change has led a number of
economists to study the validity of using this specific indicator. Patents have for example
been used as a straightforward proxy for technological change or innovative activity. The
work done in this field by Schmookler (for example, 1966) initially tried to use patent
statistics as a measure of innovation and discovered that because of the number of patents
which are not necessarily worked, it was perhaps more accurate to use them as a measure of
inventive activity, i.e., as an input measure.
Another usage was made of patents in the neotechnology hypothesis by Freeman
(1963), which measures technology in terms of the temporary monopoly rights given to a
product which is patented.
A number of researchers have also related this measure to that of input measures such
as R&D in order to check its significance as a measure of technological change. Intuitively,
one would expect a significant relationship between these two measures, as the size of
investment in R&D would influence the number of inventions and hence patents applied for,
while the number of patents granted would encourage a firm to invest more in R&D activities.
In their survey, Pakes and Griliches (1984) for example found that there was a strong
correlation between patenting activity and R&D expenditures in general. This confirmed the
earlier findings of Schmookler (1966) and Scherer (1984). They have also been used to check
the correlation between firm size and inventive or innovative activities (Acs and Audretsch,
1989 and Griliches, 1990 for example). The results show significantly that patents can indeed
be used as a fairly good proxy measure for firm activity devoted to invention and
technological change. Soete (see for example 1981 and 1987) has also used patents
extensively, as a proxy measure for technology gaps and technological change.
The use of output measures such as patents should however be kept in perspective,
considering some of the problems one could encounter when using these statistics. This is
especially true for modern biotechnologies such as genetic engineering for which patents were
not granted at all until relatively recently. The first signs of acceptance that genetically
modified organisms could become proprietary knowledge, came in 1980 in the landmark case
of Diamond us CTiajfcra&arfy, when the US Supreme Court granted the first patent to a "new"
organism. Thus even in industrialized countries, patents granted recombinant DNA based
products is relatively new and since it is not retroactive, this could create some discrepancies
in using patents to measure technological change. For example, because monoclonal
antibodies were never patented, all subsequent innovations based on hybridoma technology
have not been granted patents either**. Thus in some cases, available patent statistics do not
capture the importance of the invention or the appearance of new biotechnology based
products.
Another reason is that with very sophisticated biotechnologies, where competition
between the large multinational firms is very strong, the companies often tend to resort to
trade secrecy rather than patenting". In developing countries a further problem is that the
* Orsenigo, L. (1989) and Daly, P. (1985).
" Orsenigo, L. (1989), p 58
31patent system has not as yet incorporated biological technologies, making the use of this
measure impossible in their case. We could use the number of patents filed by developing
country nationals in industrialized countries, as an indication of technological progress in
these countries, however because their own national patent systems do not grant patents for
biotechnology innovations, a use of these data for developing countries becomes meaningless
when measuring innovation. The use of patent statistics in this thesis (see Chapter 3 below)
is thus restricted to those granted to industrialized country nationals.
Despite these potential problems however, the use of patent statistics in the past (see
for example, Soete 1981) has demonstrated a significant degree of success in measuring
inventive activity in new technologies. Its close correlation with R&D investment as pointed
out above, is also a good indication of its goodness of fit. Thus, although there are some
problems with using patent statistics, and these problems should be kept in mind when
examining patent statistics, they appear still to be a good measure of inventive activity by
companies, both large and small. In Chapter 3 below therefore, we use statistics from the
European Patent Office as well as the US Patent Office to examine technological change in
biotechnology in industrialized countries. Developing countries in general, as mentioned
above, have yet to recognize patents granted to genetically engineered products, and are hence
not included in the analysis.
In what follows, we first describe the major, modern and not so modern
biotechnologies which are in use today, before moving on to describing major developments
in industrialized and in developing countries.
2.2. The Technology Clusters
Fransman (1991), describes three broad groups of biotechnologies in use at present:
1. flecomfc/nanf IWA (rDNA) which is also broadly referred to as genetic engineering. It has
a wide range of applications such as in the pharmaceutical, chemical and food processing
industries.
2. Ce//yksjo«, which enables the combining of cells so that their desirable characteristics can
be used to produce stronger and more resistant cells. Monoclonal antibodies (MABs) are one
such example. MABs are pure antibodies which are produced by fusing antibody producing
cells with cancerous cells. The antibodies produced from this fusion are stronger and more
robust, with a greater resistance and an ability to multiply continuously. MABs today form
the basis of many diagnostic kits which are widely available to diagnose a number of
common diseases, both in industrialized countries, but also increasingly, in the advanced
developing countries.
"Ssf fcji;.- '<••••••$.
323. Finally, taoprocew fec/ino/ogres allow biological processes to be upscaled into large
industrial production. This is an important category given the increasing significance of scale
in industrial biotechnology, especially in industrialized countries".
Thus generally defined, modern biotechnology consists of these three groups of
technologies. There are also two other kinds of techniques which can be added to this list,
namely cell and tissue culture and bioinformatics.
4. Ce// and tissue Cw/rwre: This technique was first developed in the late 1890s". After a
century of improvements, the technique is relatively different than when first conceived. It
enables the propagation of tissue m virro, within the controlled environment of a laboratory,
in which the tissue or cell can be exposed to the required conditions. The surviving cells
adapt to the new environment, and form a ca//«s, from which reproduction and eventual
development of the new plant or tissue takes place. A number of different techniques are
included within this technological cluster: c/ona/ propagation which involves the asexual
multiplication of plant tissue into new plants, so/nac/ona/ variation which occurs when callus
tissue is regenerated into plants and is useful for selection of specific traits, anfner cw/fwre
where tissue culture is performed from pollen and is therefore much more difficult, and
embryo rescue which is especially useful when unlike species are crossed and the likelihood
of regeneration as a result is small. In addition, genetic tagging and engineering can also be
used to select and introduce desired traits into plant tissue that is then regenerated with the
new trait'*.
The goals of genetic engineering are similar to that of tissue culture, namely improving
certain desirable characteristics, such as productivity and disease resistance. However the
costs of genetic engineering are still high, requiring skills related to genetic manipulation, as
well as sophisticated capital equipment required in the laboratory. The major difference
between the two techniques is in the degree of precision. While tissue culture results in the
production of plants similar to one another, genetic engineering is much more precise, in that
it can produce plants with identical characteristics and replace unwanted characteristics
altogether. Due to its highly scientific and costly requirements, genetic engineering is
therefore only available to industrialized countries and also a few advanced developing
countries. •-••-• •• • •• - • - - •<• •••;>*• .;&;'*;<*>'.> ^^;-*u-vnJ-; -•••" ••-*
5. Finally, a new group which is expanding rapidly, is Bio/n/ormatics. As the name suggests,
this is the use of information technology in biological screening and identification of genetic
structure. The human genome programme is currently benefiting enormously from
bioinformatics. The use of robots which use image-processing software to identify spots of
DNA suitable for analysis contained on culture plates as well as to pick up the DNA. It is
Fransman, 1991, p 19 argues that scale appears to be becoming more important, largely an
observation from most older technologies and sectors where scale appears to become more significant
as the technology matures. We discuss this is more detail at a later stage in this chapter.
" Kenney, M. (1986), pp 250-1. - ,,b
'• Persley, G.J. (1990), pp 32-42 , _•.> *\
. 33 .;'-..:... ' . • . - ::.:/,;estimated that this will save years of work in identifying the structure of the human
genome". Similarly, the use of biosensors can be extended across sectors including health
(monitoring glucose levels for example), pollution control (detecting pollutants in water and
air) and industrial processes'"'.
In the next section we describe in turn, the major sectors where biotechnology is
making a mark and follow its developments over the last two decades in industrialized and
developing countries.
2.3. The Development of Biotechnology
The development of biotechnology as a commercial activity especially in the USA appears
to have been facilitated by a complex set of interactions between governments, public research
and development and regulatory institutions, and private sector entities. We describe these
interactions in brief below, before examining the sectoral development and diffusion of this
technology.
The pattern of development described below is perhaps more closely related to patterns
of innovation in industrialized countries. However, although developing countries have had
a somewhat different experience, there are a number of similarities which we explore in the
following two chapters.
a] Pure scientific research. ' • '^' <^ •"&;••**<;-.' >M ^
The first stage in the development of biotechnology as a commercial activity, came
mainly from research interests and programmes at universities and research institutions.
Those institutions of higher learning which had a strong tradition in the life sciences and also
specific medical and biological research, were especially important in developing a trajectory
for generic research in new biotechnology in its early stages. The leading discoveries and
techniques of the 1950s, 1960s and 1970s were the result of such generic research funding
largely by university research programmes*'. ;;.- ,:-...-; •; ^ ^3^
b] Industry-University Cooperation:
Following close on the heels of these early successes, private sector recognition of
their importance came in the form of research grants to universities and research groups. The
1970s also saw a stagnation in University research budgets which provided an impetus to
increasingly look for outside sources of funding as well. Initially started as collaborative
research projects between medical institutions and faculties and the pharmaceutical sectors,
where the progression from biological technologies was most direct and advanced**, they
" New Scientist (1994), February, p 20. < ~
• i *° Ernst and Young (1992), p 21. , >., , , ;, ^. , <^
" The most extensive study of University-Industry Research arrangements especially in the US
during the 1970s and 1980s is probably Kenney (1986).
* Orsenigo, L. (1989), p. 85. • " ,,; :.V ^ , j^?
34soon expanded into a number of other sectors, including agriculture and environmental
biotechnologies. A primary reason for this collaborative research on the part of industry
appears to have been to make use of the public knowledge base built up at the universities
in generic science and technology. The motivation for researchers and faculty members was
provided by the finance, which would help them to maintain their research programmes which
would otherwise have faced drastic cutbacks. Cooperation of this nature often also consisted
of university professors being appointed as board members of private companies.
c] Formation of private companies or New Biotechnology Firms (NBTFs):
The 1970s and 1980s, especially the late 1970s and the early 1980s, saw a sudden
increase in small scale firms which came to be known as the New Biotechnology Firms
(NBTFs) (seeyigure 2J. below). These firms were formed essentially to transfer knowledge
and technology from universities and generic research institutions to industry and were
frequently spinoffs from University research. Often, it was University professors and senior
researchers who went a step beyond being board members of firms, to leave their faculty
positions and form companies of their own, to continue their specific research activities.
These NBTFs became most active in the pharmaceutical sector. Although the intention was
to become full fledged companies researching and producing their own products, they were
largely unable to achieve this goal for a number of reasons. Firstly they were formed by
researchers, many of whom had worked in Universities, with no first hand knowledge of
running a company. Secondly, the research done by these firms was often very narrow,
relating to the specific research interests of the founders and researchers. Finally, the
companies lacked the technical, managerial and marketing skills needed to combine their
success at the pure and applied research levels with success at the commercial level (Kenney,
1986). Thus many of these companies became input suppliers to the large multinationals
which possessed a combination of these skills essentially lacking in the NBTFs.
d] Mergers and Takeovers . ••
In the late 1980s, many of these small companies, despite seeking help from the stock
market were unable to match the long term funding requirements of biotechnology in
Pharmaceuticals, and either went out of business, or merged with other companies. The stock
market crash in 1987 was part of the reason for funds drying up, leaving a number of
companies unable to function effectively. In 1990, Hoffman LaRoche announced its partial
takeover (60 percent) of the most successful genetic engineering company, Genentech, a
merger which was overwhelmingly supported by Genentech's shareholders^. By the early
1990s this trend had increased, with a number of small US firms being taken over by both
national and foreign based multinationals or their subsidiaries (see table 2.1.).
In 1993 it was estimated that there were almost 1,300 registered biotechnology
companies in the US**, although many were experiencing difficulties as evidenced from a
*' US OTA (1991), p. 56. .-.-..-- —.,., ,
" The figure given by Abrams (1993), p. 775 is closer to 1,200, while the Ernst and Young
(1993) estimate is closer to 1,300. - , „,-. ... ,, .,... .,„..-
35fall in venture capital offerings in 1993 and an overall drop in stock prices'". In the UK this
number was almost 200 in 1992. According to a recent survey of 166 firms in the UK**,
biotech efforts in the UK are approximately 6 years behind the USA, in terms of profit levels
and sales. Nevertheless, according to the same survey, the companies should be doubling
annual profits from US $ 627 million in 1992 to approximately US $ 1.3 billion by 1996.
As the number of biotechnology products which are commercialized, increases, the various
industries will attract more and more entrants. This is especially so in the case of periods
immediately following key innovations, such as the gene splicing technique demonstrated by
Cohen and Boyer and the discovery of MABs, which have enabled the production of a
number of products which can be patented individually.
Fig 2.1 Formation of NBTFs by Year (US)
1970-1991
140
70 71 72 73 74 7*5 76 77 78 79 610 8'1 &
Year
& & 8*7 8'8 8'9 9*0 9'1
Biotechnology faces an uncertain future, depending very much upon the regulatory
environment and upon building public confidence, where because of the long lag between
investment and product development, the initial investments made have not yet provided
investors with sufficient dividends. The public's confidence in the small biotechnology firm
appear to have declined following the stock market crash of 1987. This was compounded by
a number of firms declaring losses and bankruptcy. The many buyouts and mergers shown
in table 2.1., many between biotech companies and multinationals are also indicative of
financial problems being faced by the small firm.
* Bio/Technology (1994), March, Vol. 12, p 232.
** Bio/Technology (1994), March, p 230.
















































































































* Only deals completed by June 1992
Source: Reproduced from Ernst and Young (1992), p 54.
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By mid 1992, deals between 62 of these firms had been completed while a number of others
were still being negotiated, out of a total biotechnology sector of 1,231 firms (about 20% of
all biotech firms).
Despite this however, recent reports argue that the growth in strategic alliances,
especially between small companies, to some extent is ensuring their survival. This is evident
from the number of large pharmaceutical companies who are seeking out the expertise of
smaller companies, not through buyouts but through strategic alliances. Eli Lilly for example
has ongoing alliances with at least 11 biotechnology firms'". The return of the small
biotechnology company, after a decade of financial problems, is also evident from the record
*' Bio/Technology (1994), Vol. 12, July, pp 652-653.
38number of public offerings that have been made this year*®. Ernst and Young for example
has estimated that in 1993 biotechnology companies raised US$ 5.2 billion, US$ 2.9 billion
of that coming from strategic alliances while $2.3 billion was raised publicly and privately*'.
This increased confidence on the part of the investor, both private and corporate, may be due
to a number of products which have recently been approved for use especially in the USA,
and a greater incidence of companies recouping their initial investments as a result of
increased product sales. Thus, the rumours of the early demise of the small biotechnology
company may indeed have been greatly exaggerated.
2.4. Sectoral Developments in Biotechnology
Thus it appears that in general, industrial biotechnology has finally achieved success in
commercial production of modern biotechnology products. However, the steps leading up to
this achievement, especially in terms of market structure and linkages between private and
public and generic and applied research, have been different in different countries. For
example, the small, specialised biotechnology firm is a phenomena especially true for the
USA, while the large firm and often the public sector, appears to be dominant in other
countries. The differences across countries are discussed in more detail in the next two
chapters. Sectoral changes however have tended to be more similar, especially across
industrialized countries and across developing countries, primarily because of traditional
strengths and the scientific, especially biological nature of biotechnology. The latter has been
important in providing a primary boost to some sectors over others. In developing countries,
the former appears to have played a more important role than the latter, perhaps because of
the difficulties of linking basic and applied research, a problem which although present, was
not as hard to overcome in the industrialized countries.
Sectoral developments in biotechnology can be broadly classified within three major
sectors: (i) the pharmaceutical sector, which includes both human and animal health, (ii) the
agricultural sector where some degree of overlap occurs with both environmental technologies
and with animal husbandry and health technologies, and finally, (iii) the environmental sector
which has gained importance during the last couple of decades due to an increasing
occurrence of environmental problems and disasters.
The pharmaceutical sector, because of its requirements of large initial financial
investment, but also large potential gains has grown most rapidly in industrialized countries,
and as mentioned above, has formed the focal point for the NBTFs. The agricultural sector
has been slower to use biotechnology, perhaps because of the longer lags between innovation
and application and also lower returns, while the environmental sector is only taking off now.
In developing countries on the other hand, traditional strengths in agriculture and low levels
of financial capital have resulted in biotechnology applications being strongest in this sector.
Bio/Technology (1994), March, 453-454. Although the observations are preliminary, they may
point to a change in confidence in the small firm, whose likely cause is the number of recent product
approvals by the FDA «
*' reported in Bio/Technology (1994), Vol. 12, July p 652. - - . ;*>-?* .A'i 0 *' f 'Pharmaceutical technologies still tend to be based on older biotechnologies, while
environmental technologies are strongly directed toward agricultural problems.
The Newly Industrialized Countries of the east, find themselves in an intermediate
position aided greatly by large amounts of financial capital to invest in technology transfer,
and traditional strengths in bioprocessing technologies to overcome the hurdle to industrial
scale up. While this appears to be the general trend, below, we describe these sectors in more
detail, highlighting some of the problems that have been faced by industrialized countries
along the way, a taste perhaps of things to come for the developing countries.
2.4.7. 77ze P/jarmaceurica/ sector:
The US patent office approved the first biotechnology based drug, recombinant human insulin
in 1982. Since then, the number of patents granted to pharmaceutical products has increased
rapidly and by August 1991, there were as many as 19 biotechnology based- pharmaceutical
products on the US market'".
Table 2.2. Market value (mil US$) and product estimates

















































































Source: Ernst and Young, 1992, p 22.
US OTA, 1991, p75.A number of others are in the pipeline, awaiting patents on their inventions, or completing
testing and trials before being approved by the FDA for commercialization. As mentioned
before, the close links between generic biotechnology research and the medical and
pharmaceutical sector has resulted in this sector becoming the largest and most successful (see
table 2.2).
Although dominated by the US and especially small DBCs, there are also a number
of European multinationals such as Hoffman LaRoche, Glaxo, Bayer etc. who rank as
important contributors to biotechnology research and product development. Hoffman
LaRoche's merger with Genentech and its involvement in Cetus and most recently, Syntex
and other NBTFs, demonstrates the interest these companies are expressing in biotechnology
research. There is therefore some indication that biotechnology research is attracting a larger
range of companies especially as the pool of new products and innovations becomes larger,
innovation not only adding to the variety of products available, but also to quality, in the form
of new products which offer treatments for diseases which were unavailable previously. Thus,
from a list of products, which are now available on the international market (US OTA 1991,
Ernst and Young, 1992, Bio/Technology, Various issues, 1994), it appears that innovation will
result in an improvement in consumer utility through the production of both higher quality
and also greater variety in this sector.
2.4.2.
In a world where there is a perennial shortage of affordable food and the search for cheaper
food, the research community is constantly looking for ways in which to increase output, or
increase the productivity of land. Biotechnology offers one such option, and the level of
confidence in this is evident from its increased application to agriculture. In developing
countries, less sophisticated biotechnologies are being used to improve the yield of grain and
other essential products, whereas genetic engineering applications are also reaching the
product development stage. The International Agricultural Research Centres such as
CIMMYT, IRRI and ICRISAT devote their research in the main to improving agricultural
output in various crops which are essential to the region.
Although less likely to be categorized as essential foods, the highly publicised
introduction of Calgene's F/avr Savr Tomatoes*', which are said to have a better flavour and
a longer shelf-live than ordinary tomatoes is only one of the many examples which exist due
to the application of biotechnology in industrialized countries. Bovine growth hormone,
through which milk production can be increased, is another example. Monsanto's Bovine
Somatotropin (BST) has recently been approved for use by the US Federal Drugs
Administration, and its sales to customers controlling 15 percent of the US dairy cattle, within
the first three months after approval, have far exceeded all projections". Growth hormones
are also being tested on a number of other animal species to produce leaner meat, and also
The US came a step closer to approving Calgene's tomato for marketing recently, and estimates
are put at 90 days for full approval. (Bio/Technology, May 1994, pp 439^141). Similarly, DNA Plant
Technologies recently introduced its VineSweet Brand of tomatoes on the market (Ernst and Young
1993).
" Bio/Technology (1994), vol. 12, pp 570-71. -,
41in aquatic life to produce larger and healthier varieties. There are also close linkages with
the pharmaceutical industry in the production of animal health products, such as vaccines and
diagnostic products for the detection of diseases in animals. Many of the companies doing
research on animal health are in fact the same companies which work on human health.
In applications to plants, there are also a variety of new products and new areas of
research. The use of biopesticides and bioinsecticides are seen as an healthier alternative to
their chemical counterparts. However, their applications are limited due to the fact that they
have to be tailored to the needs of individual plants, or specific land requirements. The
market for one such biopesticide would therefore be a limited one and perhaps not worth the
trouble to many of the large agricultural concerns. Another area which is promising is
herbicide resistance. Large companies such as Monsanto are doing research on developing
plants which are resistant to their own herbicides and to collateral damage from their
pesticides.



















































Source: Ernst and Young, 1992, p 22.
Yet another research area which is more complex but has a larger potential market is
the improvement of the qualities of the plant itself. Older technologies such as tissue culture
and micropropagation which are not recombinant based, have been used in the past to select
certain desirable characteristics, which can then be reproduced in controlled environments.
New genetic engineering techniques are much more powerful and effective in that they can
be used to detect the genetic structure and the desired gene in a particular plant. That gene
can then be reproduced and inserted into a plant to produce a new "genetically engineered"
plant which contains the desired characteristic. Calgene's tomato is an example of such a
technique. The development of transgenic plants which are resistant to particular pests or
climatic conditions can result in major changes not only by increasing yield but also by
42changing the environmental zones in which particular plants can be grown due to their
climatic requirements".
Thus, although the initial research emphasis of biotechnology firms appears to have
been pharmaceuticals, more recently, attention seems to have shifted substantially to
agricultural biotechnologies**. The ag-Wo/ec/z sector, as it is called, has experienced a major
boost with the US Food and Drug Administration (FDA) approving a number of genetically
altered products as well as its declaration in May 1992 that no new testing will be required
for genetically engineered food products. During the period 1991-1992, the number of ag-bio
companies grew from 89 to 123". The largest of these (see table 2.3), are still smaller than
their counterparts in the pharmaceutical sector, in terms of sales and stock market value (see
Appendix I below), although all indications are that these are set to expand as more and more
products are cleared for field testing and reach the market stage'*.




























Source: OECD (1993), p. 9
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" Such developments are also bringing major changes to agricultural production and international
trade patterns. Developing countries which are often highly dependant upon their cash crop exports
are especially vulnerable to the development of substitutes and "climatically engineered" varieties.
This is the subject of Acharya (1993b) and is discussed further in Chapter 7 below.
Ernst and Young, 1992, pp 5-7
Ibid, p 21.
Ibid., p. 21
" t*i" ««*•*•*•:However, the real problem with commercialization here appears to be a lag in-
government approval of products. This is in part because of testing requirements and the
considerable lag which is common in agriculture between testing and application.
Nevertheless, restrictions on testing have been reduced considerably as is evident from table
2.5. below which shows that permits for the release of genetically engineered crops have
increased greatly since 1990 in the USA. This is also evident from data (tables 2.5. and 2.6.)
collected by the OECD on the release of genetically engineered transgenic plants for field
trials".




















































Source: OECD (1993), p. 10.
" OECD (1993c). The study included a survey of field releases in the following countries:
Belgium, Canada, Denmark, France, Germany, Japan, the Netherlands, Norway, Spain, Sweden,
Switzerland, UK, USA, Australia and New Zealand.
44 •-.;•'As the table shows, 45 percent of all permits issued thus far, were issued in 1992. Of this,
table 2.6. shows that the USA and Canada by far account for the largest percentage of field
releases since the late 1980s.
A recent interim report by the European Commission's Biotechnology Coordination
Committee (BCC) comparing regulation and R&D in Europe and the USA concluded that at
the R&D stage (ie., including testing), "there is a remarkable similarity between the US and
EC as far as risk assessment of an environment release is concerned. However, in the US the
scope of the regulations is different and within that defined scope there exists greater
flexibility"**. Thus there is some indication that European countries in general are more
stringent with regard to environmental release for field testing, than the US. There does
however, appear to be a tendency to relax these regulations through the EC", as a recent
directive on the banning of BST indicates. This may in part be due to the experience which
has been gathered with previous field releases during the late 1980s, which give some
indication of requirements and conditions that would minimize pollination with wild varieties
or other varieties being grown around the testing site*".
Even if the product is eventually approved by the appropriate government body,
consumer and environmental groups still tend to frown on genetically engineered products,
and the next hurdle to be overcome will be socio-economic pressures such as these, rather
than simply the regulatory environment. The appearance of genetically engineered foods in
supermarkets, first in North America and more recently in the UK", may be some indication
that consumers will slowly begin to accept these products.
2.4.5.
This is perhaps the most underdeveloped of the three sectors but is an important sector all the
same because of the general interest in the environment and environmental technologies and
because of the potential biotechnology holds for the environment, both with respect to
industry and also in agriculture. In industry, a number of companies have developed methods
to clean industrial wastes and to recover metals from waste waters". One of the world's
worst oil spill at Prince William Sound earlier in the decade was partly cleaned using "oil-
recovering" bacteria. Indeed the first patent granted to a genetically engineered organism in
the US in 1980 was for such a microorganism which could break down the major components
* European Biotechnology Information Service (EBIS)(1993), March, Vol. 3, no. 1, p.3. ,
" Bio/Technology (1994), March, Vol. 12, p233. '' " *"''
°° The study by the OECD (1993c) gives examples of cases of testing across various European
and North American sites which have provided measures of buffer crops and distance from other crops
in order to minimise cross pollination. Other factors such as wind have of course also to be taken into
account, when releasing transgenic plants into the environment.
" Bio/Technology (1994), April, Vol. 12, p 351.
** The process marketed under the name of AMT-BIOCLAIM contains a metal removal agent and
has been successfully used to recover metals from wastewaters containing differing degrees of metal
wastes. See Acharya and Spencer (1990b) for more details.
45of oil". The sensitive nature of the environment and also the recent movement to control
environmental pollution has led to strict legal arrangements regarding the release of
environmentally sensitive biotechnologies. For most industrialized countries and also for a
number of developing countries, the restriction of the release of genetically engineered
organisms into the environment has become part of the regulatory framework. With the
FDA's recent statement that no new testing will be required of genetically engineered food
products however, there appears to have been some easing of this restrictive environment**.
This is also apparent from the number of environmental release permits for the testing of
products, issued in 1990 and 1991 (see tables 2.4 and 2.5).
Biopesticides are another environmental technology which, especially for agricultural
nations, this provides a safer alternative to chemical pesticides which have caused
groundwater pollution in the past. The excessive use of chemical pesticides during the green
revolution has also caused severe problems in developing countries, where this technology
may be highly relevant today.
The general sectoral pattern of development, with the pharmaceutical sector leading
the others, is observed in a number of countries around the world. Private sector investment
in this sector is also generally the highest, although a number of private companies are
gradually becoming involved in agricultural research. In part, this is because of the tedious
process of testing and approval as well as consumer disapproval associated with genetically
engineered agricultural products and also partly because Pharmaceuticals have potentially
larger profit margins, providing companies with a greater opportunity to recover their initial
costs. However, as the benefits of new agricultural products appear to outweigh the
immediate risks to the environment and because of the size of the market, it is likely that
biotechnology will become a major player in the agricultural and agri-business sectors as well.
Similarly, environmental biotechnologies which have suffered from a lack of sufficient
attention until now will gradually become more important as the environment becomes a more
high-profile issue, not only in industrialized countries, but also in developing countries.
The challenges for policy, especially the regulatory environment, are to reach a
balance between regulation and innovation. For example, excessively restrictive policy on
the testing of genetically engineered organisms may hinder innovation, especially in
agriculture. On the other hand, a weak regulatory framework may create other hazards
associated with genetically engineered products, and the introduction of foreign genes into
local varieties and into the local environment.
Conclusions -• -•
In this introductory chapter to biotechnology, we have described the way in which
biotechnology has progressed from basic biological research at universities and research
" As pointed out earlier in the text, in the Diamond vs Chakrabarty case which involved a non
recombinant microorganism, the Supreme Court in the US allowed the patent, ruling that it was, "the
product of human ingenuity having a distinctive known character and use", (OECD 1985, p 104).
" Ernst and Young (1992), p 10 -.,...,. .- .;,, ->•;',: .-<.-,;..,:.-institutions, to a modern, applied technology with enormous potentials. Collaboration between
universities and the private sector led to successful product development albeit after several
years of research and investment. The private sector and public offerings were crucial in
providing the large sums of money required for these initial investments which government
funding for basic research was unable to provide. Thus as we saw above, the number of
companies or New Biotechnology Firms as they were known expanded rapidly in the 1970s
and the 1980s largely as a result of raising venture capital funds and stock market capital.
More recently, and especially to compete with the all round expertise of the large
multinational, these companies have increasingly resorted to marketing or R&D alliances, to
compensate for size and limited scope in marketing in various parts of the world.
The second portion of this chapter provided a brief survey of the major sectoral
developments in biotechnology. For a number of reasons, the most important of which
include linkages between medical faculties and modern biotechnology research, as well as the
expectation of extraordinary economic profits in the long run, initially led to the establishment
of modem biotechnology in the pharmaceutical sector, which has continued to grow and is
by far the most successful, especially in the industrialized countries.
The relative successes and failures of companies and public sector holdings in
developing capabilities in biotechnology and translating generic research into commercial
products, were however different in different parts of the world. As we will see in the two
chapters which follow, there are significant differences especially between industrialized and
developing countries for a number of reasons, including technology gaps, infrastructure
requirements, credit access and relationships between the centres for generic research and
commercial ventures. Researchers and companies in developing and industrialized countries
have therefore had to overcome very different problems in order to achieve their successes.
In the next two chapters, we describe the environment and infrastructure for
biotechnology research and commercialization in industrialized and then in developing
countries. The aim of the two chapters is to provide an overview of biotechnology R&D and
patterns of invention and innovation in these two groups of countries, in order to ascertain
what the basic requirements are to facilitate the successful diffusion of this technology. The
relationships between the invention of higher quality products, and the demand for greater
variety, or alternatively higher quality, will also be examined. An interesting issue here
would be the relationship between the diffusion of higher quality products and the impact on
variety. A greater rate of diffusion in terms of increasing market share of the higher quality
product, would necessarily reduce the market share of the older qualities, thus implying that
a faster rate of diffusion would destroy variety. The conclusions may provide guidelines for
government policy and the development of an environment which would facilitate both
innovation and diffusion nationwide.
473. From Human Insulin to the
Oncomouse: Patterns of
Innovation in the Triad
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Introduction
The establishment of biotechnology as a new technology has taken place most rapidly in the
countries of the triad, North America, Europe and Japan. Early recognition of the potential
of this technology, by the government who developed policy guidelines enabling its diffusion,
by public sector research institutions and universities and by the private sector whose funding
of basic research led the way in investment in new biotechnologies, is the main reason for
the large technology gap that has developed between this group of countries and the rest of
the world.
Implicit recognition of this technology came in the late 1970s and early 1980s in most
of these countries, when the government established either guidelines or policy frameworks
for the development of biotechnology. University-industrial collaboration as described in the
previous chapter was also instrumental during this period and led to many of the key
discoveries made during this period which established biotechnology.
In an attempt to understand some of the basic needs of a new science based
technology such as biotechnology, this chapter and the next are devoted to outlining the basic
patterns of development in industrialized (this chapter) and developing (next chapter)
countries. From the point of view of this study, which examines the impact of new
technologies on economic growth, technology gaps and trade, it is important to establish the
interactions between sectors, institutions and the role played by basic scientific knowledge in
developing technological capability. Institutional arrangements such as the scope of
intellectual property rights are also important, especially for issues such as innovation and
imitation, and may therefore relate directly to the technology gap in many cases.
In this chapter therefore, we look specifically at the countries of the triad and examine
the patterns of development of biotechnology, looking especially at government policy and
the interplay between industry and basic research in developing both generic scientific
knowledge and also commercial products. The significance of these relationships will be
expanded upon more theoretically in chapters 8 and 9 below, where we develop a growth and
trade model, based on observations about the patterns of innovation from these chapters on
biotechnology.
493.1. Biotechnology Policies and Industrial Research in Industrialized
Countries
The late 1970s and especially the early 1980s appear to have brought with them many
changes relating to issues of competitiveness and technological leadership. The challenge to
Europe and to the US was especially strong from Japan and the Newly Industrializing
Economies of East Asia. The rapid development of the electronics industry in Asia was a
further demonstration of the potential of this latter group to narrow the technology gap
between themselves and the industrialized countries*'. Technological targeting therefore
became the norm rather than the exception during this period.
Most industrialized countries established government policy frameworks during this
period, with an aim to improving international competitiveness in biotechnology. The then
Federal Republic of Germany has the distinction of being the first country to launch a
concerted national effort in biotechnology. Established in 1972, the German Le«fun£5/?/an,
focuses on traditional German strength, namely industrial biotechnology, primarily
bioprocessing technologies, although a considerable amount of funding is also provided by
the Ministry of Agriculture, for agricultural biotechnology**. The National Research Centre
for Biotechnology was founded in 1974 and the initial government strategy was strengthened
in 1984 with a broad framework outlining national priorities and objectives in biotechnology,
including the following:
1. To enable top scientific performance through the proper allocation of political and financial
resources
2. To foster industrial innovation
3. To promote R&D in the field of health
4. To evaluate risks associated with new techniques and to adopt safety regulations
5. To increase the pool of R&D professionals through the support of young scientists, and
6. To encourage international cooperation and technology transfer*'.
Downstream biotechnology in Germany has been dominated by the large companies
such as Hoechst, Schering, Boehringer Mannheim, Bayer and BASF, building upon and
exploiting their expertise in industrial biotechnology related techniques. Close linkages
between the large chemical and pharmaceutical companies and universities have greatly aided
in strengthening both generic and applied research in biotechnology. An important component
of these contractual arrangements was training. Schering for example, made arrangements
with universities in Berlin to train its scientists during the 1980s. Where there were
weaknesses in basic research at German universities, companies used the option of moving
further afield, notably to the USA. Examples of this include Hoechst's contract in the 1980s
with Massachusetts General Hospital, to train its scientists in medical biotechnologies, and
" Daly, 1985, p 59.
" OECD (1988), pp 21-22.
" US OTA (1991), p 233.
30Schering's contract with Genex, one of the more successful venture capital companies in the
USA, to expand its basic research capacity. As a result of some of these linkages, Germany
has recorded greater successes over the years in Pharmaceuticals, although its traditional
strength still lies in fermentation and bioprocess technologies**.
French expertise in biotechnology is based mainly in Pharmaceuticals and in the food
industry. As with Germany, there are a few large multinational firms which dominate the
commercial biotechnology business, such as Rhone-Poulenc and Elf Aquitaine. Rhone-
Poulenc has recently formed a company, Bio-Avenir, a collaborative research venture with
public sector research institutions to provide a boost to the research network in France. The
programme which initially has a duration of five years was started in 1991 and is supported
by a budget of FFr 1.61 billion (about US $ 295 million) of which government support
amounts to about FFr 610 million (about US $ 115 million)*'.
Despite this however, the establishment of biotechnology in France has been facilitated
and led largely by the French government. The Programme Mo^i'/isaf ear's aim is to provide
seed money for R&D research™. Unlike in Germany, where traditional research strength lies
in the universities, in France the public research institutions have received much of the
government's financing intended for biotechnology research. The programme, established in
1982, provides seed money especially in two areas of priority research: development of new
diagnostics and vaccines especially an AIDS vaccine, and the development of expertise in
agri-food biotechnology". Since 1985 however, when French government funding peaked,
low levels of funding especially when compared to other European countries with similar
programmes in biotechnology, has led to a degree of weakness in the French programme".
This is also the case in Britain, where following the publication of the Spinks Report
in 1980, the government was initially mobilized into action. It increased funding to the
research councils, specifically for biotechnology research and training and began a number
of initiatives to bring public and private sector together to do both basic as well as applied
research".
Since then however, British universities have faced major staffing and budgetary cuts,
as government funding dried up in the early 1980s. Although there is some private sector
funding in terms of contract research, it has not been sufficient to compensate the loss of
these government cutbacks and it is likely that Britain is falling behind a number of other
European countries in basic research. As with France, Britain's major weakness lies in
developing and strengthening existing relationships between generic research and the more
downstream aspects of biotechnology R&D. However, it has been argued that its long
" See Sharp (1985), Ch. 5 for details and also Orsenigo (1989).
" Ward (1993), p. 798. ,. .
'° OECD (1988), p 23.
" Ibid, p 23.
<• -.
" US OTA (1991), pp 234-5
" Sharp (1985), Ch.7. "**'••--.:^ .•.•• :•«-,-i, = ..4 . ;; -• i
,:'•••.. . '•'[ Ji •• ;•tradition in industrial research and development has helped British companies and research
based firms to overcome some of these problems'".
The controversy over the patenting of Monoclonal antibodies (MABs)", first
developed in the UK, also led the government to establish the company Celltech, in 1980,
soon after the Spinks Report. Celltech was formed by capital from the government and four
private sector entities, mainly to facilitate the transfer of technologies, especially genetic
engineering, from the public sector so that they could be developed further and
commercialized. Today, it is a leading company in state of the art biotechnology research and
has formed strategic alliances with a number of established companies, both for research and
for marketing purposes'*. Britain also has a far better developed venture capital market than
most other European countries, and although Celltech was a creation of the British
government, the strengthening of the venture capital market is already producing results
(Bio/Technology, April 1994).
The absence of the small firm in Europe stands out in strong contrast to biotechnology
in the US where biotech R&D was led by the small venture capital firm. In Germany the
first private venture capital fund was set up in 1983 and although a few firms have appeared,
equity market restrictions and a tradition which favours links between academia and the large
company", appears to have been opposed to such developments. Similarly, France does not
have a well developed venture capital market and although there are a number of small scale
biotechnology firms in the country, they tend to be offshoots of the large established
companies. Britain on the other hand appears to have been more successful of late in
encouraging investment in small scale firms. According to a recent survey, the UK now has
166 biotechnology startups, in biopharmaceuticals, diagnostics and ag-biotech. These
companies it is estimated, will double their total turnover by 1996, making takeovers,
especially by the large companies more likely™.
In the United States, although there are no specific policy guidelines on biotechnology
as in many European countries, the government performs a central role in defining and
creating an environment which is conducive to private sector R&D in biotechnology. United
States federal funding remains the largest in the world in absolute terms, although as a
percentage of GDP, it has dropped". There are indications that overall government funding,
including the activities of the National Institutes of Health (NIH), National Science
Foundation (NSF), the Environmental Protection Agency (EPA), the National Institute of
™ US OTA (1991), p 80
" Monoclonal Antibodies (MABs) were never patented because of the failure of the British
National Research and Development Corporation to recognize the potential of this technique and to
file on behalf of the inventors. Subsequently, a number of key innovations following from the initial
technique were patented by researchers in the US (Fransman, 1991, p 16).
™ Fransman, M. (1991), p 35.
" Sharp (1985), 65 - • '-• " v."-... .-• V.. ; -^;:" V^..
"-•"••." Ward (1993), p 230. - •-,"-':-;•'"... •^;-.-.-'\ c->t', qq -jv^. .AT i ;•-'I *
" US OTA, 1991, p 21-23. .; ;^; .c^i ;r«feii «Science and Technology (NIST) and the Departments of Energy and Agriculture, is slated to
increase by roughly 4 percent in the 1995 R&D budget. The enormous human genome
project is one such example where the NIH is estimated to receive and spend about US $ 152
million in fiscal year 1995, an increase of 18 percent over the previous year*". This tradition
of federal funding has meant that the development of basic biotechnology R&D has been
fastest in the US.
However, where the US stands out among the industrialized countries, is in the
linkages between private and public sectors and in the market structure of biotechnology
R&D. Unlike many European countries, the early linkages between private companies and
universities through research grants, led to the formation of the specialised biotechnology
firm, which had all the advantages of a strong background in basic research (since many were
formed by university researchers), combined with an emphasis on applied research and
commercialisation. In Europe, although linkages between large private sector companies and
universities followed a pattern similar to that established in the US, there were two reasons
why the US has been more successful at commercialization of biotechnology: (i) firstly, in
the US, these linkages were developed relatively early on in time, giving US companies a
headstart in building up linkages between basic research skills and empirical research; and (ii)
secondly, the structure of university contract research which was more accessible to academics
in the US than in Europe, because of the close relationship which developed between
university and industry during the early 1970s*'. This gives both companies as well as
researchers the freedom to excercise their entrepreneurial tendencies, unlike in Europe where
this is a relatively recent phenomena.
Private sector linkages with universities and research institutions have a long tradition
in the US and much of the present biotechnology research infrastructure is based upon this
tradition". Sharp (1985) argues that this tradition was further strengthened by the presence
of a venture capital market willing to take on high risks in the short run. This supplementary
funding which was used by a number of small companies, before eventually going public
proved extremely useful in the beginning, especially in the pharmaceutical sector where it is
estimated that the development of a new drug takes on average, 10 years and costs anywhere
between US $ 100 to US $ 150 million*".
Japan has perhaps been the most successful in overcoming some of its traditional
weaknesses, notably in Pharmaceuticals and its intellectual base. Its traditional strengths lie
in fermentation and food preservation. Like in the European countries, biotechnology
*° Bio/Technology (March 1994), p 222
" Sharp, 1985, pp 42-3.
** For example, medical research especially targeted toward special topics or issues, such as
cancer research in the USA have a long tradition of both government as well as private funding.
Sharp (1985) and especially Kenney (1986), provide excellent analyses of the changing role of
University-Industrial Cooperation in the USA. Sharp (1990) also discusses the strengths of the US
research infrastructure over that of other countries, especially through the development of the small
firm.
" Correa (1991), p. 7 referred to in Reid etal. (1993)
53research and development in Japan is led by the large industrial houses and corporations.
Unlike these countries and the US however, Japan does not have a tradition of strong
university research in the life sciences", and has had to catch up in rDNA based
technologies. While in the US and to a lesser extent in Europe, companies and universities
had stepped up their efforts to make breakthroughs in biological research, Japan by the end
of the 1970s lagged some 5-6 years behind the US". Japan has therefore had to catch up
with Europe and the US especially in areas such as rDNA and cell fusion where it has been
particularly weak. This has been done largely through training, mainly in the US and through
the formation of mergers and strategic alliances with European and American companies.
According to the US Office of Technology Assessment, between 1982 and 1989, some 266
deals were signed between US biotechnology companies and research institutions and
Japanese Companies**. Japanese companies have also made their mark in the US capital
market by signing 12 equity arrangements during the same period, many of them specifically
for marketing in Japan.
The Government effort to develop biotechnology has been led by the Ministry of
Trade and Industry (MITI), whose role has been important in the shaping of the structure of
industry in post-war Japan*'. Others include the Science and Technology Agency, and the
Ministries of Agriculture, Health and the Environment. MITI has also been instrumental in
setting up and supporting the Protein Engineering Research Institute (PERI) which was
established in 1986**. Thus through a combination of investment and strong policy
guidance, the latter especially from MITI, combined with a private sector willing to invest in
new technologies to overcome its traditional weaknesses, Japan has been able to catch up with
most other European countries and overtake some. This is also evident from patent data,
which we examine in the next section.
* Thus while most industrialized countries in Europe, North America and Japan have
set up national programmes to encourage research and development in biotechnology, they
have all had varying degrees of success. The major causes of this appear to be industrial
strength, regulations and government funding to support basic research. In Europe for
example, the strongest country Germany, has had a strong national programme on
biotechnology which has focused national biotechnology research on particular aspects of
biotechnology. However, it has also been fortunate in that its intellectual and industrial
strength has enabled German biotechnologists to not only improve basic research facilities and
training of young researchers, but there has also been a translation of these efforts into
commercial output by industry. France, on a smaller scale has also been able to use its
strengths especially in immunology, using the skills of basic research institutions such as the
" Sharp (1985), p 41.
" Ibid, p 49. «'-'' v -,,;i? "
«" US OTA (1991), pp 59-60.
" See for example Johnson (1984) or Okimoto (1982) for a discussion of the role played by MITI
in the development of industry in Japan.
" OECD (1988), p 23. . V^: ; *S«^ M -?,. -^ V .:;,;.••»-^; s^.O *
:• ...••, . . - #••' - - . .Institut Pasteur, while relying on large industrial companies such as Rh6ne Poulenc to
commercialize.
Britain, especially the basic research sector has faced a decline in government
spending on biotechnology related generic research. The emergence of private companies in
the country may help to some extent in overcoming this funding bottleneck, however, private
sector research tends to be more applied, and support for training is low, unless related to
specific research projects. Unless universities and basic research organizations can find funds
outside of government sources, in the long run, a decline in basic research may severely
hamper the future of applied research and training.
Outside of Europe, Japan and the USA have both relied on a combination of
government policy and funding, and the private sector to encourage biotechnology R&D.
Japan's traditional weakness in its natural science base meant that the government had to
provide a stronger push to industry to invest in generic research and training as well as
commercial development of products in Japan's areas of traditional strength, especially
bioprocessing. In the USA, the phenomenal rise of the NBTFs was already discussed to some
extent in the previous chapter. This, combined with traditional strengths in basic research,
both at universities as well as national programme such as cancer research, not only provided
a framework for research priorities but also enabled the government to strengthen these
traditional areas, by funding basic research. These initial injections of money are paying off
today, in the form of a highly developed pharmaceutical sector greatly aided by biotechnology
research, a growing agro-biotech sector and projects which will earn US scientists and
industry international recognition such as the human genome project. . ..
3.2. Rates of Innovation: Some Evidence from Patenting Data
Having isolated some of the characteristics of and strengths and weaknesses of biotechnology
programmes in various countries, what can we say about the specific products and inventions
that are generated as a result of these programmes. As pointed out earlier (see chapter two
above), it is difficult to measure the degree of innovativeness by using input indicators such
as R&D funding, which are not only difficult to obtain for most countries, but are often
misleading because they may not reflect private sector investment adequately. Given the
primary role played by the private sector in applied biotechnology research, this would most
surely be a biased estimate.
Output indicators such as patents on the other hand, are also problematic and for
biotechnology, the categories are not very clearly defined*'. This may lead to double
counting in some cases, especially if a disaggregated approach is taken. In a detailed study
some years ago for example (Marstrand, 1981), some of the author's results tended to be
biased because of this problem of double counting (Marstrand 1981, Wheale and McNally
1986, and OECD 1982). Despite these problems however, and keeping them in mind, we
" Biotechnology patents are found in over 20 classes, spread out over 4 sections in the
International Patent Classification published by the World Intellectual Property Organization (WIPO),
which serves as a guide to most major patent systems across the world (Wheale and McNally, 1986,
p. 640).
55look briefly in this section at two sets of international patent data: data from the US Patent
Office and from the European Patent Office on biotechnology and examine the impact they
may have on the future development of biotechnology.
The data on US patents refers only to patents granted by the US patent office, between
the years 1962 and 1991, whereas the European data available, relate to the shorter time
period of December 1978 to August 1993 in the case of filing, and from 1980 to August 1993
for patents granted.
As is evident from table 3.1 below, which shows patents granted for biotechnology
products from 1965 to 1991, (category 435 includes genetic engineering, enzymes,
immobilized enzymes, tissue culture and amino acid based technologies and products and 424
measures drugs and bio treating compositions which include both second generation and
modern biotechnology based drugs'"), there appears to have been a sharp increase, between
1970 and 1975, followed by a decline during the early 1980s (fluctuations from year to year
can partly be attributed to the number of personnel employed at the patent office and whether
they are able to analyse each application adequately in a given period of time"), followed
by a steady increase in patents granted during the latter half of the 1980s. Between 1988 and
1989 especially there was a large increase in these figures. The figures for 1991 are
significantly lower than those for earlier years, because they are partial year figures.
Table 3.1. US Patents Granted for Biotechnology
(Categories 435 and 424)'
Year 65 70 75 80 82 83 84 85 86 87 88 89 90 91
Catcg
435 103 138 368 391 421 377 364 376 453 634 655 840 858 902
424 131 163 333 346 409 305 463 452 439 580 619 948 890 1000
TOT 234 301 701 737 830 682 827 828 892 1214 1234 1788 1748 1902
• Categories 435 and 424 are broad cluster classifications which include a wide range of secondary
biotechnologies as well as genetic engineering.
Source: US Patent Statistics, US Patent Office 1993
Similarly in the case of the European patent office we see an increase in total
biotechnology patents granted from 191 to 4,619 between 1980 and 1991 (table 3.2 below),
while the total number of applications rose from 1,204 to 10,368 in the period 1978-1991
(usually it is estimated that European office patent statistics tend to be underrepresentative of
international patents until 1986 or 1987. This and the fact that these statistics only continue
until august 1993, make the earlier years and 1993 figures rather unreliable).
" US Department of Commerce/Patent and Trademark Office (1986). The use of such a broad
spectrum of technologies, ensures that we measure both patenting activity in modern biotechnology
based techniques, but also in products, most of which relate to new drug manufacture.
" US OTAF (1982), p. 10. See also the paper by Wheale and McNally (1986), p. 644.
56Patents granted by the European Patent Office, show that approximately 50 percent
of patents filed seem to be granted for Japan and for France and Britain. There is an
estimated time lag of 2 years (Bio/Technology, April 1994), between the filing of a patent and
the patent being granted or rejected, so for example, in the case of Japan, out of 1811 and
2021 patents filed in 1989 and 1990 respectively, 997 and 1168 were granted. For the US,

































































































TOT 191 1079 1579 2355 2866 3198 3498 3067 3178 3917 4252 5025 5597 6299
Source: European Patent Office, 1994
Table 3 J. European Patent Applications''
(1978 to 1993)



































































































* Here we refer to the following categories (A01G, A01H, A01K, A01N, A23L, A23K, A61K, A61L, A61M,
B65B, C07C, C07D, C07H, C07K, C08J, C12K, C12M, C12N, C12P, C12Q, and G01N) which include both
secondary biotechnologies relating to medicine and agriculture and genetic engineering.
Source: European Patent Office, 1993
In addition, we can also see, that in terms of absolute levels, Japan appears to be catching up
with Europe and has even overtaken both Britian and France and is approximately at the same
level as Germany. This is especially evident from the data in table 3.2. below. The data for
1993 in figure 3.3. below are partial year figures, which is why they appear to be significantly
lower than those for the years before.
57In the case of patents granted by the US Patent Office, we see again, a sharp increase
in patents granted during the latter half of the 1980s. We also see that Japan has surpassed
all the European countries surveyed and is only second to the USA. The dominance of the
USA may in part be due to the first to invent standard in the US versus the first to file
standard in Europe and Japan. However, although this may explain the stronger showing of
the US, it still does not explain the stronger performance of Japan over Germany, the pattern
of which is somewhat different in the EPO's statistics. There may however be a tendency
for a European preference to apply first for a patent at the European Patent Office or a
Japanese preference to apply at the US Patent Office. Nevertheless, both sets of data do show
the success of Japan in catching up with European countries and coming close to challenge
the USA in terms of patents filed and granted in biotechnology.
Table 3.4. US Patents Granted for Biotechnology
(Categories 435 and 424 for selected Countries)'
Year 65 70 75 80 82 83 84 85 86 87 88 89 90 91
US 177 217 412 430 514 413 537 528 598 830 856 1222 1167 1298
50 41 52 46 37 51 68 93 79 95
63 53 63 60 63 82 89 135 120 108
44 40 31 33 32 48 61 83 76 81
143 128 133 152 159 179 183 237 276 287
Source: US Patent Statistics
* • Thus as expected, in general, the US tends to be the leader both in the European
statistics as well as for patents registered and granted by the US patent office. In Europe,
Germany, also as expected, is the leading innovator in the field of secondary and rDNA based
biotechnologies. However, in both sets of statistics it is also apparent that the greatest degree
of catching up has been achieved by Japan. Beginning with the lowest number of patents
granted by the European patent office along with the UK in 1980, Japan has overtaken both
the UK and France and for the last few years has even been granted a larger number of
patents than Germany. A similar trend is observable in the US patent office's statistics,
although the number of patents granted to Japan has been consistently higher than those
granted to any of the European countries surveyed". Thus in terms of closing technology
gaps, from ./jgnre 5.2. below, Japan's catching up especially in the pharmaceutical sector
where its traditional weakness" lies has been especially notable (see also tables 3.2., 3.3.
and 3.4. above).





















** This may be due to a European preference to apply first for a patent at the European Patent
Office, or a Japanese preference to apply first to the US, rather than any inherent bias at the US Patent
Office. This in itself is an interesting topic, but not particularly relevant to the present discussion.
We therefore will not refer to this any further, only alluding to the possibility here.
" Sharp, M. (1985). ..-• : ' = o•• :.
•• .'• . ' ' - •'. ,"•= • 58These are the general trends. A closer sectoral examination, also provides a
preliminary measure of specialisation in these countries. The largest sector as indicated by
the number of patent applications and patents granted each year appears to be pharmaceutical
and medical biotechnologies. Table 3.5. below, shows the trends in this sector as indicated
by patents granted for these technologies to those countries surveyed. We have used patent
data from the European patent office (classifications A61K, C07C, C07D, C07H, C07K,
C12N, C12P, C12Q and GO IN, which appear to cover most of the patents filed within this
broad sector). The large increase in patents both filed and granted appears to support our
earlier claim that because of the close linkages between medical research and modern
biotechnologies, the sector affected earliest has been the pharmaceutical sector. Once again,
the USA and Germany dominate, with the Japanese demonstrating their success in catching
up. France also has done fairly well, especially in the most recent years, relating well to the
earlier discussion of the French emphasis on medical biotechnologies, especially through
funding of specific institutions or programmes.
Table 3.5. Pharmaceutical and Medical Biotechnologies Granted by the RPO
(Granted 1980-1992)
Year 80 81 82 83 84 85 86 87 88 89 90 91 92 93
437 448 534 464 458 576 674 756 1037 1148
143 164 165 123 132 134 170 216 262 256
556 519 517 423 455 486 555 579 691 794
165 184 168 156 145 168 206 198 320 357
272 292 347 293 300 383 479 632 754 878
TOT 158 812 1199 1649 1875 1978 2059 1752 1802 2179 2512 2927 3714 4132
Source: European Patent Office, 1994 ^-,^
Agriculture still tends to lag behind but appears to be making significant gains on
the pharmaceutical industry in recent years, especially in the US (The classes we have used
here include A01G, A01H, A01K and A01N which appear to cover most patents filed by
companies active in agricultural biotechnology). Table 3.6. shows that Germany and the US
tend to dominate with Japan and to some extent, France following close behind. Patents
granted to Germany however appear to have fluctuated quite sharply, declining considerably
during the latter half of the 1980s and rising again in the early 1990s. This may in part be
due to the changing laws regarding the release of genetically engineered organisms into the
environment, over which there has been considerable discussion in Germany.
The aggregate figures in table 3.6. show a considerable increase in agriculture
patents granted in the late 1980s and early 1990s. This gain appears to be largely the result




































































































































Source: European Patent Office 1994
Thus a preliminary look at patent data, both in the US and in Europe, shows a
rising rate of patents granted, but especially of patent applications. While the US leads in
both categories, Germany and especially Japan, have demonstrated considerable catching up
abilities. The main difference between these two countries is that while German companies
have traditionally been strong in secondary biotechnologies, as is evident from the slower rate
of change in patents granted to German applicants and their high levels, Japanese applications
began from low levels and have had high growth rates. This appears to support earlier
observations about strengths and weaknesses of biotechnology in both countries and the
success of Japan in overcoming its initial weaknesses through forming strategic alliances with
foreign universities and companies.
5.2.7. A/eayurm^ /fates o///mtariort and /nnovarion
A lack of more precise data about input indicators such as basic and applied research
expenditure for many new technologies, as well as figures on sales of new products, has often
led to a reliance on patent statistics as measures of the impact of a new technology on the
economy (Wheale and McNally, 1986). Because biotechnology is a new technology,
biotechnology based products are only now beginning to appear on the market, while many
others are still in the pipeline, waiting for approval from health authorities, or awaiting the
results of field testing, before they can be put into production and offered on the market
Precise data on all these various stages is scanty and its use would therefore probably lead
to large biases in any analysis. Patent data is often perceived as providing information of an
intermediate kind, straddling both basic research as well as the final stage of product
development. Its use as a measure of the degree of innovativeness in a sector or of a
technology should however be viewed with caution, especially in sectors such as
Pharmaceuticals and techniques such as genetic engineering, where considerable lags may
exist before a patented product (an invention), moves to the stage of becoming a product
available to consumers (an innovation).
For our purposes, we use the patent data set described above, to calculate growth
rates of patents granted, which can be used as a proxy for the degree of inventiveness in the
60biotechnology R&D sector. As explained below, this approximation will be used in the model
developed in chapters 8 and 9.
In the case of European patents granted (see table 3.2. above), growth rates were
first taken over 13 years for which statistics were collected (1981-1993). Incomplete data for
1981 and for 1993 however reduced the sample size to 11 years, from 1982 to 1992. The
newness of the EPO and especially the particular difficulties associated with granting patents
for biotechnology, meant that the sample was further reduced to 7 years, from 1986, when
patents granted by the EPO are generally accepted to be more trustworthy, to 1992**.
Similarly in the case of US patents (from table 3.4. above), the first set of growth rates were
calculated for patent statistics over 28 years (1964-1991) for which data were available. The
second set of growth rates for the US patent dataset measure change over the period 1981 to
1991. The reason for using this specific period was that patents for many modern
biotechnology based inventions, especially genetically engineered products and processes,
have only been granted since the early 1980s. Since the objective of this exercise is to
determine the growth rate of modem biotechnology inventions in the USA and in Europe, the
division of the US dataset into two periods in this manner, ensures that patents granted to
older biotechnologies are not overestimated. The division also provides an estimate of
inventive activity and relative strengths and weaknesses in modern biotechnologies, as
opposed to older biotechnologies. As table 3.7. below, shows, this second set of statistics are
indeed comparable to the rates of growth registered at the EPO (10.27 percent according to
US statistics and 10.71 in Europe, averaging out to 10.487). We therefore use this as an
estimate of the rate of inventiveness in biotechnology in industrialized countries.
The growth rates, when compared across countries, with the exception of Germany,
are fairly compatible with expectations, demonstrating quite effectively relative strengths in
old and new biotechnologies. The earlier period in the US data measures growth rates of both
old and new biotechnologies, whereas the second period measures only the new technologies.
As per expectations, the US and Japan register high growth rates during the second period.
A comparison across the growth rates in Europe and in the US show that in Europe, the
growth rates of European patents, again with the exception of Germany, tend to be higher
than their growth rates in the US. This may be due to the first to invent requirement of US
patent legislation which may put foreign inventors at a disadvantage during the application
process in the US". This may also be a reason for the higher growth rates at the EPO,
although it is more likely that this is due to the shorter period of time that the EPO has been
in existence for.
** Data were also incomplete for 1993 which may have led to downward biases in total patents
granted. This year was therefore omitted as well in the latter calculation.
" Section 104 of the US patent law provides that a patent applicant cannot establish a date of
invention by referring to an activity, ie. R&D in a foreign country. This implies that the earliest date
that can be used in many such cases to establish the date of invention, is either the filing date of a
corresponding patent abroad or the date the invention was replicated in the US. (Bio/Technology, May
1994). This has recently been amended by Article 29 of the TRIPS agreement of the Uruguay Round
of Multilateral Trade Negotiations (GATT, 1994). In addition, the plant variety protection act in the
US also stipulates that the filing of a certificate in the US cannot take place more than one year after
the patent was filed in a foreign country (Bent et.al. (1987)).
61Table 3.7. Percentage Growth Rates of Patents Granted by Country






































Source: Calculated from EPO and US Patent Data.
The general tendency in both sets of statistics for the US to be the leader is also
as expected, as is the growth rate of Japanese patents. Germany however is an outlier as is
the UK with its high growth rates of patents granted, especially in the US. However, the
latter may also be attributed to the close ties between the US and the UK, especially during
the 1980s, when both countries were establishing their "special relationship" with each other.
Germany's weak performance however is only in growth rates and not in levels,
demonstrating an initial strength in secondary biotechnologies. The fact that the growth rate
of its patents is rather low may also be an indication of closeness to the technological frontier,
i.e. a high level of technological capability. Another reason for low growth rates may be due
to the fact that there is some truth in the arguments of biotechnologists that the country's
strict laws regarding genetic engineering may be stifling biotechnology activities by its firms
(Bio/Technology, May 1994, pp 441-442) by preventing the handling of genetically
engineered materials for research. However, this argument relates more to release of
genetically engineered products into the atmosphere and therefore would be expected at a later
stage, after the patent has been granted.
The growth rates measured above were calculated discretely, on a yearly basis for
each country. In order to avoid any potential problems related to fluctuations because of
patent office activity from year to year, as mentioned above, the growth rates were also
calculated over both time periods in both the case of the US Patent Office and for the EPO,
using a log linear time series regression, lnK = o^ +a,lnX, +w, where a, measures the slope
or the growth rate of the function over time. The results are presented in table 3.8. below.
As is evident when comparing the two tables, the use of logs has greatly reduced
the difference between the two sets of time periods for which data were examined. The
average in the second case across countries is also different now from the earlier case. In thecase of the US Patent Office this average is more or less the same at 10.6 percent during the
1964-1991 period and 10.47 percent for the 1981-1991 period whereas for the European
Patent Office equivalent figures are 7.61 percent in 1982-1992 and 9.01 percent in the later
period, from 1986-1992. Despite this difference however, the discrepancy is not that great,
and we would conclude that the annual growth rate of patents or innovation, is in the area of
9 or 10 percent in both cases.
Table 3.8. Growth Rates of Patents Granted by Country







































Source: Calculated from Patent Data from the European Patent Office and the US Patent
Office __ . . .^... , .|-,.-. • ., .. . -. . ... ..,,.. ,-*?-•
The estimated growth rates of patents granted during the 1980s by the EPO and the
US patent office, should however, be viewed with some caution for the following reasons:
1. Firstly, there are considerable differences, not only in the manner in which patents are
granted**, but also in the categories under which biotechnology patents are granted.
2. Secondly, there are still major differences between the US and the EPO in what can and
cannot be patented. The most major difference between the two in relation to biotechnology
is that while patenting of plant and animal varieties which are genetically engineered are not
** For example, the US has a first to invent policy whereas the EPO uses a first to file policy to
assess patents. In the US, it has been argued, this creates considerable lags because of the amount of
research that has to be carried out to determine who invented first.allowed within the framework of the EPO", the US allows the patenting of such species.
This also causes some discrepencies in the data used above.
For these two reasons, there are considerable differences between US and EPO
patent statistics in biotechnology and it is for this reason that we have used both. However,
these arguments relate mostly to levels of patenting, and may not have much of an impact on
growth rates in both set of data. Nevertheless, in calculating growth rates, we have used an
average of both sets of growth rates, to serve as a measure of the rate of annual biotechnology
inventions in industrialized nations. We do not have similar statistics for developing countries
and so have to use another proxy which is discussed in the following chapter.
5.2.2 77H? /tofe o/Size zn B/otec/ino/ogy
As biotechnologies become well established, especially as is the case in Pharmaceuticals and
now in agriculture and agro-industry, there appear to be two major changes taking place.
First, as we have already mentioned, there were a large number of takeovers especially of the
small NBTFs by large multinationals in the 1980s. The Hoffman LaRoche-Genentech merger
in 1990 created a stir in biotechnology circles and observers predicted an increase in such
takeovers as the success of the small companies tempted the large companies, who until then
had refrained from investing as heavily in biotechnology, into entering the marker'*. The
easiest and most expeditious way to do this was to merge with or takeover the smaller
companies. Although takeovers and mergers have increased since that time, most of them
appear to have taken place between the smaller NBTFs rather than solely between the large
companies and the NBTFs (see table 3.1. above). Nevertheless, it appears that the large
chemical and pharmaceutical giants have become more heavily involved in biotechnology
R&D in the 1990s than in the last decade. In an attempt to quantify the increased rate of
participation by the large firm in biotechnology R&D, as compared to the small biotechnology
specific firms, we looked at patent data from the European patent office.
We took the 30 largest chemical and pharmaceutical companies (by total company
sales in fiscal year 1992) as well as the top 25 NBTFs (only 25 NBTFs had been granted
patents at the EPO in the dataset used), active in the pharmaceutical sector, (see appendix I
below for a list of these companies). Patent statistics from the patent office for the
pharmaceutical categories mentioned above were obtained and group averages during the
period 1978 - 1992, in the case of applications and the period 1980 - 1993 in the case of
patents granted, were taken. The samples were reduced to 15 as a number of the large
companies registered patents below 3 and in some cases, zero patents over the period
surveyed. The results are shown in/i£Mre.r 3.7. a/id" 3.5. for applications and 3.2. and 3.4. for
patents granted, below. The decline in the 1992-93 period is due to partial year figures on
patents and cannot be therefore attributed to a declining trend in applications or patents
granted.
" As mentioned above, the major exception here is the oncomouse, which was first rejected in
Europe, then patented in the US and finally patented in Europe, despite its laws against patenting
animals, because it was deemed that the suffering caused to the mice which are used in cancer
research, was more than compensated for by the benefits to human beings.
" US OTA, 1991, p 54.
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Figure 3.1 European Patent Applications
Av. of Top 15 Corps and NBTFs 1978-91
1978 1980 1982 1984 1986
Year
1988 1990
-•- Corporations -•— NBTFs
The figures show constant growth, with minor annual differences in applications (#£wre 5.7.)
especially for the top 15 firms, while for patents granted, the Corporations had tended to
dominate but there was slow catching up by the NBTFs in terms of patents granted (/Jgnre
5.2.), showing perhaps an increasing importance of small size. In the last year in fact it looks
as though the NBTF has overtaken the large company.
In the case of the largest 6 companies and NBTFs, both for applications (##«re
5.5.) and for patents granted (/igwre 5.4.), the small firm has dominated especially since the
mid 1980s (for patent applications, which given the estimated time lag of 2 years before
patents are granted, fits well with ,/IgHre 5.4. in which patents granted to small companies
overtook patents granted to corporations beginning in 1987). The early 1990s have shown
an even greater tendency for small firms to dominate.
Thus from an initial analysis of patent data, there does not appear to be an
indication that size is becoming increasingly important with respect to biotechnology R&D.
In fact, it appears that in some cases, smaller firms have been more successful at innovating,
indicating a tendency toward small companies. The fact however that the top 6 NBTFs show
a stronger performance in patenting than the top 15, demonstrates that size is important to
some degree, but that it is a combination of size, skill, and research base, rather than just size
which is important for consolidation in biotechnology R&D.
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Figure 3.2. European Patents Granted
Av. of Top 15 Corps and NBTFs 1980-92
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-•- Corporations -•— NBTFs
Figure 3.3 European Patent Applications
Av. of Top 6 Corps and NBTFs 1978-91
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Second, as the industrial development of biotechnology accelerates, a number of researchers
have pointed to increasing economies of scale. Fransman (1991), shows from data released
by Celltech, that the cost of production declines significantly after batch yields rise above 100
grammes". Although this in itself does not point to significant economies of scale, it does
imply that there is some point at which the cost of production declines. Given that the initial
investment costs are still high, this implies that this cost reduction will only be achieved by
those companies that have the means to make this initial investment.
If the case is that economies of scale become more significant in time, then the
implications for developing countries are, that there will be a tendency towards greater
concentration in the industries where biotechnology has made the greatest strides. Although
the observations are rather preliminary, they do appear to imply, as one would expect, that
as the industry consolidates its position, economies of scale become important. This may in
turn mean that in the longer run, the larger companies may succeed in pushing the small
companies out of the production process, pushing them either completely out of the market,
or reducing them to centres of excellence for research, relying on their patent monopolies for
further investment
While economies of scale are becoming important however, fixed costs and demand
are other important factors in determining total costs and the tendency toward larger or
smaller firms will depend greatly upon the ability of these firms to lower fixed costs. There
is some indication that the NBTFs are already beginning to react to this need. In the
beginning when they were formed, they were largely research intensive. However, the
Fransman (1991), p. 24.
67intention was to build a successful marketing and commercial network by which they could
compete with established pharmaceutical or ag-bio companies. Unfortunately, new biotech
firms never had the resources nor the years of experience which could enable.them to
compete. The one notable exception is Amgen, which has succeeded in creating a fully
integrated firm which does not require the kinds of marketing and licensing arrangements that
even the most successful NBT companies such as Genentech, have required.
Strategic alliances have been an important aspect in helping NBTF's overcome
some of their weaknesses, especially if it enables them to benefit from the complementary
research or product development experiences of other companies. The evidence therefore is
not clearly in favour of the large companies or of the NBTFs. There may be some
consolidation as scale becomes more important. However, the advantage of the small firm
came from its specialized line of research and its success in patenting new products. The
expertise developed by these firms thus demonstrated, multinationals such as Hoffman
LaRoche, although they have taken over smaller companies, have allowed them a great deal
of flexibility in designing and running their own research programmes, in recognition of this
excellence. In the future the survival of either the small firm or the large corporation in
biotechnology will depend greatly upon the ability to reduce fixed costs and to develop means
by which to reduce total costs. One way is through forming networks and strategic alliances,
a path that many NBTFs are beginning to follow.
Conclusions
In this chapter, an examination of the patterns of invention and innovation in
biotechnology in industrialized countries revealed a number of crucial elements. The presence
of a strong scientific base, especially in molecular biology, and a trained labour force is vital
especially in the initial stages when generic, pre-competitive research appears to be more
important. Although cooperative agreements were formed between universities and the
private sector, the role of the government at this stage of research was important especially
for training and funding basic research"*.
Government policies in all three groups of nations has focused on two aspects of
biotechnology related activities:
1. Broad targeting of generic, basic research in the biological sciences and medical research.
2. Building and incentive and regulatory framework for applied biotechnology R&D.
With respect to the first, the US Federal government has been the largest finance
source for basic research institutions of which the National Institutes of Health have been one
of the largest recipients. The enormous Human Genome programme is the latest in this
targeting of the enormous skills present in the USA in basic research. In contrast, on the
'°° Kenney (1986) for example provides a survey of the initial research effort in biotechnology,
especially with respect to the influential relationship which was forged between government, university
and private company, during the 1970s and led to some of the most important breakthroughs as a
result.
68 -other extreme, Japanese industry has been unable to benefit from such a resource base, as
Japanese universities have in general been unable to compete with the US or with Europe in
terms of basic research"". The involvement of the government in the form of guidance
from the Ministry of Trade and Industry (MITI) has provided much of the impetus for
overcoming some of these initial problems and Japan through this different approach is now
in a position to compete with Europe and US in modern biotechnology. European
biotechnology is dominated by a small number of large firms and its disadvantage has been
a lack of venture capital funding to encourage start ups as in the USA. Countries such as
France and Britain especially have faced difficulties in funding research because of a lesser
capability in applied research, than in Germany (Sharp, 1985).
Given the number of cooperative arrangements which were made during the 1970s
and 1980s (see Kenney, 1986), it appears that the private sector is also highly dependant upon
the skills and abilities of this scientific base. In fact many of the founders of the New
Biotechnology Firms (NBTFs) which were established in the USA, were originally university
Professors or involved in collaborative research with the public sector (Sharp 1985, Kenney
1986, Daly 1986). Thus the development of a strong base in scientific research and training
appears to be an important prerequisite, as one would expect of a science based technology
such as biotechnology.
The second conclusion we can reach is the relative importance of the private sector
in industrialized countries at the applied research stage. Their experience in production and
scale up, as well as their established sales and marketing networks have been crucial in
transforming the results of generic research into production. In fact, it is pointed out (US
OTA, 1991), that one of the inherent weaknesses of the NBTFs was a lack of development
on the production side. In other words, their research capabilities were considerable, but
many were unable to keep up with the downstream skills of the Multinationals, once the latter
had entered the biotechnology market. Strategic alliances, especially in the area of marketing
have therefore provided an important method by which the smaller firms are able to overcome
some of their weaknesses.
Finally, an important implication for entry into R&D, both for companies in
industrialized countries, as well as in developing countries, that is the allegedly growing
importance of size was also given some attention. Patenting data indicates, that although the
large corporations are still lagging behind somewhat, the rate of catch up is quite rapid. This
may in part be due to takeovers and mergers with the smaller, research intensive NBTFs.
Other evidence from industrial processing, although still rather preliminary, also points to the
fact that size may become more important as biotechnology establishes itself in economic
production sectors (see Fransman above). On the other hand, recent evidence from stock
market activities in the US and the UK (Bio/Technology, April, May 1994), indicate that there
is growing interest in funding small biotechnology companies, and that small venture capital
companies appear to be making a comeback to some extent. Although most of these
discussions tend to be rather anecdotal, the implications for size may not be as drastic as have
been suggested. In fact, as we have argued in the last section above, the earlier failures of
some small biotechnology firms may have been due to the degree of their specialization in
research. Strategic alliances, especially for downstream activities such as marketing, are being
US OTA.1991, p 155.
69used more frequently by a number of small companies and may in the long run be key to
their survival. The longer term implications for size may therefore be ambiguous"".
In the next chapter, we continue our examination of innovation patterns in
biotechnology, by looking at a different group of countries, namely developing countries. The
experiences of industrialized countries, as discussed in this chapter are compared and
contrasted with the development of biotechnology in developing countries, especially as it
may relate to rates of innovation.
"* Developing countries, as we discuss in the following section however, will still face growing
problems because of scale effects. This is also largely due to the increasing cost of entering the
market and the additional problem of scale up compounds the size of the barrier they face.
704. Biotechnology in Developing
countries: Contrasts and
Comparisons
"According to our start'srics iir, 50% o/ tfie popM/atton /ives 6e/oiv fne poverty /me in
misery and 50% afeove tfie poverty /me m utter misery"..../?. AT.
Introduction
The survey of biotechnology in industrialized countries revealed two important components
in biotechnology R&D: first government guidance through policy, as well as its funding of
basic research appears to have been important. Second, these have been combined with
private sector funding of applied R&D, leading to commercialization of products, either
through the NBTFs as in the case of the USA, or through the large established firms as in
Europe and Japan. In general however, despite differences between countries, the main trends
seem to suggest that a combination of these two components to overcome traditional
weaknesses and enhance their particular strengths in biotechnology related R&D were used.
The reason for a combination of government policies and funding especially for basic
research, rather than private sector funding which seems to be largely devoted to empirical
research, lies in the linkages between productive sectors in the economy and basic and
empirical research. In general, while basic research and training have benefited greatly from
government support, and supplemented by industry, empirical research has tended to be
largely dominated by the private sector and less so by the government. In the USA for
example, we saw that the emergence of the NBTF ensured that research shifted from a more
basic theoretical and training level, to applied product oriented research. The reasons for the
close association of the private sector with product oriented research lie in a number of
incentives such as monopoly profits from patents and the privatization of technology, as
opposed to universities where in general technology remains within the public domain"".
"" In biotechnology however, a number of patents have also been granted to universities and
public research institutions, for example, the granting of patents to universities in recent years, such
as the Cohen-Boyer patent, has led a number of other public sector institutions, to seek similar
protection, either through IPRs or through a restriction on exchange of sensitive material. The
International Agricultural Research Institutions have thus far resisted this trend (see Barton and
Siebeck, 1992). This is also partly due to a CGIAR directive which reaffirms that both genetic
material as well as patented material used by the Centres should be made freely available to all clients
although there is some evidence that this may change in the future as the availability of material even
from public institutions becomes more restricted (van Wijk, Cohen and Komen, 1993). Thus, although
universities and research institutions tend to patent proportionately less than private agents, this appears
to be rapidly changing.
71 .Another important reason for why empirical research devoted to product development
appears to be better served by the private sector (see for example Kim and Dahlman (1992))
is the private sector's close relationship to the market and to market trends and demands as
well as well established marketing networks to diffuse the new product or technology more
widely.
Government policies and frameworks, especially relating to regulation and intellectual
property regimes have also played an important role in the development of this technology
in industrialized countries. Where NBTFs did not emerge, such as in Europe and especially
in Japan, the government has often been the compensating factor in providing financing in
the form of loans or venture capital, or by developing links between research and production
through the formation of networks. In countries such as Germany and Japan where linkages
between industry and universities are strong, and there is a traditional emphasis on
downstream product oriented training and research, the success rate of diffusion has been
particularly high, while France and especially Britain have suffered because of weaker
linkages between private and public sectors especially for applied research and
commercialization.
One would expect the pattern of innovation and diffusion in developing countries to
be somewhat different for a number of reasons, most obviously, low levels of scientific and
technological capabilities both in basic research and training, and also in applications, and the
high fixed costs required for basic and applied biological research, both for the government
and for the private sector. In this chapter, it is the intention to examine the patterns of
development of biotechnology in developing and newly industrializing countries and to
attempt to compare and contrast their experiences with those of industrialized countries. In
the first section, we present a general discussion of biotechnology in a number of developing
countries and argue that because of a lack of private commitment early on, government policy
was and still is especially important. This is followed by a more detailed sectoral and policy
related examination of six countries in south Asia. The emphasis is placed upon the role of
the government which was crucial for initiating basic research in biotechnology, and the
private sector, whose involvement in accelerating applied research is now paying off.
The final section traces conclusions and patterns of biotechnology development in
these countries, contrasted with the experiences of industrialized countries.
4.1. Biotechnology R&D in Developing Countries
In sharp contrast to the developments in industrialized countries, most developing countries
have as yet no modern industrial biotechnology. In fact most developing countries, those that
have programmes on biotechnology, still tend to concentrate on second generation
biotechnologies. Although many countries such as Brazil, Mexico, Cuba, India, and China
are funding research on rDNA based technologies, applications in these countries are still by
and large, restricted to the older biotechnologies.
Public programmes to promote biotechnology were established in most of these
countries in the mid to late 1980s. However, even though these came close on the heels of
similar programmes established in the early 1980s in Japan and Europe, biotechnology
research has not progressed as rapidly in the developing countries. There are a variety ofreasons for this, the most important perhaps being a lack of funding for both basic and
applied research, weak linkages between basic and applied research and also a variety of
restrictions on trade and capital investment, both of which have played important roles in the
transfer of knowledge and capital equipment in industrialized countries.
The notable exceptions among developing countries are the countries we know as the
Newly Industrializing Countries (NICs), not just the four tigers, but also other countries in
south-east Asia '°\ such as Indonesia and Malaysia, which have made rapid strides in
developing a capability in the new biotechnologies by establishing multiple centres of
excellence (Komen and Persley, 1993). According to the US Office of Technology
Assessment (henceforth, US OTA), Taiwan, of all these countries is perhaps the best placed
in terms of its research potential as well as the amount of investment capital available to it
"". However, Korea and Singapore have also made important investments in the US
market, which both countries are using to transfer knowledge and technology back to the
home countries. Their weakness, as with Taiwan, lies in a shortage of trained technical staff
and training programmes at home.
The second tier of developing countries who are making some progress in
biotechnology research, are those who have developed some capability in scientific research,
but who are still lagging behind the NICs, largely because of traditional bottlenecks, in
infrastructure, in economic regulations and more often than not, a lack of access to capital
markets.
In Latin America this has been the main problem despite the fact that biotechnology
policies were implemented in the early 1980s shortly after a number of industrialized
countries defined their national programmes.
Although government policies to develop biotechnology began in Brazil in the early
1980s with the establishment of the National Biotechnology Programme (PRONAB), in 1981,
this period marked the debt crisis in much of Latin America, and consequently PRONAB was
unable to be very effective until the mid-1980s. Most of its funding was devoted to training
and it is unclear what its impact on applied research has been "*. However, Brazil's major
difficulty appears to have been to obtain sufficient funding for its biotechnology programmes
both for training and also for basic and applied research. The main task facing the
government now, is to attract both foreign investment as well as to increase local private
participation in biotechnology projects.
Argentina has had similar problems in funding biotechnology activities. The only two
major sources are the Government, through its National Programme on Biotechnology which
was established during the late 1980s and the United Nations Development Programme
(UNDP), through its Regional Biotechnology Programme. Activities within the National
Programme include funding of projects outlined and also training. With respect to the latter,
Argentina has set up a number of undergraduate and postgraduate courses in biotechnology
related areas, ranging from agriculture, a priority area, to more specific skill related areas,
"* For a more detailed discussion of the development of biotechnology in east and south Asia
please refer to Acharya (1992b and 1993a).
"* US OTA (1991). , ? W ^tSiTt^a^ *'
"* Clark, N. and C. Juma (1991), pp 63-66. .**» ««•,
73such as gene mapping and genetic engineering. However, a lack of resources to expand and
broaden its research infrastructure has led to considerable bottlenecks, in training and also in
bridging the gap between generic research and commercial development "".
The Cuban biotechnology programme is often referred to as one of the success stories
in the region. Its successes in modern medical biotechnology follow largely from the
accomplishments of the Cuban revolution in medicine and health care, which included
developing a distribution system which made modern medicines accessible to its urban and
rural populations. The Centre for Biological Research (CIB), was established in 1982 to
develop and produce interferon as an anti-viral agent "*, and has grown to become the
country's major research laboratory. Its success in a short period of time resulted in a
recommendation by the Bio/og/ca/ Fronf, a panel consisting of scientists and policy makers
which operated outside the bureaucratic framework, to form a larger research institute, and
the Centre for Genetic Engineering and Biotechnology was formed in 1986, with a mandate
to do research on proteins and hormones, vaccines and medical diagnostics, energy and
biomass, plant breeding and engineering and the genetics of mammalian eukaryotic cells "*.
In contrast to the Cuban case, countries like India and China have been less successful
in developing downstream biotechnology, despite having the capability in basic research.
While India has a well developed infrastructure in agricultural research, largely following in
the footsteps of the green revolution, it appears to have distributed its limited resources too
thinly, across a wide range of sectors and technologies. The success of Cuba appears to
largely have come from its use of one basic product, mferferon, to enter the field of medical
biotechnology, after which attempts to broaden the biotechnology base were more successful
than in many other countries in the region.
In India, despite its traditional strengths in agricultural technologies, the Councils of
Scientific and Industrial Research (CSIR), encouraged research in a wide variety of areas,
including medical and industrial research, without much heed to downstream production.
Thus although India boasts basic research skills that can compete on an international level,
there are very few modern biotechnology based products which have emerged thus far.
Instead, much more promise seems to be shown by the less sophisticated biotechnologies,
notably tissue culture and micropropagation, where a growing interest has resulted in a sudden
increase in producers and exporters, ranging from the very small scale fanner, to the large
industrialist. . ,io?fl •• -... ;^_-
Similarly, Chinese scientists may be most effective in concentrating on biotechnology
research in areas where China has traditional strength, such as the fermentation industry.
Taiwan and South Korea both have recorded major successes in this sector and have used it
to enter the biotechnology market, initially in this sector, but have later diversified.
The last tier of countries includes the least technologically developed countries. Many
countries in Africa have only recently developed national programmes on biotechnology, and
the majority still depend only upon university research programmes for research on
Acharya, R. and J. Mugabe (1995b).
Fransman, M. (1991), p 63.
Ibid
74biotechnology whose budgets tend to be small "°. Kenya, Ethiopia and Tanzania have
specific policy documents on biotechnology, outlining national priorities and goals for this
technology. Ethiopia's National Science and Technology Plan identifies two major
technologies as priority technologies: microelectronics and biotechnology. Zimbabwe is
presently in the process of defining its Science and Technology Policy. Most of the other
countries in east and west Africa are still lagging behind these countries and depend more on
implicit Science and Technology policies defined within their national development goals, and
already established institutions, to carry out biotechnology R&D '".
Being largely agricultural countries, it is natural that most of their biotechnology
activities are agricultural as well. Animal husbandry and diagnostics and vaccines to detect
and prevent common diseases in the region are also important research activities. In
agriculture, attempts are being made to improve local varieties and their productivity, largely
through tissue culture. The crops are mainly subsistence crops which are grown
predominantly in the area, such as cassava and sweet potato and which are important for the
agricultural base in these countries, while some countries are also doing research on important
cash crops, such as pyrethrum, tea and coffee in Kenya and coffee and tobacco in Zimbabwe.
Similarly, animal biotechnology tends to concentrate on diseases common to the area. Here
research is relatively advanced because of the presence of three major international research
centres which are funded by the Consultative Group for International Agricultural Research
(CGIAR), namely the International Laboratory for Research and Animal Diseases (ILRAD),
the International Centre for Insect Physiology and Ecology (ICIPE) both based in Kenya, and
the International Livestock Research Centre for Africa (ILCA) in Ethiopia. The work done
by these centres, because it receives international funding and support from the international
research community, is far more sophisticated and includes the use of genetic mapping and
engineering techniques to develop vaccines for animal and insect diseases predominant in the
region.
The combination of low skills and low R&D investment in biotechnology, has placed
these countries at a particular disadvantage vis a vis industrialized and industrializing
countries. As the cost of developing new products declines and as the technology frontier is
pushed further outward by these latter groups of countries, the least developed countries may
be in a position to enter using lower level techniques. However, their ability to catch up or
to narrow the technological gap between themselves and the more technologically advanced
industrializing countries, will depend very much on access to information and training
programmes, and a skilful management of their scarce financial and human resources.
In agriculture thus far, where a number of developing countries have established a
research and training base, largely as a result of the research requirements of the green
revolution, the greatest use has been made of biotechnologies in these countries, ranging from
simple plant breeding techniques to the more powerful gene tagging and engineering
techniques. With few exceptions agricultural research has remained largely a domain of the
"° Acharya, R. and J. Mugabe (1995b). " • ' •;V • C -
'" Ibid.
75public sector, especially for subsistence crops and to some extent cereals "*. However, with
the rise of ag-Wo as it has come to be called, this is likely to change in a similar way, with
entry barriers to modem agricultural biotechnology also slowly becoming higher especially
for a number of developing countries who are already lagging behind.
This brief survey shows that in most developing countries, the majority of
biotechnology research appears to be influenced by policy. Government policies have pushed
biotechnology in a direction which addresses national problems of food security and health
care, especially in developing medical products for local diseases. Government activities and
funding in turn, have been dominated by basic research and training. The major problem
faced by most developing countries, including the NICs, is that of developing a steady supply
of skilled researchers who can contribute to biotechnology research. This problem is most
acute in a number of African countries where the research and training base is still very weak.
While this section has given a broad overview of some of the problems faced by
developing countries, from the point of view of this thesis however, the intention of
examining biotechnology in developing countries is to study the patterns of imitation and
innovation. A relatively more in depth analysis of biotechnology activities is therefore
needed. For reasons of practicality, six countries in the region of south and south-east Asia
were surveyed. These countries, i.e., China, India, Philippines, South Korea, Taiwan and
Thailand, present a wide range of capabilities and comparative advantage, as well as an
intermediate level of scientific and technological capacities and have demonstrated
considerable skills in biotechnology R&D, both of a basic and an applied nature.
4.2. Building Technological Capability: The Case of South-Asia
In this section, we examine research and development activities relating to biotechnology in
countries which find themselves in an intermediate position, ie. having the technological
capability for imitation, but not yet belonging to the group of countries who can be called
innovators. Although much of the research in these countries is still confined to public sector
laboratories, the private sector is slowly developing capabilities and investing in biotechnology
in a changing international environment where interactions between countries especially with
respect to the flow of goods and services, capital investment and exchange of knowledge is
becoming more liberalized. Many of them have a comparative advantage in natural resource
and agriculture based products. Biotechnology we argue will tend to enhance this comparative
advantage based on endowments. However, the ability of countries to develop their scientific
and technological capabilities will determine their ability to develop dynamic comparative
advantage and indeed change their static comparative advantage in the long run through the
acquisition and development of these new technological capabilities.
'" For example the system of Land Grant Universities and Experiment stations set up in the US
to do the more experimental, applied work required of agriculture (Evenson, R. E. (1993)). Most
developing countries have also established extensive networks of agricultural research institutions,
many of them employing a number of extension workers to diffuse new varieties into national
agricultural systems.
76This section is divided into two broad parts, covering government and private sector
activities and their contribution to basic and applied research in biotechnology. The following
section is a case study of productivity increasing technical change in agriculture and its
implications for economic welfare and growth. The final section draws some basic
conclusions on patterns of innovation and imitation in industrialized and developing countries
and their implications for consumer welfare.
4.2.7. 0/ G Po/j'cy
The lack of a large private sector has made government activities an important component of
efforts to develop national capabilities in biotechnology. This as we saw in the previous
chapter was also important especially for generic research and training in a number of
industrialized countries. In developing countries, this component tends to be all the more
important given the absence of private sector activities, especially during the early stages of
R&D. Table 4.1. provides some statistics of R&D capabilities of selected developing and
industrializing countries.











































































Source: National Science Council, Taiwan (1993), Report on the Survey of R&D in Science
and Technology, Korea (1993), Dr Tae Ik Mheen, Director Genetic Engineering Research
Institute (Personal Communication).
77For the newly industrializing countries and the more advanced developing countries such as
Taiwan and Korea, there is already evidence that overall government spending on R&D forms
a relatively high percentage of Gross National Product especially in Korea where spending
has almost reached the two percent level. Countries such as China and India, where
investment in R&D is also quite high, are however still lagging behind.Nevertheless, that
increasing importance is being placed on investment in both research and training, is clearly
evident from these positive trends both in industrialized countries, and increasingly in lagging
countries such as India and China where the number of researchers as a percentage of the
labour force is still quite low, indicating a need for a large injection of funds in this direction.
Biotechnology has also formed part of this trend in both sets of countries. As with
industrialized countries, most of the countries surveyed here, formed national programmes in
the early to late 1980s. This followed closely the pattern established in industrialized
countries, ie., national guidelines outlining priority areas of research as well as funding for
basic research and training. National programmes on biotechnology have by and large been
coordinated by national government departments or centres and laboratories of excellence.
The former, as in the case of India, Thailand, China and the Philippines, are largely semi-
autonomous public sector bodies set up for coordinating national biotechnology policies, and
disseminating funding for priority projects. These national coordinating agencies, the National
Centre for Genetic Engineering and Biotechnology (NCGEB) in Thailand, the China National
Centre for Biotechnology Development (CNCBD) in China, and the Department of
Biotechnology (DBT) in India, were all set up in the 1980s to perform the important task of
implementing national policies on biotechnology and are in charge of overseeing national
projects in priority areas. The Philippines' National Plan on biotechnology was approved in
1990 by the Science and Technology Coordinating Council (STCC), which implements and
coordinates national science and technology policies. The plan outlines a number of projects
within five priority areas of agriculture, aquaculture, health, industry and the environment.
In the case of Taiwan and Korea, the task of developing capabilities in biotechnology
have been left up to national centres of excellence. The Development Centre for
Biotechnology (DCB) in Taiwan and the Genetic Engineering Research Institute (GERI) in
Korea, not only coordinate national research projects, but are used to set a standard for
biotechnology R&D. Supplied with modern equipment and some of the most highly trained
staff in the country, these laboratories present all round excellence in modern biotechnology
R&D '".
The importance of involving the private sector, especially through cooperation with
basic research strengths, was recognized at an early stage. Most, with the possible exception
of Korea, whose previous experience with industrialization led to the formation of large
companies who were well equipped to deal with the large sums of up-front investment needed
for modern biotechnology, recognized the need for investing in applied research. Public
sector institutions, while possessing the capabilities for basic research, had in many cases very
little experience with commercialization "*. On the other hand, the relatively small size
'" Based on a survey conducted in 1991 in six Asian countries. For more details please refer to
Acharya (1993a)
"* Chandrasekhar (1993).
78of the private sector, when considering the size of investments that had to be made, made it
difficult for private companies to operate alone in many cases. This recognition has led to
efforts to try and pool the resources of these two sectors. In Korea, the Korean Genetic
Engineering Research Association (KOGERA) and in India, the Biotechnology Consortium
India Limited (BCIL) were formed to deal specifically with this task. KOGERA to date has
been relatively successful in harnessing the potential of the private sector for large national
projects, especially concerning environmental biotechnologies. The BCIL was only formed
in 1991 and it remains to be seen how successful it will be in fulfilling its task.
Other countries, rather than setting up new organizations have used a previously
established infrastructure to tackle this problem. In Taiwan for example the DCB's role is
also to encourage and improve cooperative research between national universities and research
institutions such as the Academia Sinica, and private companies, and has been instrumental
in commercializing a number of products developed at the DCB through the private sector
'". Similarly, in China, the torch and spark programmes which were established to
commercialize technology and diffuse it amongst the rural population respectively, have been
used for biotechnology as well. Thailand's NCGEB has also been instrumental in performing
this task, while in the Philippines the National Institutes of Biotechnology and Applied
Microbiology (BIOTECH), is not only a national laboratory for biotechnology, with a large
percentage of its staff seconded from academic institutions around the country, but has also
been rather successful in commercializing a number of products in recent years.
4.2.2. itejearc/i and Training
One of the most uphill tasks faced by most developing countries is that of acquiring qualified
personnel. Biotechnology, although science based, straddles a number of different research
areas, and breaks down traditional boundaries between natural science subjects. Most
countries, until very recently, did not include specific biotechnology courses in their national
curricula. A major portion of government funding for biotechnology in recent years therefore,
has gone into designing and setting up courses in biotechnology. As a result, a number of
universities in the region offer training courses or degrees in biotechnology.
In Korea, other than the GERI, of the 103 or so universities and colleges in the
country, 17 universities have initiated new departments of biotechnology, both at the graduate
and undergraduate levels. In addition, 15 universities and colleges have established
biotechnology or genetic engineering centres on their campuses "'. Taiwan, on the other
hand, has relied more on sending students abroad for training, at least in the short term. The
growth of biotechnology in the country in the last decade or so has however, lured a number
of these researchers back and their expertise is being used to set up courses and a research
network in Taiwan '". : •""•"" •-•-- - •••--• -• -••••-
'" Personal Communication with members of the DCB, December 1991. *"••
'" Han, M. (1990), p, 14.
'" The National Science Council in Taiwan is the body in charge of funding public sector
institutions. This funding includes both research programmes at prestigious institutions such as the
Academia Sinica, and also programmes geared specifically for training young scholars in the biological
79Most of the other countries surveyed however, have been unable to overcome the
problem of training as quickly, for two main reasons. First, many of them have not built up
sufficient strength previously in science and technology, especially in terms of human capital.
Second, a lack of financial resources have created major blocks to further investment in
training or in collaborative projects with foreign universities or training institutions. Although
statistics specifically on training are hard to obtain, if the figures on total government
investment in biotechnology are anything to go by (public funding worth $ 3,430,217 in 1991
for India "*, $ 1,355,389 in 1990 for Thailand '" and $ 1,056,500 in 1991 in the
Philippines '" compared to $ 17,469,400 in 1989 in Korea '"), the magnitudes invested
by countries such as Korea are far higher, both in absolute and in relative terms, than those
of the other countries in the region.
Those with some degree of previous capability, for example India have been somewhat
more successful than Thailand or the Philippines, where a major shortage of skilled staff
continues. The DBT in India has thus far helped over 19 universities across the country
establish postgraduate training programmes in biotechnology. Short term training courses (2-4
weeks each) especially for those already working in the field and requiring an update on new
biotechnology techniques as well as fellowships to study abroad are offered each year.
Thailand and the Philippines still tend to rely largely on foreign training for their researchers,
although the longer term goal is to develop local programmes of a similar nature. The
Philippines at present makes efficient use of its few human resources through a system of
exchanging and sharing researchers between research institutions and universities, while
developing training programmes in biotechnology.
Research collaboration is another important manner by which technical knowledge can
be transferred. Access to knowledge, especially information about regional R&D programmes
and research on matters of common interest, such as disease control and prevention, is vitally
important in a fast moving field such as biotechnology. Although still in a stage of infancy,
this method is also being pursued by a number of countries in the region. There are two
major ways in which this is being tackled:
1. The setting up of centres to promote collaboration between researchers at an international
level and also to exchange information and technologies between countries. One recent
example of this is the China-EC Biotechnology Centre which aims to improve research in
agricultural and medical biotechnologies. Housed by the China National Centre for
sciences It is estimated (personal communication with officials at the National Science Council in
Taipei, August 1994) that as many as 2,000 Taiwanese researchers return from the US each year.
'" Estimated from the Annual Financial figures of the Department of Biotechnology 1991-2
"' Calculated from the Annual Report of the National Centre for Genetic Engineering and
Biotechnology (NCGEB), 1990-91.
"' Proposed budget for Biotechnology Mega-Projects in the Biotechnology Action Plan (Padolina,
1990).
"' See figure 4.2. in this chapter.
80Biotechnology Development (CNCBD) in Beijing, and supervised both by the CNCBD and
the Commission of the European Communities, the Centre's main function is to provide a
basis for improved cooperation between research institutes in China and in member countries
of the European Community. The Centre was established in November 1991 and will also
manage all forms of collaboration between the EEC and China, including doctoral and post-
doctoral training, visiting exchange programmes, jointly organized workshops and symposia,
as well as any form of joint research programmes. A newsletter has also just been launched
which will keep researchers informed about ongoing events and research activities, both in
European countries as well as in China (IBIS, 1991). Similarly, Thailand set up the US-
Thailand Commercialization of Science and Technology Programme (UST/COST) in 1990
whose participants include the US Agency for International Development, the Board of
Science and Technology for International Development (BOSTID) of the US National
Research Council and Biotechnology International, a programme at the University of
Maryland in the USA'".
2. To overcome the problem of access to information, a number of countries in the region
have also established biotechnology databases, and computerised networks which can be
accessed by researchers and industrialists across the nation. In India for example, the BCIL
has established the Bio-Informatics Network in India which has contributed greatly to
improving the flow of information to Indian researchers'". Similarly the NCGEB's
documentation centre includes international newsletters about developments in the field of
biotechnology, both in terms of scientific breakthroughs as well as policy changes (NCGEB,
1991).
Thus to summarize, while developing countries in the region followed shortly after
most industrialized countries in establishing national R&D programmes in biotechnology, the
pace and method of R&D has been very different. Developing countries in south-Asia, even
with a relatively well established research network, have faced severe shortages of trained
personnel and commercializing products developed through biotechnology. The main causes
appear to have been financial and imperfect information flows, both of which are being
addressed with varying degrees of success. However, the largest obstacle which most still
face is the prospect of commercialization. The importance of the private sector in terms of
its marketing and production experience was stressed in the previous chapter, and for
developing countries, it is no less important. In the following section therefore, we examine
the role played by the private sector thus far, and examine its importance both for basic
research as well as in the production of higher quality products.
"* Biotechnology and Development Monitor (1992), no. 12, September, pp 11-13.
'" BCIL (1993). Although the network is relatively small and young, BCIL has had considerable
success in a short period of time in providing this service to industrialists and also researchers in the
country. Another, larger database, but which as yet only includes some information on biotech, is that
maintained by the Technology Information, Forecasting and Assessment Council (TIFAC).
TIFACLINE, a database which provides relevant information such as patent status and major producers
and markets for energy, environmental and food technologies, has recently been established and is also
accessible from nodal centres which have been established across the country (TIFAC, 1994).
814.3. Private Sector Commitment to Biotechnology
In the previous chapter, it was argued that the private sector has played an important role
especially in commercializing the results of basic research in biotechnology. This has been
the case especially in the USA where the NBTF and its success gradually led to the
involvement of the multinational firm in biotechnology R&D. In developing countries as we
show below, the private sector tends to be smaller, both in absolute size of sales, as well as
in production scale. For example, the size of investment made by individual companies in
India (figure 4.6.) is small compared to sales in Taiwan (figure 4.4.) which in turn is smaller
than sales figures for biotechnology firms in the US and Europe (see appendix I for the
annual sales figures for twenty five biotechnology companies in 1992). This, combined with
little or no access to investment capital has meant that the private sector has been slower to
respond. Nevertheless, a number of successes in recent years, especially in simpler
technologies, have gradually revealed the nature of the relative strengths and weaknesses of
the private sector and its potentials and problems.
Of the countries in the region, the private sector is perhaps most well established in
Korea and Taiwan. Both countries established strong government led policies in the early
1980s and established national institutions and laboratories for innovation, as well as for
linking basic research performed in public sector laboratories with downstream product
development which was dominated by private companies. The importance of Korea's private
sector is apparent from the size of its total contribution to biotechnology R&D, which now
exceeds similar government contributions (see table 4.2 below). It grew at an average annual
rate of 44.5 percent, as compared to the government contribution which at 29.4 percent, was
almost half that of the private sector, during the 1980s.










































Source: Han, M.H. (1990), p 14 and Tae Dc Mheen, Director, GERI (Personal
Communication).
The two kinds of large firms which dominate industrial production of biotechnology
products are the c/wefcoiy, and the pharmaceutical companies. Many of these companies have
82reached an advanced stage of technological and scientific capability. This is evident from the
number of companies which have invested in industrialized countries, either through direct
buy outs or through collaboration, both at the industrial as well as the research level. Two
of these for example, Cheil Sugar which is a part of Samsung and Lucky Limited, which is
owned by the Lucky Goldstar group, not only have expansive R&D facilities in Korea, but
have also established wholly owned subsidiaries in the US. Cheil Sugar established
Eugenetech in New Jersey which carries out research in cell biology and develops cell lines
for the production of new drugs, for example alpha interferon. Lucky set up Lucky Biotech
in California in collaboration with Chiron. The research skills, primarily in cloning and
growth hormones, are concentrated in the subsidiary company which probably benefits
immensely from collaboration with researchers in the USA, while the results are then sent
back to the parent company for further development and scale up where production costs are
lower '". Thus, while the company uses the knowledge intensive skills of researchers in
industrialized countries, the actual production is carried out in Korea, where engineering and
production, although requiring skilled labour, are cheaper than in the USA. It is also
important to add here, that production costs can be lowered further by adapting the technology
and the production process, to use abundant factors such as unskilled labour more intensively.
In the pharmaceutical sector the largest company, Dong-A controls 10% of the Korean
market, while Chong Kun Dang and Yuhan have a market share of about 5% each '".
The sector most active in biotechnology research as measured by sales is the
fermentation industry where Korea has a natural comparative advantage arising out of
traditional biotechnology applications in this industry. Output in the pharmaceutical sector,
although less phenomenal, is also rising at an extremely rapid rate. Vaccines and diagnostics
especially have shown high average growth rates and it is estimated that by the year 2000
Korea will produce 2% of the world's biologically produced Pharmaceuticals '**.
Although comparable figures on government and private sector investment in
biotechnology, are not so readily available in the other countries surveyed, with the possible
exception of Taiwan, the private sector is in general less active in biotechnology R&D in
terms of absolute size, in the region. Even in Taiwan, it appears that funding is dominated
by the government, especially in the area of applied research, demonstrating perhaps a
reluctance on the part of industry dominated by small and medium sized enterprises, to invest
in biotechnology research '".
124 Yuan, R. and M. Hsu (1991).
'"Ibid.
"* US OTA (1991), p 237. '~ """' "' ; ~"
'" Personal communication with members of the Development Centre for Biotechnology in Taipei
in October 1991.













Source: National Science Council, Government of Taiwan.
Nevertheless, it is clear that private investment is rising. This is demonstrated by the large
number of firms active in biotechnology research and development as well as from the
increasing number of products which are being marketed by these companies. For example,
"new" biotechnology firms which have been formed since 1982 showed estimated total assets
of US$ 70 million in 1989. This number has increased considerably since.
Table 4.4. Estimated assets of new biotechnology companies in Taiwan
Company
Tai-Fu Pharmaceutical Corp.
Tai-Da Pharmaceutical Co. Ltd
General Biologicals Corp.
BGH Biochemical Co. Ltd
Life Guard Pharmaceutical Inc.
Ever New Biotechnology Co. Ltd
Search Biological Technology Corp



































Source: Soong (1991), pl7.As one can see from this list, unlike Korea, where the firms are mostly already
established chaebols, new biotechnology in Taiwan appears to feature a number of
biotechnology specific companies. This appears to be largely the result of a venture capital
funding system which was initiated by the government, the result of which has been the
establishment of 13 venture capital firms since 1986 (table 4.4).
Table 4.5. Market Projections of Products in Taiwan
























































































































Source: National Science Council, Taiwan.
* Exchange rate for 1994 (US$ 1 = NTS 26.9) used.
.•"!! '
In terms of total sales, Taiwanese biotechnology companies recorded a figure of US$ 22
million in 1987. In 1989, annual sales totalled US $ 44.67 million for pharmaceutical
products, US $ 279 million for foodstuffs, US $ 65.96 million for agricultural supplies and
US $ 13.83 million for services "*. By the year 2000 Taiwan is aiming at about 2% of the
world market in biotechnological products '*'. Projections made by the National Science
Council in Taiwan also show the market value of a number of Taiwanese biotechnology
products into the mid 1990s. Table 4.5 for example, shows phenomenal growth in some
Sasson (1993), p 349.
US OTA (1991), p 240.
85products, in terms of their market size in the early 1990s. For example, in the case of
antibiotics and diagnostic reagents, the size of the market has expanded considerably, resulting
also in an interest in developing capabilities in these areas. The Taiwanese pharmaceutical
industry is dominated by foreign multinationals who largely use Taiwan for bulk packaging
and formulation rather than scientific research. The pharmaceutical sector therefore is not
well developed in Taiwan and one of the primary goals of the national biotechnology
programme is to develop these capabilities further "°.
Thus as projected by the National Science Council in Taiwan (table 4.5), the market
for agricultural and medical products will be especially strong, a projection reflected in the
number of companies in Taiwan which are involved in agricultural products such as
biopesticides and insecticides and antibiotics and diagnostic R&D '".
The success story in terms of agricultural exports in this region has been that of Thai
exports of orchids. Although the technology is relatively low-tech in the traditional hierarchy
of techniques in biotechnology, namely tissue culture and cloning, the success of Thai orchid
growers and exporters is phenomenal. A large number of these private companies are
concentrated around Bangkok and it is estimated that their average turnover is valued at about
US $ 20 million annually. Indications thus far are that this market, especially in
industrialized countries, is likely to continue growing for a period. Moreover since Thailand's
food processing industry has been expanding at the rate of about 20% per year, it is likely
that government support, as well as private investment in agricultural biotechnology, will
grow in order to take advantage of this expansion of value added products '". Present
government policy, despite the emphasis on other export crops such as rubber and rattan,
recognizes this success by encouraging the development of tissue culture based temperate
flowers for which there is a large regional market
In India, private firms have also been most successful in the agricultural sector.
Indian producers of ornamental plants and flowers have largely followed in the footsteps of
Thai exporters. India's local market however is large enough to absorb much of this surge
in production and with a growing middle class, local companies are finding tremendous
success in India itself. There are, however, some companies which have built up their export
markets as well. This is largely in response to the incentive system built up by the Indian
Government, which has set up export processing zones and provided tax incentives to
companies to export. Two of the most successful tissue culture companies in India, have now
established separate biotechnology divisions or laboratories where tissue culture techniques
are being applied to a large number of indoor plants and commercial plants and although the
size of the initial investment and sales is still small relative to industrialized countries,
considerable interest has been generated as a result of the initial successes of tissue culture
companies (see table 4.6 for a list of a few of these companies).
"° The pharmaceutical sector in India and Taiwan is the subject of a forthcoming study (Acharya,
1995)
'" Development Centre for Biotechnology (1994), lists all companies active in the various sectors
which are dominated by biotechnology R&D.
'* Singh (1989), p 148. ••-,..OMI $^- XTi A'FO &? '•

































































































Source: Department of Biotechnology, Government of India, (1992).
Similarly in the pharmaceutical sector, private companies are actively pursuing
biotechnology research. While most of this research is geared to the local market, such as
87diagnostic kits, which have been developed for a number of diseases and are available on the
local market, there appear to have been minor successes on the export front as well. Genei
Limited is the country's first manufacturer of indigenously-designed recombinant DNA
research tools. It presently exports some of its products to the USA.
In both Thailand and the Philippines, agricultural biotechnology will continue to
dominate exports. There is also a large potential market in the industrialized world for exotic
fruits such as star fruit, rambutan, durian, shiitake mushrooms and Amaryllis. Thailand is
presently doing tissue culture research on a number of other agricultural products such as
palm oil, rubber, rattan, banana and rice. Similarly, the Philippines is encouraging tissue
culture in agricultural products which have a large potential export market, such as coconut,
rattan and bamboo, the first two forming major exports. Biotechnology can be used to
enhance production and strengthen already strong markets or to exploit potential ones. There
is also considerable demand in south Asia for a number of temperate climate crops such as
strawberries, asparagus, carnations and roses, some of which are already being produced in
high altitude areas in this region. However, biotechnology research which enables the
adaptation of some of these varieties to certain climatic regions, can potentially ensure their
all-year round growth. Thus, especially for those countries with a large agricultural base and
a diverse climate, the potentials for biotechnology based agricultural exports are enormous.
However, the key to successful development is matching production and marketing
capabilities.'"
Another area where there is great scope especially for China, Taiwan, the Philippines
and Thailand, is in aquaculture. Until recently, aquaculture in south-east Asia and other
countries included in this survey such as India was largely dependent on traditional techniques
such as controlling alkalinity, oxygen content and traditional breeding methods. Recently
however, biotechnology methods have increased their attraction by improving productivity and
product quality. Since the first international symposium on marine biotechnology held in
Japan in 1989, there has been growing interest in the use of modem biotechnology techniques
to improve marine output.
i The market for shrimp and other aquaculture products, it has been estimated, has been
growing since 1970 and is expected to continue to grow at about 5% per year, placing
pressure on existing shrimp farmers to improve productivity. With the exception of India,
most of the large producers and exporters of aquaculture based products in the region, have
registered high growth rates in aquaculture production (see table 4.7), and the Indian
government hopes to catch up through biotechnology, especially to produce shrimp, prawn
and carp. The steadily growing aquaculture market has increased competition between a
number of countries, with many of them stressing the use of biotechnology in aquaculture to
improve productivity. Countries more advanced in biotechnology such as Taiwan will
probably be quicker to benefit from this expanding market














































Source: FAO (1991), Se/ecterf /ndicators o/Foorf and AgricM/fure in As/a Paci/ifc
Thus it appears that the private sector has largely determined its own priorities and
often the public sector or policy making body has had to follow by offering funding for
further research. This is especially so in agriculture and moreover in commercial agriculture,
where private companies have been quicker to take advantage of the opportunities offered by
export markets. This is perhaps not surprising, especially since the returns on subsistence
agriculture, Pharmaceuticals and industrial biotechnologies are longer term. Tax holidays and
the creation of exclusive export processing zones have also played a role in encouraging
investment from the private sector, especially in particular industries. In Taiwan for example,
companies investing in biotechnology are provided a five year tax exemption as well as tax
credit for R&D. In Korea, foreign investment is encouraged by providing tax exemption on
technology and also on customs duty. Local investment, especially for small companies, is
provided in both countries by venture capital funding, which as discussed earlier has been
more successful in Taiwan, perhaps because of an older emphasis on small and medium sized
enterprises. In India and China also, both local and foreign private investment is being
encouraged by the formation of exclusive export zones, where a hundred percent of
production for a certain number of years is exported. Lower customs tariffs on raw material
imports such as basic enzymes have also played a role in encouraging biotechnology research,
especially in India where economic liberalization policies are reducing restrictions on
international trade and investment.
The setting up of regions or areas of excellence, most notably the phenomenon of the
Science Pant has also recently found favour in many developing countries. Taiwan for
example has set up the Hsinchu Science Park which is located 80 miles south of Taipei and
contains many of the new biotechnology companies which were formed in the 1980s "\
Similarly, Daeduck (or Taejon) Science and Industrial Park in Korea, located in the centre of
Science Based Information Park (SBIP) information package, 1994
89the country, is home to many of the large companies involved in modern biotechnology
research. In India, although a number of export zones have been created by the Government,
the city of Bangalore in the south has emerged as a centre for scientific research, and a
number of biotechnology companies, both old and new have established laboratories and
offices in and around the city '".
Thus, governments are increasingly taking the back seat, as applied research becomes
the domain of the industrial sector, whether it be private or public. Increasing financial
returns from the simpler biotechnologies such as tissue culture are also encouraging
companies to invest in more expensive and advanced techniques in agriculture, and
increasingly in industry and the true potential of these companies may only become apparent
in a few years from now.
Having examined the attempts made by government and the private sector in
encouraging biotechnology development, in the next section, the technology itself is
examined. In Chapter 3 above, patents applied for and granted to inventors in industrialized
countries were used as a proxy measure for invention in biotechnology. In this chapter, we
look at the application of biotechnology to a specific sector which is highly relevant to
developing countries, namely agriculture. Much of the research on improving productivity
and increasing disease resistance in developing countries has concentrated on cash crops,
because of their export value. In the following we present a case study of one such cash
crop, where field trials we argue demonstrate the potential of this new technology and is a
sign of success to come.
4.4. Patterns of Innovation in the South
Unlike the previous chapter, where international patterns of patents granted were used to
observe and compute invention and innovation rates in industrialized countries, it is not
possible to use this measure for most developing countries. In many of these countries,
patents are not, as yet, granted for biotechnology innovations and international patents granted
elsewhere for biotechnology products are not recognized either "*.
As is evident from the last section on private sector activities in biotechnology in
developing countries, however, attempts are being made to increase scientific and
'" It has been argued (see for example Reddy and Sigurdson, 1994), that the presence of a large
pool of scientists, which graduate from one of the foremost scientific institutions in India, the Indian
Institute of Sciences in Bangalore, has prompted many R&D based ventures, both domestic and foreign
to locate to this part of the country. In 1993, it was estimated that of a total of 337 biotechnology
firms and public R&D institutions across the nation, the greatest concentration were in the south (113)
of which Bangalore is a major base (BCIL, 1994). Bangalore is also becoming a centre for Electronics
R&D where the Government is building a software technology park (Far Eastern Economic Review,
December 1992). The government of the state of Kerala is also proposing a science park for
biotechnology in that state (Personal communication, BCIL, august 1994).
"* With the TRIPs agreement in the Uruguay Round, this has changed, but most developing
countries have been granted a grace period up to 10 years before they adjust their patent laws (GATT,
1994).technological capabilities and there is some evidence of the use of less sophisticated
technologies. Much of this activity, as we have noted, is taking place in agriculture, where
less sophisticated technologies, such as tissue culture, are being applied to agricultural
products, primarily to increase productivity, but also to select preferred characteristics, which
may raise the product's quality as well. In this section we take one such example of an
agricultural product, whose productivity is being raised through tissue culture techniques in
India. The success of field trials may have important implications, not only for raising its
own productivity, but also by providing valuable information for raising the quality in a
number of other important crops.
Thus, while private sector activities have been largely confined to particular sectors
such as agriculture, where the innovations are incremental and therefore relatively less R&D
intensive than other sectors such as Pharmaceuticals, it is evident that the desire to invest in
biotechnology is there. What is lacking is an infrastructure, which will enable private sector
companies to invest in more risky ventures such as health related biotechnologies, or
industrial biotechnologies, which require greater investment in R&D. The task facing the
government therefore is to provide the private sector with economic incentives and a capital
market structure enabling them to invest in these ventures, while at the same time ensuring
that national goals are met by putting in place an appropriate regulatory infrastructure.
ProdKcrivz/y En/iancmg /miovarioAw: 77te Owe 0/ Cardamom in
Cardamom is a widely used spice native to India. Of the two varieties, the small green
cardamom is commercially produced both on plantations and on small holdings. India was,
until the 1970s, one of the world's major producers and exporters of this high-value spice.
Other cardamom producing countries are Guatemala, which today is the number one exporter
of cardamom, Sri Lanka, Tanzania, Papua New Guinea, Nepal and Bhutan. In India, it is
cultivated in elevated areas between 600 and 1500 metres above sea level, in the southern
states of Karnataka, Tamil Nadu and Kerala. The total cultivated area in India is, at present,
estimated to be about 100,000 hectares '".
Approximately 50-60 percent of the cardamom produced in India is exported, its
international price making it a valued foreign exchange earner. The main export markets for
cardamom lie in the Middle East and Japan. Some is also exported to North America and
Western Europe. However, while India used to control most of the export market, its position
has slipped down to seventh place in recent years, while Guatemala has taken over as leader
in cardamom exports.
Over the years, India's productivity and market position have steadily declined. While
India's productivity averages only about 60 kg per hectare, Guatemala, the largest exporter,
has a productivity of over 250 kg per hectare. There are several reasons for India's low
productivity, including the age of the plantations, irrigation methods, the size of the
landholdings, pests and climatic problems.
Following the success of a private cardamom plantation owner in using tissue culture
to raise the productivity of the cardamom crop, the Indian government initiated a field trial
in 1989 to determine the extent of productivity and quality increases that would be possible
Cherian (1986), p33.
91if tissue culture plantlets were used. The Managing Director of the private company, A V
Thomas and Co., argues that, through tissue culture, the production of cardamom can be
raised from the present 4000 tonnes to about 8000 tonnes per year, i.e. doubled "*. The
company began using elite varieties, which were first isolated from old plantations and then
multiplied. These varieties have the added advantage that they can be cropped in two years
instead of the traditional three. By using these varieties, yield per hectare has increased from
70 kgs to 250 kgs, and earnings per hectare grew from Rs 60,000 to Rs 250,000
(approximately US $ 2,400 to US $ 10,000) "».
In response to this success, the Indian government initiated field trials, in cooperation
with A V Thomas, to increase the productivity on its own small holdings, which are leased
out to small scale farmers. From the initial results'*" below, (/igur&s 4.3 fo 4.8), it appears,
that the tissue culture varieties, on average, tend to have higher yields although there is some
variance among and within the regions.
In order to determine the impact of a large scale adoption of this technology upon total
production of cardamom a time series analysis was carried out to measure changes in
productivity. The annual data relates to production, yield levels, international prices and
annual area planted.
Figure 4.7. below shows the rate at which Indian production of cardamom has grown
between 1960 and 1989. The estimates were obtained from time series data (annual) from
1960 to 1989. The linear equation estimated was K = a,, + a,Xj + u , where output F,
is a function of time and of an error term. The regression estimates an intercept CC(,, of
1122.4 tonnes with a slope of 28.87. The low R squared of 10.8 % is probably attributable
to the substantial fluctuations in output from year to year, and also probably because there
have been other factors that have affected yield levels such as variable productivity.
Nevertheless, the estimation gives a time trend which is increasing, although not very steeply.
Table 4.8 shows the results of two sets of time series regressions that were estimated. The
first regressed the variable Indprod, corresponding to Indian output y, on time, while the
second repeated the regression using Gnprod or Guatemalan output, as the dependant variable.
The next equation estimated was log linear: lnK = a,, + a,lnX, + M . The
dependent variables are Lnlndprod, which is the growth rate of Indian output and LnGnprod,
the growth rate of output in Guatemala and are estimated as functions of time.
"• Eapen George (1991), Financial Express, 11 July.
"' India Today (1991), 15 September, p 99
'** These results are based on unpublished data, from field surveys which were obtained from the
Cardamom Board of India, during 1991.


























The slopes in both cases, show that Guatemalan growth rates far exceed Indian ones.
Figure 4.1. Indian Cardamom Production
1960-1991 Regression trend
6'2' 6(4 ' & ' 6k ' 7*0 ' ' 7*4 ' 7*6' 7*8 ' 8b '
Year
' 84 ' 6)6 '
Whereas Figure 4.7. shows the trend for Indian production between 1960 and 1991,
F/gure 4.2. compares regression results of Guatemala and India, showing that while
production in both countries has continued to rise over the years (in this case Guatemala was
a late entrant into the market and therefore the trends are measured between 1970 and 1990),
Guatemalan growth rates have outstripped Indian production by a magnitude of 6. Thus any
attempt by Indian farmers to recapture market share has to address the problem of
productivity in Indian cardamom production.
93The Indian government, acknowledging the success of the private sector in improving
cardamom productivity, launched the field trials in 1989. Although preliminary, the results
of the field trial may prove interesting for overall Indian productivity in cardamom.
The question then is whether tissue culture in any way is able to affect this time trend
and if so, what this affect will be. For this, we turn to the results from the tissue culture
trials (Figures 4J. to 4.5. below). The tissue culture trial, initiated in 1989, was expected to
begin yielding results for full scale replantation of the total area devoted to cardamom
production in India. A total area of 100 hectares was selected in various parts of traditional
growing areas in the country and planted with tissue culture (TC) and open pollinated (OP)
varieties in an 80 to 20 percent ratio respectively.
Figure 4.2. Growth Rate of Output
India and Guatemala (1970-1990)
70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
Year
Guatemala -•- India
The results, although not finalized, have revealed varying degrees of productivity
increases, depending upon the varieties and the areas they were planted in. The figures below
demonstrate some of these initial results for mean production rates in 1989 and 1990.
Preliminary results were also available for the 1991 planting period. Figures 4.3. ami 4.5.
show mean production rates for ri//er (stems of the plant which are renewed every year and
are related to the productivity of the plant. Measuring yield increases in tillers therefore is
important for determining the overall productivity of the plant),''" production.
Already at this stage, mean production levels of the sample reveal an increase in
productivity averaging 9.8% in 1990 and 15.27% in 1991 of the tissue culture varieties over
the open pollinated ones.
'*' The cardamom plant is a rhizome, ie. most of the plant is below the ground. The underground
rhizomes produce tillers or stems which grow above the ground. These stems are renewed each year
and add to the plant's productivity. A mature cardamom plant of five years usually possesses between
50 and 100 tillers and its productivity depends upon the number of tillers it produces.
94Figure 4.3. Tissue Culture Cardamom!
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Figure 4.4. Tissue Culture Cardamom
Mean no. Panicles produced/plant 1989
Zones 1-6
I Tissue Culture | Open Pollinated
Similarly, overall productivity averages have also increased for pamc/e (These are
offshoots from the tillers which contain the cardamom pod and an increase in panicle
production implies a greater amount of cardamom produced per plant), production and also
of the number of capsules containing cardamom, produced per panicle (Figures 4.4. a/u/ 4.5
are for 1989 data while ./zgures 4.7 and 4.5 are for 1990 data).
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Figure 4.6. Tissue Culture Cardamom
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97These average an 8.32% increase in the mean number of panicles produced from the
1989 sample and of 19.8675% from the 1990 sample. Data gathered in the 1991 case was
too preliminary to reveal any significant results about cardamom production, although the total
number of tillers had increased by 15.27% over the open pollinated varieties. The number
of cardamom capsules produced per panicle also registered growth rates of 36.31% in 1989
and 22.39% over the 1990 period. However, an increase in the productivity of tillers implies
that the production of capsules also rises. Thus the growth rate of tillers and capsules is taken
to be cumulative in both years.
The growth rates thus estimated were then used as shift parameters to measure the
extent of change in production and rates of production if tissue culture varieties were used
for cardamom production. It should be emphasized here, that obtaining estimates in this
manner is simply an attempt to show how biotechnology innovations (in this case higher
yielding and disease resistant varieties) can enable a product to improve its market share.
Thus, rather than deriving results from the field trial figures to make projections for
the future, these estimations are used to discuss the potential for developing countries to
increase their market share in traditional products through the use of higher quality tissue
culture plants.
The projected growth rate of the total quantity of cardamom shows a steady increase,
especially for the results extrapolated from the 1989 field trial figures. Even if one takes the
lower estimate from the 1990 field trial figures, there is a considerable increase over current
levels, although the growth rates remain the same, i.e., there is simply a shift upward in both
trends (see/igMre 4.9. below).
It should however be stated that since the figures are only for two years, it is difficult
to estimate the growth effects of the new varieties. The estimates here only use the field trial
results to estimate yield increases. The growth rates shown in these figures therefore most
likely underestimate the growth rate of production if tissue culture raises productivity.
Figure 4.9. Growth Rate of Outputlndia
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A comparison of these growth trends with the current trends in Guatemala (see/igMr«
4..Z0.), show clearly that Indian productivity rates even given the estimated increase in
productivity if tissue culture was used (assuming that the same results would hold in a more
widespread use of the new varieties), are not sufficient to match Guatemala's, although there
is some evidence of catching up, especially from the results of the 1989 field trials.
The results for recapturing market share by Indian producers from their competitors,
especially Guatemala, are therefore not entirely convincing, although a rise in productivity of
the rates measured from the field trials, will indeed make Indian cardamom more competitive
in die international market. The inability to measure changes in the growth rate from the
preliminary field trial figures may however, have underestimated the potential of tissue culture
varieties to enable Indian producers to catch up with their competitors.
Thus, in this case, biotechnology has the potential to enable Indian producers to
recapture a part of their market share, although the extent of this will depend upon growth
rates in production which will enable them to catch up with their Guatemalan counterparts.
With respect to our earlier discussion on increasing quantity, quality and variety, in
this case, productivity increases imply an increase in quantity, but it is not clear what the
implications for variety would be. According to a recent survey (Kumar and Menon, 1992)
of farms included in the field trials, there is a general tendency for farmers to plant more than
one variety of cardamom '**. In the case of tissue culture specifically, the survey of farms
chosen for the field trial showed that 43% of all the farmers surveyed (including those who
'*' The survey found that in general there tends to be a bias in favour of larger than average size
farms participating in the field trials (Kumar and Menon (1992), p 13).
99were not included in the biotechnology trial), have chosen to plant more than one variety of
cardamom '*', although it is not clear whether this will mean rising or declining variety.
Although the results of this trial are preliminary and it is not clear what the rate of
diffusion of the new varieties will be, they show clearly that the tissue culture varieties are
higher yielding and will not only increase the productivity of Indian cardamom, but may also
hold promise for a number of other crops where productivity is declining. The implications
for variety however, may be negative depending on how many varieties are eventually
adopted by farmers, and the number of older varieties that are replaced.
Conclusions
In this chapter, we have examined the main features of biotechnology R&D in developing
countries. As with industrialized countries, the government in developing countries, has
played an important role in encouraging and developing an environment conducive to
biotechnology R&D. The presence of a small private sector, unable to provide sufficient
financial resources for biotechnology R&D, in fact, meant that the government's role was
further expanded in developing countries. However, as with industrialized countries, the most
important contribution of the government has come in "public domain" activities such as
training and the funding of pre-competitive research. A boost to the older research
infrastructure additionally, has been provided by newer, more flexible policy making and
research and development bodies. JW; •
In developing countries, despite efforts by the government, the private sector has been
relatively slow in entering biotechnology and since it is the private sector which tends to have
the expertise required to commercialize new technologies, commercialization has been
relatively slow in these countries. The government has also faced greater problems than
governments in industrialized countries, namely resource constraints and a weaker scientific
and technological base needed for biotechnology R&D. Finally, weaknesses in the tradition
of cooperation between the private and public sectors, or the linkages between pre-competitive
and competitive research, has also been a major problem in developing countries, one which
governments have made a number of attempts to address.
The private sector, in turn, has had problems raising investment capital and has faced
a continuous shortage of skilled staff. Despite their problems however, both the government
and especially the private sector, have made major contributions to the development of
biotechnology capabilities in the countries surveyed. The government has also introduced a
'*' The survey which was carried out for the Department of Biotechnology, examined over 500
farms, and included both those taking part, as well as those not included in the trial. 71 out of 133
farmers (53.38%), who took part in the field trials, responded to this questionnaire. The preference
for variety will depend upon the variance of the expected harvest between the varieties. If the variance
is large, then use will be made of the highest yielding variety only if (i) the farmer is risk neutral or
(ii) the farmer is risk averse but has access to a capital market. Since the farms included in the trials
on average tend to be large, the conclusion that 57% did not plant a number of varieties could be
related back to the earlier discussion on the tendency of large fanners to have better access to capital
markets or to be risk neutral.
•; 100number of incentives, including tax holidays and lower import barriers, to which the private
sector appears to be responding.
The private sector, although a relatively late entrant into biotechnology R&D, has been
instrumental in transforming the results of pre-competitive research into commercially viable
products. The technologies being used in developing countries at present, are admittedly
simple and many do not even fall within the narrow definition of "new" biotechnology (see
chapter 2). Despite this, however, their use to commercialize a number of "new", higher
quality products, demonstrates a certain degree of capability, both scientific in developing
higher quality innovations, and commercial, in terms of developing viable products which can
respond to consumer demand for greater quality and variety.
The pattern of innovation in developing countries, although slower in pace, and
focused on lower quality technologies and products, is therefore rather similar to that in
industrializing countries. It involves a separation of organizations or companies carrying out
basic or pre-competitive research from those doing applied research and commercial
production. A major difference in the circumstances of biotechnology at present, is the
significantly different patent regimes in industrialized and developing countries. Most
developing countries do not as yet extend patent protection to biotechnology based products.
This situation is however changing rapidly and a number of countries, including Korea and
Taiwan, among the countries surveyed here, have recently revised their patent laws to include
biotechnology "*. Thus, this difference may change significantly in the next few years as
developing countries come under increasing pressure to recognize and adapt to international
IPR regimes, as can be seen from recent GATT negotiations.
With respect to the 1990s, we see a few major changes which may become more
important in the coming decades. First, biotechnology companies in industrialized countries
will slowly continue to consolidate their position, especially in the pharmaceutical industry.
Their success has led to an increase in research by established pharmaceutical and chemical
companies. This is evident from patent data (see chapter 3), which shows that the degree of
patenting by large companies appears slowly to be overtaking a number of NBTFs. However,
there is also a trend on the part of a number of NBTFs, towards forming research and
marketing alliances with large companies, and also with other biotechnology firms to tap into
their particular research or marketing expertise. Multinational companies are also forming
similar alliances which, as Orsenigo (1989) argues, are not unlike their earlier alliances with
universities, especially in the US, but also in some European countries. Thus, there is some
evidence suggesting that economies of scale, especially in downstream product development
may be becoming more important and therefore may become a determining factor in success
in biotechnology in the coming years.
The least technologically developed countries will therefore find it more difficult to
catch up, especially as the pace of biotechnology R&D in the more technologically advanced
developing countries increases. Success in entering biotechnology will depend greatly upon
an efficient allocation of scarce financial and human resources. The success of Cuba has been
discussed previously and can still be used as an example to show how a specified channelling
of resources into an area of previously built technical capability, can be used to successfully
develop expertise in incremental steps. Large countries with considerable basic research skills
van Wijk et.al.(1993).
101such as India, have quickly had to learn that possessing the scientific capability to do genetic
engineering is simply not enough if government restrictions hinder the private sector from
involving itself in downstream product development and transforming the invention into a
productive innovation.
Having discussed patterns of innovation and institutional structures supporting those
patterns of innovation in industrialized and developing countries, the next chapter returns to
the question of the impact of biotechnology on product quality and variety. The impact of
biotechnology based innovations of higher quality and productivity have had and will continue
to have an impact on the variety of products available in the economy. This point was made
with respect to consumer preferences briefly in Chapter 1 above. Chapter 5 below, focuses
on this point and discusses the issue of quality and productivity improving innovations in
biotechnology and their impact on variety.
102Quality and Variety in
Biotechnology
does f/ie^s/z remind yow o/?"
"And wnaf do ofner,/i.yn remind you O/?"
Introduction
As the previous two chapters have shown, biotechnologies, especially modern
techniques have been widely adopted by both industrialized and developing countries. For
industrialized countries, biotechnology applications are strongest in the pharmaceutical and
food processing sectors. For developing countries, biotechnology has addressed critical issues
of food security and has increased value added for a number of exports. Its knowledge
intensive nature has also enabled developing countries to diversify production and has
therefore enormous potential to increase both the quality and variety of products available to
consumers. Much of this has been achieved through building upon previously developed
technological capabilities such as in agricultural biotechnologies which were built upon
existing research networks developed during the green revolution in India, Thailand, and the
Philippines, while the eastern countries of Korea and Taiwan have relied on their traditional
strengths in bioprocessing industries. While their innovativeness has resulted in an increasing
variety of production, with a promise of a lot more to come, the interesting question to ask
is whether the new biotechnologies and the changing economic and institutional environment
will increase or decrease the total amount of product variety, both old and new, available to
consumers. In Chapter 1 above, the impact of biotechnology on variety and quality was
discussed briefly. There, it was argued that increasing quality can have differing impacts on
the variety of products available to consumers.
While thus far, Chapters 3 and 4 examined the impact of biotechnology on quality and
productivity enhancing innovations, in this chapter we look more specifically at the nature of
these changes and how they relate to consumer preferences across different sectors. The
discussion in this Chapter will lay the foundation for the structure of the endogenous growth
and trade models developed in Chapters 8 and 9 below.
This chapter is divided into three broad sections. The first two look at the impact of
biotechnology on traditional products and techniques, while the final section discusses demand
for this increased or decreased variety, as is expressed through consumer preferences.
Examples come mainly from the agricultural and pharmaceutical sectors where the majority
of biotechnology based innovations have taken place till the present time.
5.1. New Qualities For Old
As with most new technologies before it, biotechnology will bring about structural
changes which will have implications for traditional production techniques and products. The
103ability of biotechnologies to identify genetic structures and transplant genes, has allowed the
production of new species of crops. The scientist's job is to first identify the genetic structure
of a particular species and then insert new, desirable characteristics and remove undesirable
ones, producing a new species which is stronger than traditional varieties. Examples of this
include: 1) the production of plants which are able to adapt to particular environmental
conditions, such as frost which often destroys the citrus and tobacco crops in southern parts
of the United States; 2) plants which are disease resistant or resistant to herbicides such as the
work done by Monsanto to develop new genetically engineered varieties of crops which are
resistant to Monsanto's own herbicides; 3) plants which are substitutes for older products and
4) plants which are in general more resilient, bigger and higher yielding than previous
generations.
Although the process is difficult and its potential benefits long term, its implications
are enormous, both for innovators and also for consumers. The creation of one new variety
with a different genetic structure in the laboratory, would give birth to a whole new species
to replace the older varieties which are more susceptible to disease and changes in the
environment. The important difference between genetically engineered products and older
variety improvements is that while previously the goal of plant breeding was to increase
productivity through cross breeding with the variety which appeared to be most resilient, the
precision of genetic engineering allows the targeting of specific diseases and climatic variables
in developing a higher quality plant, which will not only increase output, but can also be
planted in different environments. Quality improvements can also target specific aspects of
the plant such as flavour, aroma or taste. Thus the aim of the latter is in improving quality,
whereas the aim of the former was to improve productivity''".
The new product is also in a position to address the needs and preferences of
consumers in that it may remove any inconvenience associated with traditional production
processes. In the case of agriculture in particular, prices tend to fluctuate considerably'**.
Erratic weather conditions and a number of other uncertainties and natural and man-made
disasters such as famines or floods (which although natural in the sense that they are related
to the weather, tend to have a far greater and often disastrous impact in those countries where
farming or other human activities have depleted natural vegetation which holds the topsoil
together), often prevent developing country suppliers from meeting their supply targets which
results in price fluctuations. Annual harvests also vary and the quality of the final product is
often not the same from year to year. For those crops especially which serve as raw material
inputs for industrial or other purposes, these uncertainties are extended up the chain of
production. This appears to have been a major rationale for large multinationals and
biotechnology companies to target agricultural products, and especially cash crops. In the
words of the US biotechnology firm Calgene:
'** Of course, there are fears, often quite legitimate, about the release of genetically altered plants
and animals into the environment. Nevertheless, this does not detract from the potentials of genetic
engineering for detecting and improving resistance to diseases in plants, although it is acknowledged
that government regulations concerning field testing and trial should be in place to stop dangerous
accidents from occurring.
- Junne (1991), p. 14 **-'*** * ^^i^^rf Ui*
•••'•''.' 104 ^"The value of most crops grown for food processing is
determined primarily by the crop's processing characteristics
such as texture, flavour, colour, protein and carbohydrate
content, and shelf life. Food processors have traditionally
bought raw materials in commodity markets where all products
are essentially undifferentiated. With recombinant DNA
technology however, Calgene can provide food processors an
opportunity to gain competitive advantage by allowing precise
genetic modification to develop proprietary crop varieties with
enhanced characteristics which can then be patented to grow
with their exclusive use."'*'
Biotechnology research and especially the ability to insert better characteristics into
plants in the laboratory and then to replicate the genetically engineered product, would
eliminate some of these supply constraints.
For a number of crops, initial biotechnology research came in the form of tissue
culture, and attempts through genetic engineering to create superior hybrids which are higher
yielding and more resistant to disease. In the case of cocoa, the raw material used to produce
chocolate, Africa, especially west Africa, accounts for most of the world's production and
export. For the largest African producers, cocoa is an important cash crop, accounting for 90
percent, 60 percent and 40 percent of the exports of the nations of Togo, Ghana and the Cote
d'lvoire respectively'**. In the early 1980s, 60-80 percent of the world's international trade
in cocoa was controlled by four chocolate producing companies. The tendency toward
concentration has continued since and in addition to this, major cocoa producers such as
Hershey Foods in the US and Nestl6 of Switzerland have devoted a considerable proportion
of funds for biotechnology R&D in cocoa and related products.
Tissue culture and genetic engineering can increase the yield of the cocoa bean
severalfold. The cultivated cocoa plant is based on a very narrow genetic range which makes
it susceptible to disease. Estimates are that between 20 and 30 percent of the world's cocoa
output is lost due to disease and pests and it is estimated that while traditional cocoa yields
reach a high of about 500 kilogrammes of cocoa beans per hectare, micro propagated high
yielding cocoa plants are expected to yield upto 2000 kilogrammes per hectare (Sasson 1990).
In fact, countries in the east such as Malaysia and Indonesia have greatly increased yields by
using higher yielding tissue culture varieties (see table 5.1).
Genetic engineering has the potential to further increase that yield. This would mean
a considerable increase in cocoa production, resulting in lower prices and lower production
costs for chocolate producers. This research is still in progress and it is likely that these
effects will have a long term impact.
147 quoted in Juma (1989), p 135
'*• FAO Yearbook.
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Similarly, genetic engineering is replacing the place of origin of traditional products.
For example, a recent decision of the US department of Commerce granted $1.2 million to
a Utah based biotechnology company to develop a substitute for pyrethrum through genetic
engineering. Pyrethrins, obtained from the flowers of the pyrethrum plant are a natural bio-
insecticide and demand for them has grown manyfold in an increasingly environmentally
conscious world. The plant comes largely from East Africa where traditional agricultural
technologies were not sufficient to meet demand. Many of the main producers of pyrethrum
such as Kenya, expanded production by the introduction of tissue culture and
micropropagation to meet expanding demand. The investment made by investors, the
scientific community and the farmers alike, in introducing tissue culture may therefore prove
to be in vain if a genetically engineered pyrethrum substitute were to be developed which
would make large traditional markets like the US self-sufficient in the production of pyrethrum
based insecticides.
In the case of pharmaceutical and medical research as well, genetically engineered
products which are both substitutes for older products and also entirely new products, or
previously non-existent cures for diseases, are appearing on the market. For example Factor
Vm, a blood clotting protein is lacking in Haemophiliacs, who are under constant threat of
injury, both external and internal, which can lead to bleeding and death. Factor VIII can be
genetically engineered which can then be used to treat this condition''". Similarly, research
using rDNA techniques for a number of incurable diseases, most notably cancer, are at various
stages of research or approval from the appropriate health authority. A number of other drugs
are providing replacements for patients who lack the biochemical ability to produce or process
US OTA (1991), p 79.the protein needed by their bodies"". One example is the production of human insulin, the
first rDNA drug approved in the US, while another is the human growth hormone, which is
being used on children with growth retardation tendencies. Thus advanced biotechnology
research, both in the agricultural and pharmaceutical sectors, is producing products which will
potentially replace a number of low quality products.
5.2. New Processes Driving Out Old Products and Processes
For a number of traditional, homogeneous products, not only is the problem one of
substitution by a new product, but also of increasing competition between processes. In the
case of agriculture, industrial biotechnologies are increasingly driving out agricultural
technologies and methods of production. For example, the production of high-value secondary
metabolites for drugs developed from medicinal plants and flavours developed from plants,
is increasingly replacing traditional drugs and flavourings.
Industrial techniques are pervasive challenges to producers of traditional products,
because they not only replace or compete with traditional products, but also produce
techniques which can be extended to a number of previously unrelated natural products'".
One of the first crops which was affected by industrial biotechnology based products
was sugar. Although there was some evidence of starches having sweetening properties since
the early 19th century'", the large scale replacement of sugar, especially cane sugar, can be
traced back to the 1970s with the development of High Fructose Corn Syrup (HFCS) produced
from maize or corn. HFCS, at first an expensive product of modern enzyme technology, has
today come close to meeting the entire demand for sweeteners from the soft drinks industry.
Its popularity is largely due to its particular characteristics, such as its liquid state at room
temperature, making it more convenient for use in industrial processes especially for the soft
drinks industry, and also because of the highly protected nature of markets such as the EEC
and the USA where it is being used, ensuring sugar prices which are considerably higher than
elsewhere in the world and high enough to allow competitive production of HFCS. The prices
of HFCS also tend to be more stable than that of sugar since it uses only 10 percent of the
total US corn harvest every year'". Corn also stores better and for a longer period of time
than either sugarcane or sugarbeet, adding further stability to the price since it allows
producers of HFCS to hold stocks'*. The OECD estimates that in 1983 almost two thirds
of total sugar consumption in the US was accounted for by liquid sugar'".
"° Ibid, p. 76.
'" Junne (1991), p 3.
'" Ibid, p 8.
"> Ibid.
"* Ibid, see also Ruivenkamp, 1984.
'" OECD (1989), p 86
107Further breakthroughs have also enabled scientists to produce a new generation of
sweeteners which are targeted at a more health conscious community. The brand name
NKfrajweer is one such product manufactured by Monsanto and has been followed by a
number of other competing low-calorie sweeteners. It was estimated that as early as the 1970s
some 20 sweeteners were being used in industrialized countries'^. Today the number is still
higher. While the introduction of alternative sweeteners is not a new phenomenon, and while
artificial sweeteners are still in use, the emphasis seems to have moved to natural sweeteners
in recent times. The development of Thaumatin, 100,000 times sweeter than sugar, from a fruit
found in central and south-west Africa'", may soon find its way into the market. The
sweetener which is being marketed by the name of 7a/in is still extremely expensive and
therefore not yet a viable threat to other sweeteners. However the search for other similar
sweeteners, as well as for reducing the cost of present sweeteners continues.
These developments have brought about considerable changes in the sugar market
Countries such as the Philippines which are highly dependent for their export earnings on the
international demand for sugar, have suffered considerably as a result of the collapse of sugar
prices. The emergence of HFCS and subsequent sweeteners have intensified efforts to develop
newer substitutes with a higher concentration of fructose. As a result of this, along with the
increasing success of niche markets such as low calorie products, it is likely that cane sugar
producers will have to go through major structural adjustments in the next few years. Thus,
the impact on producers of the traditional product, sugar, will be negative, although this will
not be the case for product variety. As table 5.2 below summarises, and as described above
in the text, the sweetener market has been characterised by an increasing variety of products
as an increasing number of substitutes are developed to displace sugar.
Cocoa butter has important characteristics which makes it indispensable for the
production of chocolate and account for its distinctive flavour. Biotechnology has brought
about two important changes to the pattern of cocoa production. Industrial biotechnology has
the potential to displace the use of cocoa altogether in the production of chocolate. Cocoa,
because it is labour intensive and grown largely on small holdings, tends to be higher priced
than a number of other oilseeds. Production uncertainties and a high degree of susceptibility
to disease add to the upward pressures on the market price for cocoa. Chocolate producers
have been experimenting with ways to produce cocoa butter substitutes (CBSs) through the
use of cheaper oils with qualities similar to that of cocoa. The predominant raw materials
used to produce CBSs are Shea, Illip and Sal, grown mainly in Africa in small quantities and
because of their relative unimportance as cash crops, low priced.
A number of other oilseeds which are cheaper than cocoa butter, notably palm oil, one
of the cheapest edible oils at present, are also being experimented with. The use of CBSs are
however restricted in the production of chocolate by international agreements, notably the
International Cocoa Agreement and also by a number of countries'^. So far therefore, their
use has been limited, although some countries allow their use in restricted quantities along
with cocoa butter. As long as these restrictions continue, the market for cocoa is likely to
'* Panchamukhi and Kumar (1988).
'" Society for International Development (1988).
"* Society for International Development (1988).
108remain relatively protected, although new breakthroughs may result in a relaxing of these
restrictions.
Once again, as with the market for sweeteners, the total variety of products in the
market for cocoa butter appears to be increasing as a result of biotechnology R&D. Table 5.2
shows that cocoa butter production could either be increased through secondary
biotechnologies or through genetic engineering. Alternatively, the use of other edible oils to
produce Cocoa Butter Substitutes, would increase the total variety of Cocoa Butter products
available in the market.
Other examples of such displacement abound and will become more common as
industrial scale up techniques become more advanced. Vanilla, the flavour extracted from the
vanilla pod, used widely across the world with an export value estimated to be about US $
100 million at present, has been the subject of much of this research in recent years. Recent
reports say that a California based biotechnology company, Escagenetics Corporation has now
developed a cost-effective method of producing vanilla extract through an industrial process
at a cost of about US $ 25 per pound instead of the US $ 200 per pound cost of natural
vanilla. This phytovanilla, whose patent has been applied for, is now in the process of being
commercially scaled up and will probably be available in the market soon after '*'. The
losers will be the world's producers of natural vanilla, all located in developing countries and
those consumers who prefer this product, who will have to pay higher prices as the product
increases in price, or will experience lower welfare if the product is entirely substituted away
by the biotechnology competitor.
Research on other flavours and essences such as saffron is also taking place, although
it is not at as advanced a stage as vanilla. Similarly, as shown in table 5.2 below, attempts
to develop industrial substitutes for other products and widely used drugs such as quinine
(which is used for treating malaria), will bring enormous benefits for companies which make
these breakthroughs. In the case of these products, the impact is not as clear as for the others
discussed above. The production of a substitute, especially a high quality substitute, may also
drive all older qualities out of the market. This as we shall see in the Part II below is indeed
the result in some of the new quality based growth models (see Chapter 6), where the
production of each new quality immediately results in the older quality being driven out of
the market.
Table 5.2 also shows a particular relationship between the country whose product is
displaced, in the cases mentioned above, developing countries, and the country doing the
displacing, in these cases industrialized countries. This appears to be an interesting variant
on the Grossman and Helpman argument that no innovator targets his/her own innovation.
In the case of these products, displacement is north-south, and although there is some targeting
of northern products by northern producers, this is not generally the case with respect to
southern producers targeting or displacing northern products.
RAFI Communique (1991), July.










































































































































































































































































































































































' Many substitutes are in different stages of development. The terminology used in this table uses the
following evolution in R&D: Research is the first stage, followed by Scale up which implies the first
steps from the laboratory stage to industrial production, followed finally by commercialization.
Source: Derived mainly from Panchamukhi and Kumar (1988) and RAFI Communique various issues.
112Thus innovation in this case, appears to be leading to a decline in market shares of developing
countries, as their traditional products are displaced by substitutes, lending some support to
the argument that the developing country (as a whole) share of international trade is
declining'*®.
This last point relating to traditional and changing trade relationships between
developing and industrialized countries, has important implications for traditional export
products and in the case of developing countries, agricultural products. We relate the model
on international trade, to this last point, lending interesting implications for north-south trade
in traditional and innovation products, and also for future research directions.
To summarize then, in the previous section we have identified two major displacing
effects of biotechnology which are likely to have implications for product variety:
(i) D/sp/acemeMf fey /ncreoy/ng Qwa/Zfy
Techniques to improve yield are now being perfected in many countries to develop
crops which are not only higher yielding, but also disease and pest resistant. Genetic
engineering is a powerful new technique which will create entirely new species of crops
having the potential to completely replace older products that are more susceptible to disease
and climatic changes. For example in the case of cocoa, countries in east Asia and Latin
America have displaced a number of countries in Africa which still tend to use older
techniques and varieties to produce cocoa.
In the pharmaceutical and medical sectors, high quality products are also appearing on
the market, although the lag between innovation, approval and completion of testing, is
considerable and in comparison, only a few products are available on the market. However,
judging from the number of products at various stages through this initial phase of testing (see
for example US OTA, 1991 and Ernst and Young, 1992), it is likely that the impact on older
generations of products will be large.
••'•;•*'•/ *"#'
fiij Dwpfacemenf tfiroKgft New
Industrial techniques are increasingly displacing cash crops, especially those which are
expensive, or whose supply fluctuates. The benefit to the consumer in this case, is a steady
supply and a reduction in costs. High Fructose Corn Syrup for example, was able to cater to
the needs of the soft drinks industry and also ensured steady supply by shifting to another crop
as an input, namely, corn which was not as perishable as sugar cane and could therefore be
stored more easily. In the case of vanilla and pyrethrum, both substances are exported by
developing countries, with Madagascar and Kenya respectively, being the largest exporters of
these crops. Demand for pyrethrum has increased substantially over the last decade, and the
"* See for example World Investment Report (United Nations, 1991) and Narula (1993), both of
whom have observed that from trade and investment figures it appears that the developing country
share has been declining over recent years.
113inability of east African farmers to expand production sufficiently"', has meant a consequent
increase in price. The new substitute will be substantially cheaper and will also overcome any
potential supply problems.
However, while industrial biotechnology and genetic engineering will no doubt displace
old products and processes, the implications for variety seem to be somewhat positive. As
table 5.2 shows, the number of substitutes which have often been developed, are in fact, larger
than the products displaced. Thus in the case of sugar for example, the substitutes developed
include over 20 alternative sweetening products. Many of them, directed at specific niche
markets such as the low calorie diet market, are also fulfilling certain demands which serve
to increase consumer utility. Many of these substitutes are quite widely available, such as
saccharin and nutrasweet which serve the low calorie market, and HFCS, which appears to be
widely used by the soft drinks industry. Sugar itself, continues to have a market among non-
industrial consumption, such as households, and small-scale confectionary.
Similarly, for cocoa butter, two major kinds of substitutes are being developed at
present which could increase the total variety of products available to consumers'". Thus
in these cases, new innovations would result in increasing variety.
While we have looked at the changes biotechnology introduces into the production
side, we finally turn to examine the demand side and what the consequences of increasing
quality and productivity are on consumer preferences.
5.3. Quality, Variety and Consumer Preferences
It was argued in the previous section that the two kinds of innovations, one quality
increasing and the other productivity (price) increasing (reducing) will displace a number of
traditional products, as is often the case when a new technology is introduced. From the point
of this discussion however, the interesting question is what impact this will have on consumer
welfare, and since consumer preferences can be defined in terms of variety and quality, what
are the implications of increasing quality and productivity given consumer preferences for
variety.
As is apparent from the earlier surveys on the nature of the technology (see Section
I) biotechnology has recorded successes in raising the quality of products available in the
economy. This is true both of industrialized countries, where especially in medicine, higher
quality products are raising consumer utility greatly, and also in developing countries where
greater agricultural productivity and the availability of a wide range of diagnostic kits are
being offered to consumers. The result is an overall increase in quality, but also in production
technologies and the level of knowledge in the economy.
••' '" See Juma (1989) on the topic of pyrethrum research in Kenya, and also the Biotechnology and
Development Monitor (1992), no. 13, for a recent discussion of the situation with respect to the
pyrethrum market.
"* For lovers of chocolate however, this could mean declining quality because the distinctive taste
of cocoa butter can often not be replicated sufficiently using substitutes.
114The implications for consumer preferences for variety however differ across sectors
and according to circumstances. In agriculture for example, previous experience with the
adoption of new high-yielding varieties during the green revolution show a mixed record.
Some areas saw a high adoption of the new varieties, resulting sometimes in an increase in
monoculture cropping, while in others the higher quality product was disregarded in favour
of maintaining greater crop diversity. As discussed briefly in the section on methodologies
above, this difference in adoption has in practice, been influenced by the situation of
individual farmers and the decison to maintain variety is often reflected in a desire to spread
risk. In general, it has been argued that the degree of risk sharing in this manner is most often
associated with the smaller, subsistence farmer, whose access to credit is limited, and who
stands to lose more if the crop fails (Ziesemer 1987). This was also a pattern associated with
the green revolution especially in certain parts of the world. For example, in the Punjab, in
India, it was noted that the larger scale farmers had more of a tendency in general, to adopt
the higher yielding varieties, whereas a greater crop diversity was found in the fields of small
scale farmers (Shiva, 1989).
A number of factors other than risk sharing, such as the need for better irrigation
systems which were often accessible only to large scale farmers were also associated with the
adoption of high yielding varieties and may also have contributed to the faster diffusion of the
green revolution and therefore the spread of monoculture, among large scale farms. Despite
this, the importance of spreading risk among farmers is an acknowledged factor in their
tendency to plant crops of a more diverse genetic structure. Hayami and Ruttan (1991)
dispute the argument that the green revolution tended to favour large scale farmers, although
their analysis of adoption of new varieties in thirty villages in Asia, shows that while there
was a faster rate of adoption by small scale farmers (in relative or percentage terms), it was
the medium sized farms that tended to adopt the new varieties at a higher rate in later years
(pp338-339). This appears to support the argument that while the absolute rate of adoption
is lower in small scale farms, the relative rate of adoption is lower in large scale farms. In
addition, Hayami and Ruttan agree that in cases where the distribution of land was highly
skewed, new varieties tended to reinforce this bias (p 338). , ,; :jjr: :-v-j» f* .-< «^i
Thus it is likely that for reasons of access to the higher prices associated with the new
biotechnology based varieties, and of spreading risk, the adoption of higher quality, to the
extent that it results in declining variety, will most probably be more common in areas with
large landholdings with a principle agent structure. This is already apparent to some extent
in countries such as Malaysia where large landholdings of important cash crops such as rubber
and oil palm are being uniformly planted with higher yielding varieties which are more similar
in terms of genetic make up. Thus, it is difficult to say what the impact on variety, as a result
of consumer preferences, will be in agriculture.
Similarly, with animal biotechnologies, the use of a number of new drugs such as
Somatotropin, as mentioned above, may result in a reduction of species variety as higher
yielding animals and fish, increasing social welfare and increasingly replace the older, lower
yielding varieties.
In the case of the pharmaceutical sector, the implications are less ambiguous. It would
be expected that the appearance of higher quality drugs and vaccines would make older
products, of a lower quality, redundant. This may not necessarily be the case if social
preferences are taken into account. Despite the availability of the new drug, old drugs will
continue to be demanded by society because of incomplete substitution between the old and
'.'-• "'••••• ": • .-. 115 •'. ••...new drug. A number of reasons, including allergies to particular medications, a preference
for both brand name based and generic varieties'", and the presence of different strains of
diseases which have to be treated using slightly differentiated medical treatments may ensure
that new drugs will not immediately drive out older, competing products. In the longer run
when genetically engineered products become more widely available, there will however be
more of a tendency for consumers to choose the new product rather than choose for variety.
The genetically engineered product, which is a more perfect substitute for the older product
will therefore completely displace it "\
Conclusions
Thus, two implications emerge from this chapter, relating biotechnology to the growth and
trade models constructed in Chapters 8 and 9 in Part HI. Firstly, as discussed above,
consumer preferences appear to imply a desire for higher quality, but not necessarily at the
expense of variety. Thus, even though quality improvements provide consumers with a more
desirable product, this does not necessarily result in all older qualities being rejected
immediately, although, this may be the case in the long run and is more likely to happen as
genetically engineered products become more acceptable and accessible. In fact, production
of higher quality products and products which are cheaper, tends to result in an increase in
the total variety of products available in the economy. Thus, the evidence from biotechnology
shows that consumers tend to prefer both variety as well as products which are cost reducing
or of a higher quality. We have taken the particular example of Pharmaceuticals because the
evidence here is most clear. Society will always prefer a greater variety of products, including
both higher and lower quality products.
Even though we have used this particular example to use in the subsequent growth and
trade models, there is also similar evidence from the agricultural sector where industrial
biotechnology is adding to the total variety of products available to consumers. The evidence
here is however mixed, showing that while in some cases biotechnology adds to product
variety, it can also completely displace the older product.
This last result led to the second conclusion we draw from this chapter, namely that
biotechnology appears to have an important implication for north-south trade. Of all the
products examined, the trend appears to be that biotechnology research done primarily in the
north is targeting and displacing products produced in the south. Many of these such as sugar,
'" Here the production of different varieties of the same products, depends very much upon the
type of patent regime present in the country. For example, Indian companies are able to produce and
export AZT, the drug used to treat AIDS, because the drug was developed using a different process,
than that used by Wellcome, the patent holder for AZT in the United States. Because India does not
grant or recognize product patents, this is possible under Indian patent law, but not under US patent
law which grants process and product patents. The Indian AZT is being exported to a number of
developing countries who would otherwise have to pay a higher price to import the American drug.
'" 1 am grateful to Dominique Foray, who was a discussant at the Evolutionary Economics
Conference in Strasbourg in October 1994 for pointing out this distinction between the long run impact
of biotechnology as genetically engineered products become more accessible to consumers.
116vanilla, cocoa are traditional agricultural products. Biotechnology therefore will result in
traditional products from developing countries losing value and being driven out of the market
The total share of international trade is therefore declining for developing countries,
confirming some of the earlier observations made about trade relations between north and
south.
In the next section we examine the manner in which the theoretical literature discusses
the implications of innovation for growth and trade. The way in which preferences for variety
and quality are modeled in the new growth and trade models are then related to the
implications of biotechnology R&D for quantity, quality and variety, before moving on to the
model presented in the final section. The structure of consumer preferences observed in this
chapter are used in both models and we also discuss the final conclusion, that of declining
share of trade for developing countries, in the model on international trade presented in
Chapter 9 below. ^
117Part II Quantity, Quality and Variety: The
Theoretical Debate
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^Introduction
In the previous section, we examined the changing nature of quantity, quality and
variety in developing and industrialized countries, as a result of innovation and imitation in
biotechnologies. We concluded that both quantity and quality based improvements may have
a significant impact on economic growth in biotechnology affected sectors, and also on the
variety of products available to consumers. The nature of the impact, i.e., whether it would
be variety reducing or variety increasing depends very much on consumer preferences and
would be different in different sectors. Thus to recapitulate briefly, in the pharmaceutical
sector, biotechnology innovations would mostly have a positive impact on variety, especially
in the short run, although as genetically engineered products become more widely available,
this variety may be reduced to one as consumers choose the genetically engineered products;
in agriculture, this impact was more ambiguous, depending upon the absolute or relative risk
averseness of farmers, and increasing returns in the supply of seeds'".
In Part II, we continue to examine the impact of innovation upon the changing nature
of quantity, quality and variety, but from a theoretical perspective. The literature on
technological change has gone through a number of changes, most importantly, in attempting
to endogenize rates of technical change and the impact on economic growth. The sources of
technological change in these new growth and trade models have come mainly from human
capital, learning and investment in R&D. Many of them model innovation within a sector
devoted solely to R&D, while the innovation is commercialized in a separate production
sector. The earlier papers however tended to model technological change in an aggregate
sense, i.e. without explicitly referring to the microfoundations of market structures. In these
models, technological change was introduced often as a separate factor in the production
function, either as an exogenous shift parameter as in the early models, or as a variable
characterised by increasing returns to scale as in the later growth models. In the two chapters
which this section comprises we examine three different aspects of growth models. In chapter
6 which follows immediately, a brief survey of the aggregate production function approach
is described, beginning with the early growth models and ending with the more recent "new"
growth literature of the 1980s and 1990s, which has been built upon the foundations of old
growth theory, with a number of notable differences, most importantly of presenting
technological change as an endogenous variable and in introducing different sources of
technological change in the production function.
This is followed by a discussion of the manner in which the new growth literature is
related to market structure. Here the models introduced often describe the process of
technological change in the form of new products which are introduced on the market.
Innovation and production usually take place in separate sectors and are characterised by
differing market structures. We first look at models which describe innovation in terms of the
introduction of products which are horizontally differentiated followed by vertical
differentiation. The emphasis will be upon examining the implications of these two types of
innovations on product variety. .«; -;•;'•• •.••i;.,w -*-V*VU' -,s••••;r4r?v£vi?-;- •.-.• <v -• ;•••--..
'" On this latter aspect, some of these changes were already discussed in the methodology
section of Chapter 1 and will be discussed again in Section III below.
121It will not be the goal of this section, to survey the entire literature on new growth and
trade theory. Instead, we emphasise those models and discussions which relate more directly
to the methodology described here, i.e., the way in which these models relate technological
change to increasing quality and/or variety of products present in the economy.
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122The Economics of Technical
Change: The Aggregate Approach
Introduction
The early growth models, including those which first explored the effect of exogenous
technological change on the production function, were attempts at explaining the aggregate
impact of technical change on economic growth. The empirical analysis carried out by
Tinbergen (1942) and Solow (1957) demonstrated that the size of the remfoa/ was
considerable and growth could not be explained simply by factor accumulation. The early
growth models and some more recent ones attempted therefore to explain it within the
framework of the aggregate production function. These models do not use explicit
microeconomic foundations to explain the contribution of, or production of knowledge in
specific production or research sectors. Instead, knowledge or technology (and different
models use different sources of technology), is included in the production function as a
separate factor of production.
The early literature on technological change, especially Solow (1956), Arrow (1962)
and Shell (1967), looked at technological change as an increase in per capita output and the
capital labour ratio. These quantity increases improved consumer welfare because of the way
in which consumer preferences were modelled, and led to economic growth in all of these
variables.
6.1. Growth Theory and Technological Change
The early growth models or "old" growth theory placed capital formation at the centre
of technological progress in an economy. In the traditional production function, where the
basic inputs are labour and capital, capital referring to machinery and similar forms of
physical capital, the accumulation of the latter becomes the driving force behind a change in
the production function and therefore economic growth.
The foremost contribution to the theory of technological change was made by Robert
Solow. In his model which has formed the basis of much of growth theory, Solow (1956,
1957) argued that capital accumulation would cause labour productivity to rise as well,
resulting in rising factor productivity, rather than simple capital accumulation being the driving
force behind innovation and economic growth.
123The model in its most basic form is as follows: The production function for output
includes physical capital AT(/), and technological change, A embodied in labour L,
which is fixed.
0<a<l
Exogenous technical change is defined as an exponential function A=A^e*', where y is the
rate of technical change in the economy. Equation (6.1) can be rewritten
(2(0 = tf'-A
Equilibrium in the goods market is denoted by equality between savings and investment
and labour supply growth as
The system can be solved by taking growth rates of the components of the production
function, ie. AL and




From the production function we can solve for the growth rate of capital per efficient labour
unit, £
124=> * = - (y (6.8)
In the steady state when £ = 0, then the relationship between capital and effective labour is
steady. If (Y+£) is greater than ,sfc~™, then the capital to effective labour ratio is falling
and vice versa. In this case, the assumption is one of decreasing marginal product of capital.
Thus, economic output and the total capital stock in the economy grow at a steady rate
which is equal to the rate of growth of technical progress y, and the growth rate of labour,
g. Any change in factor inputs will result therefore in allocation adjustments and the
economy will find itself back in the steady state position.
Fig. 6.1. Dynamics in the Solow Model
Technical progress in this model and others based on this model, is therefore
exogenous and has a constant growth rate of capital per effective labour unit. The resulting
increase in total output per input unit, also implies that technical change produces a growth
in the total quantity of products produced per input unit.
While the Solow model is explicitly related to increasing output from technical change
based on physical capital accumulation, human capital and knowledge have also been used to
explain technological change in the early growth model. Shell (1967) looked at technical
change based upon public knowledge while Arrow (1962) examined the accumulation of
125knowledge through learning by doing. We now examine these and the growth models which
followed them.
6.2. Endogenous Technical Change
Thus while technological change in the Solow model was an exogenous variable in the
production function, Arrow (1962) and Shell (1967) explicitly referred to technological change
in which knowledge or learning is represented by cumulative gross investment, in the case of
Arrow (1962) and by resources devoted specifically to inventive activity in Shell (1967).
Arrow's main contribution was in arguing that the role played by knowledge in
production is an increasing function of time, i.e., the amount of knowledge available in the
economy at time f, was directly linked to all cumulative capital investment in the economy
before time /. This is the direct result of knowledge associated with innovations which
cannot be appropriated. Spillovers of this nature have also been explicitly introduced into the
production function by Arrow himself, and later by Romer (1986, 1990) and Grossman and
Helpman (1991a for example). Thus in the model, economic experience measured by
cumulative gross investment, determines productivity per worker, and learning results in higher
productivity of output.
Shell (1967) describes technical change as being related to explicit investment in
inventive activity, with a change in the stock of technical knowledge described by the
equation:
/•.,% ;
"" ' A" = aa(rmO - p# •'* •'> •• : - (6.9)
i
where 0£a(f)^l is the portion of output which is invested in invention and 0<a<l is the
portion of inventions that can be called successful. Thus, as with Arrow (1962), technical
change is attributed to public knowledge and private investment in invention (in the case of
Shell), or capital accumulation (as in Arrow). ••. A •-.-•.- , : • • •. r); - :;?. -
Among the later growth models, Romer (1986) follows this approach by introducing
knowledge spillovers which are privately generated, in the production function. Two sets of
factors are therefore used in the production function, one which denotes land, labour or
capital, is fixed in supply, while the other, A", which denotes knowledge, can be accumulated
over time. Increase in production in this model comes from the use of knowledge aggregated
over the number of firms in the economy:
where A" is aggregate knowledge and N is the number of firms. Thus the aggregate level of
knowledge is increasing over the number of firms in the economy. Firms maximize profits
taking AT as given and although the private marginal product of knowledge is decreasing, the
inclusion of aggregate knowledge in the production function, adds to the productivity of
private capital and therefore to total output. This spillover is similar to that of Arrow (1962),
126with the exception that in the model by Romer (1986), this externality is due to the action of
spillovers on the productivity of private capital. The introduction of the externality moreover
implies that a market solution is not optimal, introducing the possibility of government policy
to rectify the imbalance.
In Lucas (1988), the components of production, as they enter the production function
are physical and human capital, where #(f) is the capital stock and £(f) represents capital
accumulation. The introduction of human capital as an input in the production function is
simply in terms of a measure of productivity, i.e. a general skill level in which a worker with
human capital /i(f) is as productive as two workers with human capital of —A(0 each, similar
to the aggregate knowledge defined by Romer (1986), which is included in the production
function on the right side of the goods market equilibrium equation
where c(r) is consumption, N(f) is labour, A is a general measure of technology in the
economy and is constant as in Solow (1956 and 1957 or a spillover if y>0 ) and /i^(f) is an
average measure of human capital in the economy, across all labour classes. Dynamic
technological change in the model comes from the rate of change over time of this human
capital: -• -- >•-• ^..^.J' » f . •-» • • •• q ;:-. >>• ', ft ; .^
yj"'" A(r) = A(r)*G(l-«(r)) (6-12)
where G is increasing with G (0) = 0 . Holding 8 = 1 and assuming that G is linear, this
implies that
•• .^t,,..r.";^ <(f)-A(r)o[l-«(/)] / .,.'". ;'j ;.-'..'.. «>.13)
According to this formulation if w(r) =0 then the growth of /i(f) is maximum (= a),
whereas if M (f) = 1, then there is no growth in /i (f).
Aggregate economy-wide productivity and total output is therefore the subject of these
models which follow the basic Solow (1957) production function approach, although the
sources of technological change can be labour or capital augmenting, where technical change
can exhibit constant or increasing returns to scale in total factor productivity. '* •'•' •* • "^
Lucas' (1988) second model is extended to two goods, where production is once again
a function of human capital, but where productivity growth is also dependant upon the
percentage of the workforce devoted to production. Instead of describing human capital
accumulation as withdrawing the labour force from production and into training, such as in
the first model, in this model, productivity is defined in terms of learning by doing and is
directly related to the effort devoted to production.
127c,.(fl - *,(flii,.0JV(fl , i-1,2 (6.14)
where c_ is consumption, w,(/)is the fraction of the workforce devoted to producing goodj
and where the rate of change in /i (0 can be written
where the rate of growth of /r can be interpreted here as learning by doing, which increases
with the effort H,(f)devoted to production, where by assumption, if o,>CT2 > then good one
is the high technology good. Thus in contrast to (6.13), this formulation shows that learning
by doing will increase as the amount of effort devoted to production increases. The opposite
was the case in the earlier model, where it was the amount of labour withdrawn from the
labour force which had a positive impact on technological change.
Preferences are defined by a CES utility function
a > 0 , a + a = 1 , p > -1 , y =
The allocation of production in autarky is determined by the elasticity of substitution, where
if gamma is larger than 1, goods are perfect substitutes and the economy will only produce
one of the two goods. The opposite is the case, when gamma is less than one, then both
goods are produced and the share of each good is determined by the allocation of resources
to the production of each good 8,M, = 5j«j. Determining which good to specialize in, in the
case that gamma is greater than one, depends upon the initial conditions and technologies.
Thus if the economy produces c, more efficiently at time 1, then more is produced and the
economy becomes better at producing it.
In a situation of free trade (two small countries trading with each others), specialization
is determined by relative prices and each country produces according to its initial endowment
of human capital; because of the externality created by human capital accumulation, countries
accumulate skills and knowledge over time and become better at producing the product in
which they have comparative advantage initially and specialization.
Thus technological change in this case, enhances initial comparative advantage, with
the good in which the country initially had comparative advantage, being produced in greater
quantities as a result of learning in this model.
Technical change is therefore modelled explicitly as a productivity enhancing process.
The way in which technical change has been introduced however has been different through
the years. Despite this, the earlier models appear to have been mainly concerned with
explaining some of the stylised Kaldorian facts about economic growth. Productivity
improvements as they have been modelled, mainly through the production function, imply an
128increasing quantity of production in the economy. Even in those models, such as Lucas
(1988), where more than one commodity is explicitly introduced into the model, the emphasis
is on increased production of those commodities rather than an increasing range of varieties
or qualities of products. As utility is only influenced by quantity (by assumption), this is a
meaningful approach. However, once variety and quality appear in the utility function, this
will have to be changed.
Conclusions
Thus in this first chapter in Part II, we have introduced some of the basic literature on
technological change and economic growth. The main causes of economic growth in these
models points to the importance of technological change, variously portrayed as capital
accumulation in the Solow (1956, 1957) model, as knowledge based, learning by doing in
Arrow (1962) and public knowledge in Shell (1967), as knowledge spillovers which are
privately generated in Romer (1986), as well as human capital in Lucas (1988).
The production function approach has been used largely to show the importance of
introducing scale economies in technical change and economic growth. In these models,
economic growth is largely portrayed as increasing output of a particular good. However, a
number of recent models have also described technical change in an economy in the form of
new products entering the market in each time period.
In the following chapter, we examine two of these approaches that new growth and
trade theory has taken, namely, (i) the introduction of new products through technical change
which are horizontally differentiated, i.e. are imperfect substitutes for products already in
existence; and (ii) the introduction of new products which are quality improvements over older
qualities, and are therefore perfect substitutes for the older products. The implications for
variety of both types of innovations are quite different and we discuss each in turn, before
moving on to the model of endogenous growth and trade, developed in Chapters 8 and 9, and
which is based upon some of the models we discuss in Chapter 7 below.
129Variety and Quality in Trade and
Growth Models
Introduction
In the last chapter we discussed growth models that have taken the production function
approach to technical change. An important characteristic of these models was the use of
capital or knowledge augmenting technical change combined with knowledge spillovers, that
contributed to an increase in the total productivity and therefore in the total quantity of goods
produced.
In the 1980s and 1990s, a new group of models emerged, with a slightly different
approach to the sources of technological change. The basic premise of these models was that
technological change can often be observed, not just as an increase in productivity which can
lead to increasing quantity, but also through the appearance of new goods which are (i)
imperfect substitutes for one another and are variety increasing; and (ii) perfect substitutes in
that they are higher quality products and completely replace older qualities.
For example, in the case of the first, similar products with different brand names, have
become widely available in the market and two way trade in like or similar products has also
become a common phenomenon. Similarly, in the case of the second kind of technological
change, daily observations point to the existence and appearance of products or processes
which are of a higher quality than older products. Consumers tend to prefer these higher
quality products, rejecting the older qualities from their consumption bundle in the process.
Thus technical change can result not only in quantity increases but also in the production of
new goods, similar to, or imperfect substitutes for products already in existence.
This is also the case with biotechnology where quantity increases as a result of
productivity improvements do occur, but the appearance of new products which are imperfect
substitutes for older products are also characteristics of the new biotechnology. For example,
the development of new substitutes for older products such as sugar and vanilla, among others,
is a common example which has been used in the literature (see Junne, 1991), and although
the new products may displace older products to some degree, in general the result, especially
in the case of sugar, has been a rising variety of products. In the same way, higher quality
products such as vaccines and diagnostic kits for detecting diseases or processes such as
bioremediation, to extract metals and other material from wastewaters, may also lead to the
rejection of older qualities by consumers. Thus the development of new substitutes for older
products is also an example which can be used in biotechnology and lends some substance to
the argument of increasing or decreasing variety, the former the result of horizontal
innovations, whereas the latter is the result of production of vertical innovations, which push
out older qualities.
In this chapter we look at this aspect of technical change, especially in the context of
new growth and trade models and relate them to the structure of the growth and trade model
which follows. Specifically, we will examine the way in which products enter the market and
131the implications for variety depending upon the manner in which consumer preferences are
modelled. Since the earliest models are trade models, we look at these first and then move
on to the more dynamic growth models of the late 1980s and early 1990s.
7.1. The Variety Models
With respect to the horizontal differentiation models, the appearance of new varieties has been
discussed in two ways in these models. The first is by modelling new varieties in the
production function and the second through consumer preference for variety. We begin by
discussing these two approaches and then provide a more detailed survey of the models
themselves.
7././. //orj'zonta/ Dzj(fer£/iriarion in f/ie Production Function
Increasing variety has been presented in the new growth models by including them explicitly
in the production function. Instead of consumers demanding greater variety, in these models,
final output is increased through the use of a greater variety of inputs, or intermediate
products. Increasing variety appears therefore, not from preferences but in the production
function for the final good.
In Ethier (1982), product differentiation is expressed in a variety of intermediate
products and the manufacturing sector, which produces under increasing scale economies, has
the following production function:
Af = n'
(7.1)
where JC(») is the quantity of the rth intermediate good, the parameter alpha lies between 0 and
1 and n is the number of intermediate goods used in the manufacturing sector. The
production function, indicates higher productivity from increasing variety, depending upon the
value of alpha. Lower values of alpha indicate higher productivity from a greater variety of
intermediate goods used in this sector. In a static analysis Ethier shows that two way trade
in both differentiated and homogeneous sectors follow the basic results of the Heckscher Ohlin
theory quite closely, although there is specialization in different varieties of intermediate
goods.
Romer's 1990 paper also uses this concept of increasing variety in the production
function
where //,, is human capital used in the production of the final good, F, L is labour, and JC is
the ith intermediate product, x. Output depends upon increasing variety A, of intermediate
132goods. The producing firm has to rent .*(/) units of the durable good i , which is patented,
before he/she can produce the final good y. // and L are fixed and AT, which is total
capital, grows by the amount of consumption foregone
where C(0 is consumption at time / and the relation between intermediate goods and capital
stock is denoted by AT=uJ2 •*, where u represents consumption foregone, i.e. the number of
units which are invested in the production of the intermediate good.
The aggregate stock of innovations (summed over all individuals as in Romer (1986))
changes according to
X = 8//,A (7.4)
where A can be seen as knowledge or spillovers from innovative activities (as in the 1986
paper) or as the number of varieties, so as not to get confused with //^ which is also
knowledge or human capital. These spillovers or the number of varieties increases the
productivity of human capital in the research sector. This is an important specification, which
has been used by a number of others (see below), and not only implies a growth in proprietary
information, but also in the contribution of innovations to knowledge in the economy. Thus,
the growth of knowledge is directly proportional to the stock of new varieties A, in the
economy.
The research sector exhibits increasing returns to scale, which therefore results in an
increase in the marginal product of human capital used in research. The externality produced
by the growth of varieties in the economy implies a balanced growth equilibrium, in which
growth in the economy is dependant upon the productivity of human capital, 8//^ (which is
equivalent to the growth rate of #).
7.7.2. //orizonfa/ DjjJtereHftafion 77iroM^/i
Most of the new models which have attempted to describe technological change in
terms of the appearance of new, horizontally differentiated products, have made use of the
"love of variety" approach based on Spence (1976) and Dixit and Stiglitz (1977). The love
of variety approach uses consumer preferences to indicate an increasing desire for variety.
The basic approach uses a symmetric and concave utility function where the total number of
quantities available, are demanded by consumers. This Constant Elasticity of Substitution
(CES), utility function is usually defined as
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where a is the elasticity of substitution between two varieties and n is the total number of
varieties. Restricting elasticity to be larger than one implies that marginal revenue will be
positive (or if the elasticity of demand with respect to price is lower than 1, marginal revenue
is negative (Helpman and Krugman, 1985), which implies that the utility function can be used
in models with imperfect competition.
In addition, to quantity, this function has the property of also valuing variety. The
indirect utility function therefore has the following form
|«c, (7-6)
where £/n/?, measures consumption and nls the number of varieties of product i available
where the price /?, is the same for all varieties. Then the consumer will prefer to buy all
varieties in equal quantities given the budget constraint. The utility elasticity of n "'""'> 1
is higher than that of C. Thus the number of varieties, as they increase, increases consumer
welfare, because of this form of preferences.
7.7.J. Trade a/id Grow/A and /ncreaji'n^ Variety .
Although the Heckscher Ohlin Samuelson model of international trade has formed the
basis of modern trade, its restrictive assumption of perfect competition has caused some
degree of uneasiness in using it to explain all international trade patterns. The testing of trade
theories (see Learner, 1984) has been a regular phenomenon in an effort to prove its efficacy
with respect to different kinds of trade flows. One particular area has been of special concern
and a weakness of the HOS trade model, namely intra-industry trade. Despite all indications
pointing to a dominance of this kind of trade, the HOS model with its restrictive assumptions,
is largely unable to explain it. Many of the new trade models which have been developed,
have been in response to this gap in traditional factor endowment based theory. Intra-industry
trade, as its name suggests, is two way trade in like products, and indicates some degree of
demand for variety, rather than just quantity, as the previous models have implied. Technical
change must therefore take place partly in response to this apparent demand for like products.
The group of trade models we discuss in this section therefore, relate to intra-industry trade
in horizontally differentiated products.
While the early trade models were mostly static, they were followed by a number of
endogenous growth models which discussed the impact of technical change on economic
growth within a dynamic framework. These will also be discussed below, especially in
relation to the impact of technical change on the variety of products available and demanded
by consumers in the economy.
134In a stylized north-south model, Krugman (1979) departed from the older trade and
growth models in demonstrating the appearance of new products (which were different from
oW products) as a result of technical change. The model was based on Vernon's (1966)
theory of the product cycle which argued that products are transferred to countries with lower
labour costs after a period of being produced in innovating countries. The basic idea and
assumptions of the model are simple. Two countries exist, north and south and the only
difference is that while the north produces new goods and perhaps old goods as well, the south
can only produce old goods.
Consumer preferences are based on (7.5) above. However, in the case of the Krugman
(1979) model, n is the number of northern and southern products available to consumers.
Similarly, instead of assuming productivity increases in the production function as in the other
models, he assumes that technical change occurs entirely in the form of the availability of new
products, resulting thus in an increasing variety of products rather than an increasing quantity
of the same product.
By assumption, only the north can produce new products, whereas the production of
old products depends upon relative wages. In this case, Krugman assumes that M^/WJ>1 ,
implying that the north is not competitive in producing old goods, resulting in a model with
complete specialization. By assuming a rate of innovation and imitation which is proportional
to products already in existence, he assumes technical change based on previous knowledge,
where the appearance of new products depends upon old products
rt = in (7.7)
n = M
where n denotes the number of products available, dots indicate rates of change over time,?
is a parameter, and the subscripts 5 and n denote south and north respectively. The rate of
innovation in the north is therefore proportional to the number of products already in the
economy, while the rate of imitation in the south is dependant upon the number of products
and a lag which is measured by 1 //. Thus the steady state is characterised by constant wages
and rates of innovation and imitation.
Although simple in formulation and simplistic in its assumptions, the Krugman model
was considerably influential in that it led the way for a whole group of new models which
depicted technical change as increasing variety rather than just quantity.
Judd (1985) and Grossman and Helpman (1991d) extend Krugman's initial model to
a dynamic framework. In Judd (1985), the problem faced by the country is a trade off
between present consumption, or future investment in invention which will increase product
variety. The country's utility maximization is then
max Je*'y"V<fr , OSy^'V"
0
135where beta is the rate of time preference, y(r) is the common level of consumption where the
interval of goods is described by the set [0,V(/)], and 0<<x<l , V is an integral measure
of the number of goods as before, the elasticity of demand for a good is (1 -a)"' and lambda
is a parameter describing the constant growth rate of labour, where X>0. The symmetric
structure implies that at each time consumers will consume each good at the same rate.
Innovation is measured by the equation y(f)=(e*'-ifcV)/V where ifcV measures the
amount of labour allocated to innovation. The optimal rate of innovation is therefore one
where the loss of current utility due to investment in innovation, is equal to the gain in next
period's utility from increasing variety. This model also demonstrates an interesting property
of CES functions which will become relevant in the model developed in Chapters 8 and 9
below, namely that in spite of the presence of monopoly profits from infinite patents as is one
of the cases described by Judd here, the equilibrium attained is optimal. This is because the
CES utility function, due to its assumption that all monopolies charge the same price, ensures
that the marginal rate of substitution is always equal to the marginal rate of transformation and
the allocation of consumption will be efficient at any time, given the allocation of labour
between production and innovation '**. Thus unlike a number of new growth and trade
models in which the presence of an externality from imperfect competition results in an
inefficient allocation of resources, the presence of monopoly profits in this case does not
imply that government policy to redistribute resources would be efficient or desirable.
In the case of Grossman and Helpman (1991d), as in Krugman, comparative advantage
in the production of new products is assumed to lie with the north, while the south is the
imitator. However, unlike Krugman, the wage gap between the two regions cannot be
assumed to be constant and two different outcomes may result, depending upon whether the
wage gap is narrow or large. The southern firm which has a cost advantage over the north,
prices according to the size of this wage gap, although the result is always a movement of
production from north to south.
Similarly, in contrast to Krugman (1979), instead of assuming an exogenous rate of
innovation and imitation, these rates are endogenously developed in the model. Knowledge
spillovers as in Arrow (1962) and Romer (1986), are also included both (i) in the production
of new varieties and (ii) in imitation as the south targets a given number of northern products
for imitation at any time. In contrast also to the Krugman case, they find that because of
increasing returns to scale in production of goods and knowledge, relative wages in the north
rise when the relative size of the north increases. However, while steady state growth
increases with an increase in the size of the North in the narrow gap case, in the case of the
wide wage gap, the opposite is true and an increase in the size of the south increases steady
state growth. Moreover, international trade is always welfare improving in both cases.
Intermediate product variety and trade is also discussed by Grossman Helpman (1990),
in a dynamic analysis of the impact of scale economies on trade and growth. Using the Ethier
(1982) production function shown in equation (7.3) above, the main contribution of this model
is in describing innovation and production as an interaction between two separate sectors. As
with Ethier (1982) also, the specification of the production function ensures that technical
efficiency gains are made from an increasing degree of specialization. This comes from the
increasing number of varieties (indicated by an increase in «) of intermediate products which
"* Judd (1985), pp 572-3.
136go toward the production of the final good. Thus innovation takes place entirely in the
intermediate sector and generates dynamic scale economies in the final product sector. As in
Romer (1986) above, private investment in R&D generates two kinds of products, (i) an
innovation for which innovators receive indefinite patents whose benefits are appropriated in
the form of oligopoly profits and (ii) knowledge which cannot be appropriated but instead
provides increasing returns in the next generation of innovations. The patented innovations
thus generated are bought by intermediate producers to increase the number of intermediate
varieties produced.
Comparative advantage is measured by the relative productivities of the R&D and
intermediate sectors in each country where if ^,=("tn;)/(^z.x,)° measures relative labour
coefficients of the R&D and differentiated sectors in country i , then country 1 will have
comparative advantage in R&D if t, <^ •
The results show slower growth in variety and in the world, if relative demand for the
final product of the country with comparative advantage in R&D increases. This is because
resources are moved out of the sector with comparative advantage, into the sector with a
comparative disadvantage. Thus rather than the very special Krugman (1979) conclusion that
economic growth is always increased through trade, in this model Grossman and Helpman
conclude that the assumption of different relative productivities changes this result
substantially.
In their earlier model (1989), also on trade in horizontally differentiated products,
Grossman and Helpman use a love of variety utility function
M =
n OJ "Hi; "
.- • •; 4 - ,,. ....
a^e(0,l) -'-T
•; C7.9)
which exhibits consumer preferences for increasing variety as in Krugman. c^(«) is
consumption of differentiated good i", c is consumption of the homogeneous good, and n is
the number of available varieties. In production, constant returns to scale are assumed, with
human capital and unskilled labour the two factor inputs. The assumption of different relative
endowments along with the production technologies specified, ensures that the north produces
and exports differentiated goods and imports the traditional good. s^«=i >.r ' *•>! . i
In this model, as in their later model (1991d) described above, newly invented products
do not displace older products. There are two major difference with the later model: (i) while
the 199Id model assumes differences in technologies, in 1989a they assume differences in
endowments and (ii) the 199Id paper includes knowledge, and blueprints, in the sense of
Romer (1990). The results however for variety are basically the same, where the number of
products is increasing and variety offered to the consumer is also increasing. In trade, based
on different relative endowments of skilled and unskilled labour, the result is that there is no
more R&D in the steady state and all resources are devoted to production.
In Grossman and Helpman (1991a, Ch. 3), production and innovation are introduced
usually as separate sectors following Judd (1985). Inventors are granted patents of an
indefinite duration although free entry and constant returns to scale drive profits down.
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where as in Ethier (1982), *(/) is quantity of the intermediate good i, and as in the Spence-
Dixit-Stiglitz formulation, the elasticity of substitution between any two products is
O = 1/(1-|3)>1 . The production function above, exhibits constant returns to scale in
quantities, given n. The elasticity of production of n, 1/(J, is higher than that of x.
In a second formulation, R&D activities are characterised by increasing returns to scale
as a result of knowledge spillovers and new products produced by the R&D sector have the
following technology
n = fifl (7.11)
where the rate of innovation n is proportional to the productivity, _!!. of aggregate labour
employed in the R&D sector, L_ (the previous verbal formulation had been in (7.11) with
A^(f)=l except in the previous case in equation (7.4), where A and A were used instead of ri
and ATJ. This production technology for innovation is a differential equation describing the
evolution of the number of varieties. This is similar to the equation used by Judd in (7.8),
g *•' _ Y y
where V = — describes the evolution of innovation in time without spillovers, while
it
the exogenous formulation of Krugman in (7.7), « = in, describes the rate of innovation in
the north.
In the case of knowledge spillovers in R&D, the cost of producing new varieties falls
as knowledge accumulation rises. This provides the incentive for investment in the
manufacturing firm. The increasing stock of knowledge increases the incentive to do R&D.
However, because of the resource constraint, any shift in resources from production to R&D
implies an increase in R&D at the cost of production. This in turn implies that the value of
the R&D firm rises. Thus the combined effect of investment in R&D and in manufacturing
as the cost of product development falls, implies that in the steady state, resources are devoted
to both R&D and production and the growth rate of new varieties is constant.
Thus, in these models of increasing variety through horizonal innovation, two general
observations can be made: (i) firstly, the specification of consumer utility and production
functions usually imply increasing utility or increasing production of variety. Horizontal
innovation of products which are imperfect substitutes for older products add to the total
variety of products available in the market; and (ii) trade usually leads to specialization in
different varieties of products and both countries trade in horizontally differentiated products.
Comparative advantage arises, either from an assumption of different relative factor
endowments as in (Grossman and Helpman, 1989) or through different technologies as in
(Krugman 1979, Ethier 1982 and Grossman and Helpman (1991d)). v, vsr-
138Thus the general characteristics of these models, is that innovation produces new goods
or factors which are horizontally differentiated. Their impact on variety is increasing, because
they are imperfect substitutes for older products.
In the following section, we discuss another group of models in which product
innovation is not horizontal, i.e. increasing variety, but vertical, i.e. increasing quality.
7.2. Trade and Growth in Higher Quality Products
Two types of models are identified here. In the first, the results of quality
improvements are constant or changing ranges of product variety, while in the second, creative
destruction results in only one product, the highest quality product, being available in the
market. Thus in the latter, quality destroys variety, whereas in the former, this may or may
not be the case, depending upon the model specifications.
In contrast to the Krugman paper, which examined the emergence of new products
based on a horizontal differentiation framework, Flam and Helpman (1987) developed a trade
model in which exogenous innovation is vertical, i.e., it introduces new products of a higher
quality, into the economy in a comparative statics manner.
The two country, one factor model is based on trade in two commodities, one
differentiated and the other homogeneous. Comparative advantage arises from differences in
relative labour productivities and the North has comparative advantage in new products. Unit




where a(z)/a*(z) is declining in z (an asterisk indicates the foreign country, in this case
south), A is a productivity measure, and the north has comparative advantage in high quality
products if y" > y. .
The specification of the utility function
n(y,z) = y««, a>0 (7.13)
where y is the homogeneous good, and z the quality index of the differentiated product, one
unit of which is consumed, ensures that the relationship between consumer income and the
consumption of a greater quantity of the homogeneous product, as well as a higher quality of
the differentiated product, is positive. The specification also implies that there is an income
class /, corresponding to labour class /i^, where /i is a measure of human capital, or skills,
at which the consumer is indifferent between consuming good z from the north or from the
139south. They introduce an income distribution for a continuum of individuals who populate
both regions, and belong to different income classes, as described above.
Assuming that only the south produces homogeneous goods, whereas both regions
produce the differentiated good, the question to examine is the range of z products that are
consumed by both regions in equilibrium. The assumption of northern comparative advantage
in high quality goods implies that in the central case, the north exports high quality products
and imports low quality and homogeneous products from the south. The presence of different
income classes however, is what determines the range of products consumed by both regions
and in equilibrium, they calculate the maximum and minimum quality of commodities
consumed and produced by each region, based upon income distribution and demand.
Comparative statics show that the range of products thus consumed, changes when
there is a shift in the initial parameter specifications. For example, an increase in the southern
productivity parameter, A *, has a negative impact on relative northern wage and the northern
income class, /i^, switches consumption to foreign products. This is because the price of
southern products has fallen and because northern production and northern wages decline.
However, the decline in northern wages is not big enough to make them equal to southern
wages and some northern consumers belonging to this income class shift demand to southern
goods. Thus the range of products produced in the north declines while those produced in the
south rise. The opposite happens in the case of a rise in northern productivity, where northern
consumers demand higher quality goods and because of their expanded income, the northern
range expands to include higher quality goods as well as a larger number of lower qualities
than before, while the southern range contracts. The entire range of commodities (from the
maximum quality consumed in the north, to the lowest quality consumed in the south),
however, remains the same. This is because a constant proportion is spent on differentiated
goods by each income class, which is exogenously fixed.
While the Flam and Helpman (1987) model shows that the result of quality
improvements is a constant range of products consumed and present in the market as older
varieties are pushed out, the models by Segerstrom et.al. (1990), Grossman and Helpman
(1991b and c) and Aghion and Howitt (1992), have a different implication for variety.
Segerstrom et.al. (1990), assume two countries with labour endowments which are
fixed over time and only workers in the north are capable of doing R&D. The result of each
R&D race is an innovation which provides the firm with a monopoly. There are three groups
of products present in the economy at each time, old goods, present innovations and
innovations still to come. Within each group however, goods are perfect substitutes, with a
Cobb Douglas utility function. Thus each time a new product « +1 becomes available,
consumers, given the choice of goods JC, and a^,, which, if are equally priced, would
choose the new good a*,,,, . Thus new goods substitute perfectly for old products and when
both are priced equally, the new product makes the old one obsolete.
Quality based improvements in intermediate products are introduced by Aghion and
Howitt (1992), in the production function. Innovation takes place through R&D according to
a poisson process and is independent of all previous innovations. Each innovation gives the
innovator an economy wide monopoly over a new intermediate product from the patent which
lasts forever, although the monopoly lasts only until the next innovation. Each subsequent
innovation raises productivity by a constant parameter, although the cumulative nature of
innovation implies that productivity in each period increases by A^A^y* where A,, is the
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point in time the economy has a higher A,. The assumption of monopoly in the intermediate
goods sector is made to ensure that producers cover the costs of buying the patent from the
innovators. The idea of Schumpeter's creative destruction is thus incorporated in the model
as each new innovation destroys the previous innovator's monopoly, while raising economy-
wide productivity.
The allocation of labour between manufacturing and R&D shows a negative
dependency of current research on future research. The prospects of losing monopoly from
next period's R&D because an anticipation of higher investment in R&D will increase wages
and therefore reduce profits this period, and a rising rate of creative destruction in the next
period, therefore discourages R&D this period.
In equilibrium, R&D decisions this period therefore have to take into account all costs
and benefits, including the costs or benefits of next period. The result of creative destruction
therefore is the appearance of a new quality of intermediate products and an economy-wide
increase in productivity. However, the destruction of this period's monopoly rent by next
period's monopolist results in one variant being available in the economy in each period.
Thus, the result of higher quality is a destruction of the older variety and the presence in each
period of only one variety, the highest quality.
Based on the Aghion and Howitt (1992) approach, Grossman and Helpman (1991c),
include consumer preferences for higher quality products specifically in the utility function
= J [
where oT,(co) denotes the quantity of consumption of quality y of product co at time f. The
result of R&D activity is the production of both blueprints which are appropriable and of
knowledge which cannot be patented and spills over through the production function for the
next innovation. Production is based upon a single factor, labour and is characterised by
oligopoly. Each product co can be improved with quality y being denoted by ^.(co) = V where
lambda, the quality "jump" is the same for each co. This is similar to the Aghion and Howitt
formulation of productivity increasing according to A^A^y* where A,, is the initial value
of A and y>l indicates the productivity increase each period. The consumer therefore
prefers at each time, the highest quality, with the lowest quality adjusted price. This as we
shall see, is the highest quality, or the newest innovation.
The innovator of the newest quality charges a price which, adjusted for quality, is
lower than that charged by the nearest quality: because of the assumption of free entry,
producers price at marginal cost, which is the wage rate adjusted for the quality of the
product. The price of the highest quality therefore is also equivalent to marginal cost adjusted
for quality. However, because of the higher quality, the innovator is always one step
(equivalent to lambda) ahead of the nearest rival and the limit price of each new innovation
is
141(7.16)
where lambda is the size of the quality improvement. The leader captures the entire market
by pricing below the price of the nearest rival product (which is equal to marginal cost), and
because of the lower price, is able to capture the entire market. Thus all previous producers,
who price at marginal cost, are pushed out of the market, leaving only the highest quality
product in the market.
On the demand side, due to preferences, the consumer will prefer a higher quality
product with the lowest quality adjusted price. This will always be the newest product
Since licensing of patented innovations is not possible in this model, all manufacturing
takes place by the innovator and the incentive to invest in R&D is a flow of profits until the
next innovation occurs. Innovation occurs with probability id/ at time dr. The size of the
technology "jumps" up the ladder remain constant and as in Aghion and Howitt (1992), with
each innovation the level becomes larger. The assumption of monopoly profits ensures that
while inventors never target their own good for improvement, once the improvement is made,
some inventors move toward improving the improved product. Preferences on the other hand,
as described above, indicate that consumers will only choose the highest quality, adjusted for
price. Both these conditions, imply that only one variety, the highest quality, will remain in
the market and will be consumed.
In an extension to a two country case, with three firms, Grossman and Helpman
(1991c) show creative destruction in a trade model. They assume that the north is better at
doing R&D than the south. Each jump up the ladder is exogenously given as X>1 . The
market structure consists of a northern leader who innovates and prices at its marginal cost,
equivalent to northern wage adjusted for the quality improvement; a northern firm which
competes with both northern and southern firm and maximises profits by setting a quality
adjusted price equal to or below the southern firm's marginal cost of production which is
southern wage; and finally a southern firm which imitates, prices at a quality adjusted rate
above its marginal cost. Innovation and imitation technologies require a^i and a^i
units of labour for a leader and for a follower respectively.
In the steady state, rates of imitation and innovation are constant. Each product is
improved stochastically and although the presence of three firms implies that the product can
be improved upon or copied in the steady state, there is a constant process of quality
improvement. As in (1991b), preferences in the utility function imply that consumers want
the highest quality (price adjusted).
Northern innovators improve on southern products and because labour productivity is
higher in the north (i.e. a^<a^ ), the higher quality product has a cost advantage and all
production of the new good moves to the north. Because the northern innovator is able to
price at lambda times the marginal cost of production of the nearest competitor (who is always
one step below on the ladder), and because consumers demand the highest quality, the
innovator is able to monopolise 100 percent of the market. This shift in monopoly profits
from southern to northern firm, or vice versa, or from a northern firm to the newest innovator,
ensures that all earlier monopolies (either in the north or in the south) are wiped out and only
one variety is left in the economy, that of the highest quality. TJ;.- •^•
142This aspect of both the Grossman and Helpman (1991b and c) and Aghion and Howitt
(1992) models implies that the equilibrium growth rate is not the optimal growth rate, because
of the presence of monopolies and the business stealing effect where the innovator destroys
the producer surplus of the previous monopolist and Grossman and Helpman (1991b) suggest
the use of a tax or a subsidy on R&D outlays to ensure optimum growth in R&D investment
and consumption.
Thus, in contrast to the Ham and Helpman (1987) model where a whole range of
qualities remains in the market in each time period, in the Segerstrom et.al. (1990), Aghion
and Howitt (1992) and Grossman and Helpman (1991b and c) models, only one variety, the
newest or highest quality (whether it has just been invented or whether it has been imitated),
remains.
In somewhat different approaches, Stokey (1988, 1991) and Young (1991, 1993)
demonstrate that quality improvements can have a different impact on variety than some of
the models discussed above. In Stokey (1988) and Young (1991), an improvement in product
quality results in higher quality characteristics. A range of characteristics are present in the
labour force, which in turn reflect the range of qualities produced
(7-17)
where good J provides one unit of the characteristic ze[0,s], x, is the quantity of goods and
the production function is such that g,(z) defines the allocation of characteristics z where
ze/?, defining the set of characteristics and .re/?^ defining the set of potentially producible
goods. In this case therefore, higher quality is considered more desirable because it contains
higher quality characteristics. The utility function in Stokey (1988) also indicates a preference
for higher quality
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where once again, z indicates characteristics and g,(z) indicates the allocation of
characteristics. Learning by doing is characterised by spillovers across goods. Thus, the
production function is characterised by an increasing allocation of characteristics, implying
that higher quality goods enter and replace lower quality goods.
In Young (1991), consumer preferences indicate a strong preference for variety
although consumers prefer goods with lower prices. For prices which are too high,
consumption of those goods is zero. Thus there exists some limit price, below which the
consumer demands all qualities, and above which the consumer demands zero qualities. In
Stokey (1988), this is defined as consumption in some range [A,,2J,], while consumption
below and above this range is zero. This can be derived from the utility maximization
problem of a consumer, given the preferences in equation (7.18) above





where the lower boundary A, is determined by the unit cost function and the upper bound,
depends on preferences, labour allocation and the unit cost function.
In the case of Young (1991), there is a similar limit good M, such that for all goods
*, for which unit cost requirements a(jc,0^a(M,f), consumption is zero due to high prices.
Learning by doing from cumulated labour is described as
(7-21)
where 7(r) is the current level of knowledge, L(j,f) is labour allocated to production of
good 5 at time r and learning is bounded in that the amount of labour required to produce
each good J, cannot fall below a certain level. Thus if a(i,r)=^(j) then there is no more
learning, while if a(.y,r)>a(.s) , then the result of learning by doing is higher productivity for
those goods.
7 therefore is the dividing point with J<7(r) goods having no more learning while
s£7(f) have continued learning by doing. Because both unit costs are determined by the
movement of 7 from (7.21) above, the total range of production is symmetric around 7. In
equilibrium as learning increases 7(0 grows, and learning in older products ceases, while
newer products are produced.
However, preferences in the 1991 paper by Young, indicates a preference for cheaper
goods but also for variety. The first implies that consumers prefer to consume goods in which
learning by doing is taking place, while the second indicates their preference for goods in
which learning has been exhausted. Thus a range of goods on both sides of 7 will be
consumed. Technical change ensures that 7 continues to increase according to (7.23) above,
with learning by doing exhausted in goods in the lower range. As 7 increases, goods in
which learning by doing takes place become cheaper, allowing consumers to consume more
of those goods. However, the range of goods in which learning by doing is no longer taking
place is also falling as a result of rising learning by doing in other products. The equal
division of labour between the two sectors however, also implies that the range of products
in which learning by doing is no longer taking place declines less than the range of products
in which learning by doing is taking place increases. Thus in this model, both the quantity
'";;"•:'"•' .-.- • "•• ••'•-••'••• ' :' '• 144 i.\ V-Y ."•. • .'-. ;• ••and the total range of variety consumed will increase because of lower unit costs of production
in the learning by doing sector.
In the 1993 paper by Young, an explicit innovation activity is included, as in Grossman
and Helpman (1989), where new goods are invented and patented by private agents at the rate
JV(O = _£ (7.22)
where cr^ is unit labour cost and there is free entry in R&D, implying perfect competition.




where \|/ is the rate at which learning takes place. Consumer preferences as in the previous
paper imply a desire for increasing quality, given prices and the budget constraint, and also
for variety. The difference with the previous paper is that the size of the range on either side
of 7 is determined by TV-7 because the upper bound in (7.23) above is now TV. If the gap
between innovation and learning is increasing, goods below 7 will be substituted away by
newer goods above 7, and total variety measured by T(=7-Z) +u(=yV-7) , where Z andAf
are the bottom and upper limits respectively of the range of goods consumed, increases. Z
defines the good for which unit costs of production are too high, and the consumer does not
consume goods more expensive than Z. If Af-7 >|i" (where u* is some critical value),
the newest goods do not enter the consumer's consumption bundle as their costs are too high.
In steady state equilibrium, there is a constant range of goods JV-7, implying that
# = 7 since /? = p, the latter because of the assumption of free entry into invention, which
determines the interest rate as a function of the profits of the most advanced firm and the rate
of change of the value of the firm "". Two types of steady state equilibria are examined.
In the first instance, the no growth case shows that firms will invest in invention activities
only if the cost of invention is lower than or equal to the aggregate size of the market, or if
the rate of time preference in the steady state (also equal to the rate of interest in the steady
state), is high enough to enable firms to borrow. The case discussed above where N -7>u' ,
produces the same result as in the static case, with newly invented goods not being consumed
because of high prices.
In the case of the second type of equilibrium |i*>N-7>0 , steady state growth is
positive and lies in between the two extremes discussed above. In this case, the growth rate
in the economy once again depends upon the aggregate size of the market, interest rates and
the cost of invention. The economy is characterised by rising invention, indicating an
increasing number of higher quality varieties consumed, as older varieties drop out and newer
varieties enter the consumption bundle, until the rate of invention exceeds the rate of learning
sufficiently to reach u'. Then new goods are no longer consumed, and the number of
Young (1993), pp 455-457.
145varieties consumed declines as labour is moved out of lower quality goods into innovation
activities. Thus, while the 1991 paper by Young shows increasing variety, in Young (1993)
the range of products in the market remains constant in each period.
This analysis in Young (1991), and especially the later paper (1993), is quite similar
to the dynamics of innovation and substitution in the model we develop in Chapter 8 and 9
below. While in Young (especially 1993), the dynamics are described by the equations
describing innovation and learning-by-doing externalities (TV and 7 respectively), in our case
the range of varieties present in the economy changes in the steady state according to the
relative forces of higher quality being preferred and planned learning decreasing fixed costs.
These dynamics are elaborated upon further in Chapters 8 and 9 below.
Conclusions
Thus the description of previous models of increasing variety and increasing quality,
point to a few generalized conclusions and implications for variety:
1. In the first group of models, innovation is horizontal, i.e. new products which are invented
are imperfect substitutes for old varieties and therefore are not expected to displace older
varieties. The reason for older varieties staying within the market, despite the appearance of
new products, lies mainly in the manner in which consumer preferences are modeled. The
love of variety utility function implies that a constant elasticity of substitution between
products ensures that given a certain budget constraint, consumers will prefer to consume the
same quantities of all varieties available in the market. Thus, old varieties will continue to
be demanded despite newer varieties available in the market
Another method by which these models have presented increasing variety, is by
including a love of variety approach in the production function. Thus innovation takes place
through the production of a greater variety of intermediate products, which are used to
produce the final good. By indicating a love of variety in the production function for the final
good, these models show an increasing range of horizontally differentiated intermediate
varieties in the market. Thus in general, in these models, the specification of a love of
variety, constant elasticity of substitution function, ensures that older varieties do not drop out,
and instead add to the total variety of products available in the market.
2. In contrast, the impact of increasing quality on variety is somewhat different. Here, there
arc two types of models which were analysed.
;- In the first group of models, for example Grossman and Helpman (1991a Ch 4, 1991b
and c) and Aghion and Howitt (1992), the invention of higher quality products, always results
in the rejection of the old variety from the market, leaving only the highest quality available.
The reason for this is Schumpeterian creative ^eifr«crion, with the presence of monopoly in
each new innovation wiping out the monopoly profits earned by the previous innovation.
Consumer utility in this case is maximised by consuming the highest quality, and therefore,
the older product is therefore driven out of the market, and the newest producer appropriates
all monopoly profits. Thus in models which have this structure, there is only one variety, the
highest quality, present in the market at each moment in time.
146For the second group of models, the introduction of different groups of individuals with
different levels of human capital creates preferences which are not the same for all qualities.
Thus in the Ham and Helpman (1987) model for example, different classes of individuals with
different incomes, results in demand for different groups of products having different qualities.
At each moment in time therefore, there is always a range of different quality products
available in the market because of consumer demand. Variety in this static model therefore
always remains constant but greater than one. Only the range of products produced in each
region changes if there is a change in the relative productivities of countries.
In the Stokey (1988, 1991) and Young (1991 and 1993) models however, there are rich
dynamics which show a range of goods with different qualities. Young's models (1991 and
1993), are particularly interesting and particularly relevant because they present possible
situations in which the range of qualities available in the economy, may be actually increasing
(1991), rather than remaining one as in Aghion and Howitt (1992) or in the Grossman and
Helpman models, or remaining constant as in Ham and Helpman (1987) and Young (1993).
These implications for increasing quality and variety are especially important for the
model developed in chapters 8 and 9 below, where the result of quality improvements is
shown to present both increasing as well as decreasing variety in the economy, in a dynamic
analysis. As discussed in greater detail in these chapters, this is largely because of the
combined approach used, that of introducing higher qualities through an R&D and production
sector with or without learning, and of consumer preferences which reflect a love of variety
approach, combined with preferences for increasing quality.
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In Part I and Part II above, we first presented developments in biotechnology, followed by a
theoretical section. The latter discussed the manner in which new growth and trade models
treat issues of increasing variety and increasing quality, as opposed to just quantity. The first
Part showed that innovation in biotechnology also presents both the prospect of increasing
variety and increasing quality. This was especially evident from Chapter 5, where the
empirical impact of quality and productivity innovations were discussed in relation to
consumer preferences and increasing and decreasing variety in the economy.
Part III develops and discusses a closed economy model of endogenous growth based
on increasing quality and changing variety and an open economy model describing trade
between two regions which we call north and south.
From Chapters 3 and 4 above, where the patterns of biotechnology R&D were
examined in industrialized and developing countries respectively, we have identified the basic
institutional and market structures of biotechnology R&D. In general, there appear to be two
broad sectors which carry out different aspects of biotechnology related activities: (i) a
research sector, that was initiated in the public domain, but which is increasingly characterised
by private, profit maximizing agents and with free entry by other researchers and companies.
This is especially evident from the emergence of the New Biotechnology Firm in
industrialized Countries and private/public linkages for research; and (ii) a sector which is
devoted to commercializing biotechnology, again dominated by the private sector, initially
characterised by large firms in many countries, who can provide up front financing for scale-
up and product development, and possess forward and backward linkages to resources and
markets, which have often been weaknesses of the smaller, specialized firms.
Similarly, in Chapter 5 we examined the innovation process itself, and the impact of
innovation on the total variety of products available at each time in the economy. Chapters
8 and 9 which follow, develop a model of endogenous growth and international trade, based
on the new growth and trade literature discussed in Part II and using the general trends in
modern biotechnology R&D identified thus far.
The model discussed in these chapters contains some elements from the theoretical
literature on horizontal and vertical product differentiation discussed above, and is inspired by
observations about biotechnology discussed in Part I above. In Chapter 7 above it was shown
that three types of results have been obtained from new growth and trade models: (i) the use
of a love of variety utility function results in an ever increasing variety of products as new
products never make old products redundant; (ii) the ideal variety preferences result in new
products always making an old product redundant, i.e. there is complete displacement of older
products and the remaining product is always the newest product; and finally (iii) a number
of new models have also shown results which lie in between these two extremes, i.e., a
constant or increasing range of varieties remains in the economy, with each new innovation
resulting in the displacement of one or more older products, depending upon the model
specifications.
Chapter 5 above however, shows that the impact of biotechnology is in reality a
combination of increases in quality, with increases or decreases in variety as a result of
151innovation and of consumer preferences. The models presented in the following two chapters
are therefore broader than the models surveyed in the previous chapters and in fact may be
applicable to a wide range of sectors and technologies. In this respect, the innovation in both
the closed and open economy models presented here, is that they are not technology or
industry specific but in fact more general than the new growth and trade models and therefore
make a new contribution to the recent literature on growth and trade.
It is shown that instead of just one of these cases, all three become special cases in the
models in chapters 8 and 9, depending upon fixed costs in the differentiated sector. We show
that variety can increase as in Young (1991), remain constant (for a considerable period of
time), as in Young (1993), and eventually decline as in Grossman and Helpman (1991b and
c). This is followed by a chapter summarising the results of the model and drawing policy
conclusions for biotechnology and growth.
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Introduction
Technological change and especially the use of scientific knowledge to upgrade products and
processes have become an important source of economic growth, both in the theoretical as
well as in the empirical literature in recent years.
As previous chapters in Part I have shown, the success of biotechnology both in
industrialized and in developing countries has often depended on the combined effort of basic
scientific research, institutional and government support as well as the presence of a private
sector which is able to commercialize the results of R&D. Biotechnology can lead to two
types of innovations: firstly by improving the structure of products which are already in use,
through altering their genetic structure; and secondly, by developing products which are novel
and are not presently in existence. In both cases we argue that biotechnology brings about
quality improvements along a vertical quality ladder similar to that described by Grossman
and Helpman (1991b and c), Aghion and Howitt (1992) and Flam and Helpman (1987).
However, we have also seen that society's utility function should value variety as well as
quality.
In the following two chapters, a model of endogenous growth and trade, based on
biotechnology, with some elements that are common to some of the new growth models such
as Flam and Helpman (1987) and Young (1991), is developed. With respect to empirical
observations, we relate the structure of the model to biotechnology, especially in the
pharmaceutical sector. In this sector, biotechnologies have provided researchers with
techniques with which they can understand better the relationships between chemical structure
and biological activity. This understanding is crucial for the development of new
pharmaceutical products, both for improving on present drugs and also for developing new
cures. In addition biotechnology results in a better understanding of diseases, allowing new
research to be targeted to more specific problems. According to the US OTA, there are two
basic approaches to using biotechnology in this sector: firstly to develop human proteins which
were previously non-existent, such as human growth hormone using rDNA techniques, and
secondly to design synthetic molecules which can then be used to examine the workings of
the disease thereby enabling the use of the technology in designing drugs which interact in
the disease process. The first biotechnology based drug, recombinant human insulin developed
in 1982 was one such protein which was either not available or only in small quantities before
the biotechnology product became available. Human growth hormone was another such
153protein as are some of the cancer related drugs such as Tissue plasminogen activator (tPA)
which dissolves blood clots and is known to reduce the incidence of heart attacks. Epogen,
the best selling biotechnology drug so far, has been used in dialysis related anaemia and a
number of other drugs have been developed for treating different strains of hepatitis, as well
as AIDS related illnesses.
Similarly in developing countries, although they still lag considerably behind
industrialized countries in terms of technological capabilities, new techniques such as
monoclonal antibodies are being used to develop diagnostic kits for detecting common
regional diseases. The disease prevention programme has also received a considerable boost
in many countries as new vaccines to combat some of the more common diseases in these
countries are reaching various advanced stages of R&D and will become available shortly.
Society during each time period will demand a variety of biotechnology based
products, of different qualities. This is because for a number of reasons peculiar to biology
and medicine we argue that society will continue to demand a variety of products of different
qualities, even though the highest quality is available for the same (quality adjusted) price.
For example, in Pharmaceuticals, a country will continue to demand a variety of medicines
for reasons such as allergies to particular medicines, or different strains of the same disease,
which only react to vaccines, or treatments which contain a slightly different mix of the same
basic compounds. Similarly with ag-bio products, different circumstances such as soil or
climatic conditions, would require somewhat different compositions of products which
basically perform the same function, such as insecticides or pesticides. Thus social welfare
is increased by variety.
Accordingly, this paper departs from earlier analyses, in the introduction of love of
variety preferences combined with quality, or vertical differentiation. We introduce a social
utility function, in which society prefers to consume both higher quality products, and also
maintain a range of varieties at each point in time. We assume two sectors, one which does
R&D and produces the innovation, and the second which uses the innovation to produce
higher quality products. New products in the differentiated sector may replace old products
as with previous models such as Aghion and Howitt (1992) and Grossman and Helpman
(1991a). However, like the model by Flam and Helpman (1987), this model finds that in
many cases, instead of all previous qualities being replaced by the newest quality, each new
variety joins a range of older varieties in the market. Consumers prefer both variety and
quality, and hence, there are a range of varieties demanded and consumed. The case of only
one variety being present in the market at each time as in the Grossman and Helpman quality
ladders models, is therefore a specialized result of this analysis.
There are two additional observations about variety which are made by this model:
In Flam and Helpman 1987, the analysis of variety is static and a variation in the growth rates
of different variables results in a constant range of products, with the highest qualities always
replacing the same number of old variants. In this paper, we show in a dynamic analysis that
the range may be constant, but can also increase or decrease. We find a case in which all
older varieties which were previously dropped from the consumption bundle are reselected.
This love of (complete range of) variety is also a special case of the model. We present the
exact time patterns as simulations in the final sections of this chapter.
Thus the model adds to the literature in three ways: first, because the model describes
all three cases, it is in fact a much broader and general model which contains the individual
cases described in previous growth and trade models; second, by combining both love-of and
354ideal-variety preferences, we move a step closer to the real choices of consumers, and third,
by presenting a range of products being present at each moment in time, we also present a
situation, where at each point in time, consumers choose different qualities, and where the
appearance of new innovations only gradually results in older varieties being pushed out of
the market or in some cases, not at all. Thus the increasing range of Young (1991), the
decreasing range of Grossman and Helpman (1991) and the constant range of Young (1993),
are all special cases of this model, although only temporarily with respect to the latter.
The structure of this chapter is as follows: In Section 8.1 we present the model.
Section 8.2 looks at equilibrium dynamics under the assumption of perfect capital markets,
while Section 8.3 looks at the special case of no capital markets. Finally in section 8.4 we
present the results of simulations which show a range of dynamics with respect to quality and
variety and which is followed by a concluding section.
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8.1. The model
We present a closed economy model of innovation and quality improvements. The economy
is endowed with one factor, namely labour, N with quality //. There are two sectors, one
which does research and the other produces differentiated products. Innovation takes place
in the R&D sector, which produces innovations. The innovations become an input into the
commercial sector, resulting in the production of goods with higher quality. Thus in each
period, innovations in the R&D sector result in quality improvements in the differentiated
sector, treated as quality weights, as described in Flam and Helpman (1987), given to
quantities in a love-of-variety utility function.
Following from the discussion in the previous chapter on demand, we concentrate here
on society's demand rather than that of individual consumers. The utility function specified
here therefore relates to society's utility function and budget. The intertemporal social utility
function we specify has the following form:
W V
{/ = ("<?•**"" [log
where rho is the subjective discount rate and the subutility function u, is of the Spence-Dixit-
Stiglitz type (see Helpman and Krugman, 1985, pp.118-120):
0 < 0 < 1
P> 1
.-,,r -••; a > 0 , • . ; •••>. ,,.
u =
where ^ is the quantity of quality z demanded, while z ~ is the lowest and n the highest
quality demanded by consumers. The parameter 8 represents society's constant demand
elasticity for quantity and as in the love of variety models discussed above in Chapter 6, we
155specify theta to lie between 0 and 1. However, in contrast to the love of variety utility
functions before, the specification here includes a quality weight. In the exponential function,
more importance is given to quality by society, the greater the size of alpha, while choice is
independent of quality if a=0 (see Flam and Helpman 1987 for further discussion on this
specification).
As is the case with this specification from Spence-Dixit and Stiglitz, we assume that
n, or the number of varieties demanded in each period can be infinitely large. This ensures
that as n grows, utility increases.
A society with this utility specification maximises its utility, subject to the budget
constraint
- W(0 ^ 0 (8.3)
where /?(t) is the rate of cumulative interest from time r to time T, /^ is price of qualityz
and £ is the consumer's labour income in each period.
We specify the Lagrangean,
J e "•"*-'> log « [.] J . . (8.4)
where log u is the subutility function from equation (8.2) and the time index of p^, ^ and
n, z" and £ has been ignored as before. The first order conditions from this problem are
(8.3) with equality and
..?. (8-5)
Given the inequality in (8.5) above. = 0
In the case that (8.5) above holds with equality, it generates the following price, quantity
relationship
/>• (8.6)
and from this, we can calculate the demand elasticity for differentiated goods,
156(e-i)(^-V)>._^^., (g.7)
• e«./>,
This result is identical to the one obtained from the Spence-Dixit-Stiglitz function without
quality weights. The solution to the intertemporal utility maximization problem can be
calculated by multiplying # to equation (8.5) and integrating over z
and the resulting equation after cancellation becomes
ji<fe (8.9)
, \ • - J i
In growth rates this yields the rate of change in expenditures equalling the difference between
the rates of interest and of time preference.
In the case of no capital markets, equation (8.9) reduces to
Which can be written m growth rates as
V -p ' (8.11)
where we take w// to be equal to 1. Taking the growth rate of N=e, we write
"^i-"':-/. it.. .*-e + p "":"/:.',:;?.''•;.. ..<*•">
Next we turn to supply. We begin by specifying the structure of production in the
differentiated sector first, and then do the same for the R&D sector. We assume only one
factor of production, labour N, which is allocated between the two sectors, and has human
capital of #.
Producers in this sector licence the blueprint produced by the innovator in the R&D
sector, and produce higher quality products. The production function is assumed to be
=z (8.13)
157where <^ is quantity of quality z and z is an index of varieties, ze[0,n] for which
blueprints are produced by the R&D sector and which are licensed by the producer in the
differentiated sector. Because we assume that
F/(ffJV*) = 1 (8-14)
equation (8.13) can be written
^ = z//.tf< (8.15)
By licensing blueprint z from the R&D sector, the producer in the differentiated sector
becomes a monopolist because of his impact on price according to (8.7). The monopolist
minimizes production costs
(8.16)
where w is wage per efficient labour unit and C^(.) is total variable cost. The producers' first
order condition for cost minimization with respect to A^ * is
which can be rewritten j
C/fo,,wJ/) = V = — "•••"••"•• ' " ' (8.18)
'•'•--. * ^
which is the marginal cost of the monopolist.
The producer earns instantaneous profits
where fe is the cost of licensing z from the R&D sector and is included in the cost because
the innovation is assumed to be licensed in each period from the innovator in the R&D sector.
This yields the following first order condition
158P« +*«/>/(*,) -C/(^) =0 (8.21)
which means that marginal revenue equals marginal cost which is the monopolist's optimal
pricing condition. From the first order conditions for consumer demand we have determined
the price elasticity of demand and from (8.21), we can calculate the marginal revenue of the
monopolist:
implying that
C = C'^=/>^ (8.23)
and from equation (8.19)
p, =J!L • *-' (8.24)
,/. u •_"**
Thus, (8.23) for the cost function and (8.24) for price in (8.20) yield the monopolist's profits
Ll!l -6-0 '^ ***= *> ™**'' (8-25)
ez J «
Profits have to be zero because under the assumption of free entry into the differentiated
sector, each potential producer offers all profits when a blueprint is auctioned off (see Romer,
1990).
The R&D firm is characterised by innovators who are granted infinitely lived patents
for their innovations. The production function of the research sector is assumed to be
ri = (8-26)
where rt is the flow of innovations and « is a measure of cumulated learning, from each
innovation. Delta measures the elasticity of learning. If 8 = I, the specification corresponds
to that of Shell (1967) and if 5=0, there is no learning as in Phelps (1966). As with the
differentiated sector, assuming linear technologies in labour means that equation (8.26) can
be rewritten
159fi = n'/W* (8.27)
Each innovation is patented by its innovator and licensed out to the producer of a
differentiated good. The producer maximizes the sum of discounted cash flows over time fronu
to infinity subject to the production function (8.27)
L = rfc + Jl[/»«/flV* - rt] (8-28)
where w is wage and fc is the licensing charge for innovation z; 1^ are savings received









The future impact of rt on n is taken fully into account. Here we differ from Grossman and
Helpman where n * is a public factor.
From equation (8.30)
160(8.33)
Inserting equation (8.33) in (8.31), this yields
""'Bw'-' (g.34)
If we take w as the numeraire, equation (8.34) can be rewritten
(8.35)
From equation (8.33) we can calculate the derivative of lambda with respect to time and take
growth rates
= -A, or A, = -no (O.JO)
Combining this with equation (8.32) we get
' (8-37)
which can be rearranged by multiplying with n
(8.38)
and inserting from the production function (8.27) we solve
* = ft «• = _?LL => 6 = A (8.39)
The licensing fee for the most recent variant is therefore equal to the rate of interest, corrected
for productivity in R&D or the value of new patents per efficient labour hour in R&D equals
the rate of interest. fe^ determined in this way, one can solve for ^ according to (8.25) as
a function of i? and n.
Thus to briefly describe the basic elements of the model thus far, the economy is
characterised by an R&D sector which produces a flow n of innovations based on labour
N *, with human capital // and cumulated learning n *, 0<8£ 1 . Each innovation is granted
161an infinite patent and the producer has to pay the innovator fe for licensing each innovation
z. Access to the innovation grants the producer a monopoly over the production of that
quality and the price of the new good is equivalent to the monopolist's marginal revenue or
cost divided by theta. Reinsertion of (8.25) into the cash flow function of the R&D firm yields
(8.40)
Using (8.15), this becomes
J z6
which after cancellation yields discounted cash flow
(8.41)
-«(*-') (8.42)
Carrying out the integration over new loans, # and interest cost /? W yields:
=> (8.43)
which from partial integration can be solved
J - J -/Je*f (8.44)
and after cancellation
= 0 (8.45)
The discounted sum of interest payments in excess of new loans has to equal the initial value
of wealth lent to the R&D firm. In short, total profits have to cover initial losses. The limit





For this to equal (8.3), we must have
rfc = - (8-47)
Having completed the basic specification of the production and consumption sectors,
we now move on to calculate the labour market allocation between the two production sectors.
The special case of no capital markets is examined in section 8.3 below.
8.2. Dynamics with Perfect Capital Markets
In this section, we examine the case where consumers save and invest and innovators can
borrow on a perfect capital market for their innovation costs. Before we move on to an
examination of steady state dynamics, labour market allocation has to be determined.
Substituting values for p^ and <^ from the zero profit condition in the differentiated sector




which can be written :;..•-,;-."•
;i .-j . •'•'•,• •:••• I..;"-'. V
(8.49)
Insert from the labour market equilibrium
(8.50)
Differentiating with respect to time
(8-51)
163and dividing both sides by both sides of (8.50)
-p = -/* - ^ (8.52)
Thus in the steady state, either p=7?orN = N*. However, the latter would imply
that all the labour in the economy is allocated to the R&D sector and there would be no
production of the differentiated good. Consumer utility hence would not be maximized. Thus
this cannot be an equilibrium and we therefore take the first as a solution for the steady state.
If p>/? , implying that iV* >0 , until N*=N ; this cannot be an equilibrium as explained
before. If p<7?, implying that N <0 , until N *=0 ; there would be no more innovation
and we therefore will not discuss this case. There is no reason why the economy should
approach the steady state slowly, and therefore tf = p from the beginning as in Grossman and
Helpman (1991c).
We can now calculate the labour allocation between the two sectors, under the
assumption of perfect capital markets. Substitute for £^ from the zero profit condition of the
differentiated product producer, into the profit function of the R&D sector'"
f« "*<*"" J' dt - W =0 7 (8-54)
where W is initial wealth which the consumer uses to lend to the R&D sector. Substitute
from the labour market equilibrium condition to write
= o (8-55)
'*' Since we assume that the R&D firm negotiates all licensing contracts to the differentiated
sector in period f, and n is private knowledge, a problem of time inconsistency may be caused if the
innovator reneges on any contracts in the future. If this does happen, then we cannot assume zero
profits in the long run as the innovator becomes a monopolist since he/she has higher productivity from
learning, n, than a potential late entrant who has to begin from a lower level of learning (see
Grossman and Helpman 1991a, Chs. 8 and 11). To ensure zero profits, we assume either that there
is a legal framework such as an antitrust law which prevents monopoly profits and ensures that the
innovator honours all contracts signed in period f, or we assume 100 percent tax on profits, which
removes the incentive to have monopoly profits.
-..- •• ••••.«i • , ..-:• • ., 164 • .v:: • V . •;•.•• '••which after setting w =// = 1, can be rewritten
(8.56)
to obtain the steady state allocation of labour in R&D where N * has to be constant and
J?=p. Taking the term in brackets before the integral and carrying out the integration yields
(8.57)
The richer the society is therefore, the less labour it will put into research in equilibrium.
If we take the special case of no initial wealth, then the allocation of labour in both sectors
in the steady state is
9W
(8.58)
From (8.12) we have the solution for /J which we insert in (8.39) for the case of no
population growth, to solve for ^ which in the steady state is
6 --£- (8.59)
We can calculate the growth rate of ^ before moving on to analyzing the rate of change in
z". From equation (8.6), the solution for prices, (8.24), and the zero profit condition of the
firm (8.25), we get the following relationship between fc, and fe^. where J and y are variants





165Hence &, and fy grow at the same rate, as do ^ and
(8.15), it follows that
From equations (8.25), (8.60) and
(8.62)
and we can write
Thus in the case of Shellian learning effects, the value of the license ^ is negatively
related to the learning or spillover effect and the growth rate of ^ and 6^ is constant, and
negatively related to the growth rate of innovations. If learning is Phelpsian, then ^ is only
dependant on the rate of time preference and the growth rate is zero. This is because since
we have already established the growth rate of n, we can conclude from this that as f goes
to infinity, ^ approaches but never exactly reaches zero in the case of learning. If
0 < 8 < 1 approaches zero in the long run and
Licensing fees do not fall over time if there is no learning, i.e., 5 =0. With learning,
the lower the rate of time preference and initial wealth, the quicker they fall. Next we
calculate the change in z". We begin by equating the wealth terms in the consumer's budget
constraint and the zero profit condition of the R&D sector
= J -j j^fe -«(*-<) (8.64)
Taking the derivative with respect to time r, we find that the households' excess of labour
income over expenditure has to equal the excess of labour cost over revenue in the R&D firm.
£ - (8.65)
We substitute from (8.24) for /^ and ^ from the zero profit condition of the differentiated
sector producer, (8.25)
(8.66)
with #** from (8.56). Using w=//=l, this can be written
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Differentiate this with respect to time x, for given initial wealth
equal to one as before,
(8.71)
P,, constant TV and//
.'J^;7. '..„."' (8.72)
The last equation will also be obtained in the no capital market case because W, is constant
above. Besides its impact on TV* and therefore n, it is clear that W,>0 has an impact on
the initial value of z" when calculated from (8.71), because £, n and ^ have already been
solved for, where £=w///V; ri=n*[(l -0)Ar-p8W,] and ^ from (8.63) and (8.59).
Next we define the analogous equation for the no capital market case. From that we
go on to consider the dynamics of z". This will allow for the conclusion that our model
contains the possibilities for (i) a constant range of variety as in the Flam and Helpman (1987)
and the Young (1993) models for very long time periods; (ii) an increasing range of variety
as in the Young (1991) model and (iii) a decreasing range of variety converging to the one
variety case as in Grossman and Helpman (1991b and c) models.
1678.3. The Special Case of No Capital Markets T, : - ^
If we assume no capital markets, initial wealth W, = 0 and no savings or interest, and a
regulation of monopoly that ensures zero profits each period, the costs of innovation must be
exactly equal to the revenues from licensing to the production sector, implying that
(8-73)
•...-:-.:vv$u-v
We use this condition along with the zero profit condition in the differentiated sector, to
calculate the allocation of labour in each sector. Taking the zero profit condition in the
differentiated sector, equation (8.25), substituting for ^ from equation (8.15) and inserting
we obtain
« [ ez J ' *
implying that -•->=••• • ' ^"'^ '" i ^g «> ?r-^ ^ ^
•-i:- :V. . ••;.;-.-: .-'•: •• • •'•• •' ^ " .^^•r.-:. . :• -':•''•
. ••*••••• -•'• (8.75)
Equation (8.75) can be inserted into the zero profit condition of the R&D sector, setting
equation (8.28), to zero
(8.76)
which can be rewritten as
l
J A
*: f L ° J
«: ^ ^v (8-77)
and
*:-'-• .1Jf';.. ".
-.• Trrv. • *U' (8.78) L, ^ 6 J J *
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Inserting the second equation from (8.76) into the labour market equilibrium equation
(8-79)
we obtain the resource allocation




This could have been obtained directly from (8.57) for W, = 0.
Thus, having calculated the labour allocation between the two sectors, we can now
move on to the dynamics of the system in equilibrium. The economy we have just described
is characterised by a constant share of labour in innovation, whose growth rate is described
by the production function of the R&D sector and can be shown as ;..? .< -^ ^, .,,^,-y,.,_^
ri = n*#W* orn=n«iV(l-0) (8-82)
assuming that //=1, the next step is to calculate the rate of change of z '. In equation (8.3)
for the no capital market case, income equals expenditure each period. We insert values
and ^ from (8.24) and the zero profit condition (8.25), in the differentiated sector
•• •• ; • £= LULZLk ' (8.83)
which can be rewritten .•,•-..-. • :: • • ? - - :-:-.•:•, ;.-.. •.. >v-
£-J_J^& " (8-84)
By definition #N s £ . w :cr,Vi;ou^y .;'•.--,.;:» ^-: .-;:••:•••/• -".,\. v/>h-.-;.•..:• . - • ., - ;.
Again, we assume that //, N and £ are constant. Inserting this into equation (8.84) and
taking the derivative with respect to time r,0 =£ = (8.85)




From (8.60) and (8.61) above, we established the relative relationship between 6_. and fy.
From this we also concluded that the growth rate of 6^ is independent of z. We can therefore




Inserting values for fc^ from (8.59) above, and the time derivative of n from the production
" fi








Solving for fe^z"" yields
p] (8.90)
From which we can calculate z"
170z =
(8.91)
By substituting in (8.61) we can calculate the value of fc^ as a function of fe^ and write















The dynamics of n and n are described in (8.27) and (8.63) above. Thus we can write the
general equation for z~ and n as t
ri =
?:> ';•• -:' .a-v?
-6) (8.94)
if z "<n and z" =n otherwise. If z" =n , only the most recent variant remains in the market.
This qualification will be dropped henceforth. The sign of z" depends on p -6«. p
determines the level of 6_, 8n determines the speed of the decline in ^, ^ and TV *. If the
decline in these variables is strong (weak) enough in relation to the level of p or ^, there
will be (no) room for a decrease in z" and (no) reselection of variety.
Next, since we want to examine both the cases of perfect learning as in Shell and no
learning as in Phelps, we examine the specific solution for equation (8.95) in each case.
8.3.7. 77ze Case o/De/fa = 7 (5/ie//) V: -'--.
The growth rate of £^ has been calculated from (8.63) above. Using the case of delta = 1,
we insert in (8.94) and write _-z~ =






5.5.2 De/ta = 0 (Wo Learning as in Pne//w)
If we assume no learning, ie. delta = 0, then we have the following result for the change in
z', where the only differences lie in the calculation of fe^_ and the growth rate of £^. The
value of & equals p because delta is equal to 0. We can therefore rewrite equation (8.94)
(8.98)
Thus we have two variants of the differential equation (8.94), describing the dynamics of the
re-emergence and displacement of old products. In the Shellian case of strong learning (delta
= 1), new products enter and old products are displaced according to
(8.99)
in the case of no learning as in Phelps, delta = 0 and the two differential equations which
describe the range of varieties available in the economy at each time can be written
/I = (1-0)
(8.100)
Thus while in the first case, strong learning effects, as expected, have a positive
influence on the rate of innovation, they also have an impact on the rate by which older
products are dropped or reselected from the consumption bundle (i) via the n term in (8.99)
172and (ii) via the -8n term in (8.94) which becomes (1 -6) in the Shellian case in (8.99).
This is due to two reasons: firstly, the budget constraint ensures that older products are
dropped as the value of new products consumed increases. As the latter rate increases due
to learning, the faster is the rate of rejection of older products due to the budget constraint.
Secondly, with (no) learning, the fixed cost of producers, ^, are (not) decreasing. Therefore
the equilibrium quantity produced, according to (8.25), is (not) decreasing. The consumer
buys (the same amount of) less of each good, and has (no) more room in the budget for old
varieties. In sum, given the price of each variety z, as a fixed mark up over marginal costs,
the room for variety is determined by the number and quantity of the varieties. Besides
learning, the level of fixed costs p, matters as well. If it is high, relative to its rate of decline
-8n, varieties will be selected away by consumers.
In more formal terms, if p-8n>0, z" is increasing, contributing to decreasing
variety. In the case that p -8n<0 , z ~ is increasing negatively, implying increasing variety,
as older varieties are reselected. Whereas p -8n determines the sign of z", the exponential
term from the quality weights in preferences determines the speed of the development.
The second case of no learning is more straightforward, with both innovation and
replacement being driven by the demand elasticity theta, and in addition, quality preferences.
No learning implies that the fixed cost stays constant and since consumers have a fixed
budget, old varieties are rejected in favour of new varieties which enter the consumer's
consumption bundle.
8.4. Simulations for the No Capital Market Case
In order to study the dynamic system, we ran simulations using different parameter values and
combinations thereof. Before the simulations could be run however, the initial values of both
upper and lower bounds of the integral, i.e. n and z" had to be established. With respect
to the first, different initial values can be chosen by assumption. However, for the latter,
initial values had to be calculated for each corresponding initial value used for TI . The details
of the calculations for initial values for z" are to be found in appendix II at the end of the
thesis. In this section instead, we present some of the more interesting results of these
simulations, especially as they relate to the earlier discussions on biotechnology and
innovation. The rest of the figures can be found in appendix in below. We describe first the
case of strong learning effects as in Shell and then the case of delta = 0.
&4.i 77ie Case o/S/rong Learrcing £j5*ecte
Two separate trends are recorded in the case of strong private learning effects. In the
simulations, three different initial values of rc were used, 2, 4 and 8. The results from the
first set of simulations revealed that for higher values of a and for higher values of n, the
two differential equations go out of bounds very quickly. Thus the base values used were
0.83 for 6 and 0.1 and 0.2 for a. The initial value for z" was calculated according to
appendix II which can be found at the end of this Chapter.





• z- = 1.99739 -»-n =
The value for the rate of time preference p, was varied. In the first instance low values were
used for this parameter, ranging from 3 percent to 10 percent '". In all the figures below
(also see appendix III below), the legends at the bottom of each graph, indicate inifia/ va/ues
for z' and for n.
In the case of low values of the rate of time preference, i.e when p -5n<0 , z ~ is
moving negatively, that is, the total variety of products is increasing and consumers are
reselecting older products, which had previously been rejected by them. Figures 8.7. and 8.2.
show results for n equal to 2 and for low values of p set to 0.03 and 0.04. In both cases,
variety increases as the differential equation for z" moves negatively and for n positively.
^ The reason for old products re-entering the consumers choice bundle is due to
declining fixed costs ^, which from the differentiated producer's zero profit condition implies
that the equilibrium quantity produced is also falling, which enables the consumer to spend
a greater portion of the budget on a greater variety of products. The exponential term in the
equation for z" reinforces this negative movement. Higher p implies a higher price for fc^,
and therefore a higher equilibrium value for <^; the result is less variety when taking into
account differences in scale of the axes in each case.
"' The range of values used for theta have been estimated using different models, to range
between 0.83 to 0.9; see for example Gasiorek, Smith and Venables (1991) quoted in Abraham (1994).





















z- = 3.84089 -•- n = 4
For different initial values for n, the initial value of z' varies. In general, the greater
the initial value of n, implying lower initial values of fixed costs and equilibrium output <^,
the greater the variety and difference between initial values for n and for z" and the faster
the negative movement of z". This can be seen from/zgKre.Y 8.3 ana" 8.4 (see also^Hre 8.7,





Figure 8.4. Learning (delta = 1)





•z- = 3.52612 — n = 8
For values of n where alpha is 0.2. a similar pattern emerges (see./?£«r£ A3.3 in appendix for/i
equal to 2 and A3.5 for n equal to 4; in the case of n equal to 8, the two equations appear
to go out of bounds immediately because of the high value of n. Furthermore, a comparison
of/l£Mre 8./ and A3. J shows that a higher value of alpha, implies greater variety. In general
therefore, in all cases of p-8/i<0 , the movement of z' is negative and as n moves
positively along an exponential growth path, total variety increases.
In the second instance, the case of p -8n>0 was evaluated. The values for p used,
ranged from 18 percent to 21 percent'™. The case of 18 percent is shown below injures
8.5 to 8.8, while the case of rho equal to 19 percent is shown in appendix yzgures A3.8 to
A3./7. As can be seen from these figures, the high rate of time preference completely offsets
the negative growth of z' in the previous case. With p equal to 18 and a equal to 0.1, i.e.
low quality weights, the result is an initial increase in variety, as the differential equation for/i
increases faster than that for z" (see for example yigwre 8.5). This is followed by a period
of equal growth, with the two curves almost parallel to each other (as in ./zgMre 8.6), and
finally results in the z ~ crossing the n curve, which indicates that older varieties are
eventually driven out by innovations (/jgures 8.7 and 8.8). The reason for this change from
an increase to a decline in variety, is a higher rate of time preference, implying that fixed
costs fcj and the equilibrium quantity of z are initially high and therefore variety is low.
™ This value of time preference, i.e. > 17% may seem rather large. However, if we use the
estimates of the growth rate of innovation, derived from patent data in chapter 3, (which ranged
from 10.27 in the US and 10.71 in Europe), then the rate of time preference used here does not



















Z-= 1.99956 • n = 2
However, the exponential impact of quality finally comes through, crowding out variety
through quality. The case where rho equals 0.18 and n equals 4, are shown in appendix
./igures A3.72 fo A3.75 and A3.76 to A3.7 9 for n equal to 8. A higher initial value for«
implies greater variety in the beginning because the ^ values are lower as are those for j ,
thus leaving more room for variety.

















Z-= 1.99956 • n = 2




z-= 1.99956- n = 2
This last result, with new variants driving out the old, is what we see in the quality ladders
model of Grossman and Helpman (1991b and c) and Aghion and Howitt (1992), where the
emergence of a new variety, immediately results in the older variety being driven out due to
the presence of monopoly profits from the innovation, which destroys the monopoly position
of the older product.In this model therefore, this type of creative destruction does appear to be present, but
comes at a rather late stage (usually between periods 30 and 40). Instead this case appears
to describe rather well, a product cycle type of system, with innovation initially increasing
variety because the new products are unable to compete with cheaper, older products and
finally reach a stage of maturity, often because of falling fixed costs and drive out older
products (see Scherer, 1980 and 1984 for more details on the stages of product cycles).
However, in the model described here, the decline in variety in the final stage is caused by
declining licensing costs, rather than the case often used of process innovation which reduces
the fixed cost of producing the new product. For the case of a equal to 0.2, i.e. higher
quality weights, see appendix yj£«re.y A?. 76 to A?. 7 9. Next we examine the case of
simulations under the assumption of no learning.
Simu/arions /or M? Learning (Z)e/ta = 0)
There are two major differences with the case of strong learning. Firstly, learning is not
present in the differential equation for n, and therefore has no impact on it and secondly, the
differential equation for z" does not contain a negative term as in the case of strong learning,
implying that fixed costs and equilibrium output are not driven down. Thus we can rule out
any negative movement in the differential equation for z".




















Z- = 3.84089 -•- n = 4
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Figure 8.11. No Learning (delta = 0)
alpha=0.1, theta=0.83, rno=0.03
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5
Time
•Z- = 5.21802-*- n = 8
180As in the case of learning, the initial values used for n were 2, 4 and 8, 0.83 for 0 and
0.1 and 0.2 for a. The rate of time preference p, was varied as before. However, since p
does not occur in either differential equation and only changes the initial value for z", the
changes in z" are not significant. We therefore only report on the lower values of time
preference rates used. The general result for all values of n, z" and a used, (/zgures 8.77,
S.72 and 8.75 below and also see ./igMrej AJ.2 and A5.4, A5.6 and A3.7 in appendix), is that
there is convergence in the rates of change of both differential equations, i.e., there is creative
destruction in the sense of Grossman and Helpman (1991 b and c) and Aghion and Howitt
(1992), and only one variety, that is, the highest quality is left on the market
The use of different initial values of n, as in the case of strong learning effects,
changes the time at which new varieties drive out older ones, where successively higher values
of n are associated with later time periods of new varieties crowding out old ones (see/igure.s
8.9, 8.70 and 8.77 for n values of 2, 4 and 8 respectively). This is because households can
afford relatively lower values of z" if n is higher initially, making the initial difference
between n and z" greater. See also the case of n equal to 2 and 4 when rho is 0.1, in
y 8.72 and 8.75 respectively.
2.04
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Z- = 3.94711 n = 4
Thus, to summarize, this section on simulations has given three results.
1. In the first instance where p -8«<0 , total variety increases because fixed costs faced by
the producers in the differentiated sector are declining along with the equilibrium quantity,
allowing the consumer to buy a larger range of products given the budget constraint.
2. In the second case, with p-8/z>0 , fixed costs are decreasing but high, as is the
equilibrium quantity produced. Consumers therefore buy higher quality products, with lower
qualities dropping out and variety declines. This case resembles descriptive accounts of the
product cycle as new products go through different stages associated with declining costs,
eventually driving out old products.
3. In the third case of no learning, the result is one of new products almost immediately
driving out older products. Here, because the fixed costs and equilibrium output levels are
constant, consumers, given their budget constraints are unable to buy a larger variety of
products, and given preferences for quality, older products are dropped in favour of new
products of a higher quality. The contrast provided by cases 1 and 3, when similar values of
rho are used can also be seen from ./jgnres A J. 7 to A3.4 in the appendix below.
182Conclusions
In this chapter, we have presented a closed economy growth model based on an R&D
sector which innovates and licenses its patented innovations to a production sector which
produces differentiated products. Only one factor of production is present and we have
examined both the cases of perfect and no capital markets.
The results of the simulations used to examine the dynamics of the system, presented
a number of interesting implications for variety, showing in specific, that depending upon the
values of certain parameters, the system had a wide range of implications for variety, ranging
from the creative destruction result of previous models such as Aghion and Howitt (1990) and
Grossman and Helpman, where only one variety is present, to the constant range of Flam and
Helpman (1987) and Young (1993) for long time periods, although not for the steady state,
and to increasing variety, such as in Young (1991).
This range of results also has interesting parallels with the previous chapter describing
the impact of quality improvements through biotechnology, upon older products, and
traditional technologies. For example, in the case of genetic engineering, there is a case to
be made for creative destruction as in Grossman and Helpman, with a new product completely
displacing an old product from the consumer demand function. However, in a number of
cases, old products are increasingly facing competition, not from just one product, but from
a number of different products and processes. For example, in the case of sugar, although
there was an initial fear that High Fructose Corn Syrup (HFCS), would replace sugar over the
years, although the use of sugar has declined, especially for industrial use, there has also been
a rise in the variety of substitutes being used as sweeteners. In this instance, therefore, a case
can be made for increasing variety as in Young (1991) and as in this model, in the case of
strong learning effects and where p -8n<0 .
Although it is relatively early to draw conclusions about a product cycle, there is some
evidence for this, again from the case of HFCS. When HFCS was first developed, its costs
were too high for industrial use. A combination of declining costs of production and higher
internal prices especially in the EC, have ensured that HFCS is now the most widely used
substitute for sugar and although it has not succeeded in completely displacing sugar, this is
probably due to the fact that the two are imperfect substitutes for each other. A more recent
sweetener such as thaumatin which is used in crystallized form such as sugar, may pose a
more strong challenge, although due to its high cost of production, this is only likely in the
distant future. For some cases however such as vanilla, as was seen from Chapter 5 above,
substitutes are considerably cheaper, implying a faster rate of substitution than was the case
with sugar. This may also be an indication of the long term development of biotechnology
in general. At present we find that second generation biotechnologies which are often
imperfect substitutes, tend to dominate, as the genetically engineered products are still costly
for most consumers. Thus, variety in the short run will increase. However, it is likely, that
when genetically engineered products become cheaper and more widely accessible to
consumers, they will tend to displace older products completely. Thus, the result will be
increasing variety in the short run which is gradually reduced to a single variety as genetically
engineered products become more widely available.
183Finally, the reselection of older products one can argue, is also taking place in
conjunction with new technologies. For example, biotechnologies are making it increasingly
possible to reselect traditional products, whether through conservation of traditional products,
or the use of tissue culture and micropropagation techniques to multiply traditional agricultural
products. The example of the neem tree, a tree with astringent properties which is widely
used across the Indian subcontinent by indigenous medicine, can be used to illustrate this,
where patents are now being granted to traditional products and compounds developed from
the properties of the tree, which is likely to increase their consumption by a larger group of
consumers, as the products become more widely marketed.
Thus the model presents interesting dynamics with respect to innovation and
substitution of products driven by quality weights and the dynamics of variable and fixed
costs. In the next chapter, we examine these dynamics in the context of international trade
and economic growth. The extensions will be particularly relevant to some of the
displacement problems between northern and southern products, which we have described
above.
184Extensions to International Trade
fne commKmfv passes ./rom peaceaiZe savagery to a prefatory p/ia^e o/ /(/if,
cond/rions 0/ emu/arion c/tange. 77ie opportanzry and fne mcenfive to emM/afion
in scope and urgency "....7. Vefe/en
Introduction
In the previous chapter, we examined technological change within a closed economy with two
sectors and one factor of production. The results as we saw show a constant rate of
innovation and economic growth, combined with differing rates of growth in product variety,
depending upon consumer preferences for quality or for variety. In this section we consider
trade between two countries.
We begin with an integrated trade equilibrium where it is assumed that factors of
production can move between the two economies and then move on to examining the trade
equilibrium, where the two countries or regions consider only trade in goods and factor
movement is not allowed. We assume in the first instance that only the north innovates'",
i.e. has an R&D sector, while both countries produce different sets of differentiated products.
Since we assume that technologies of production are the same in both countries, the ability
of a country to do R&D implies a greater knowledge. Thus, the north produces higher quality
differentiated products while the south produces lower quality differentiated products. Unlike
a number of previous models (such as is the case of the quality models of Grossman and
Helpman), we assume that international patents are enforceable, that is, countries cannot
imitate, but have to pay royalties for the use of any patented innovations. Thus, the
differentiated sector in both countries has to pay for any innovation produced by the R&D
sector. We also assume that no innovation is licensed out to any two producers, ensuring
thereby that the range of products produced by producers in the south is always different from
that produced in the north.
Of the few recent models which have examined innovation and imitation in the
presence of international patents, the one by Helpman (1993) is most relevant to the analysis
here. Helpman (1993) interprets stricter intellectual property rights in a two country model
based on Krugman (1979) as a reduced rate of imitation. Thus, the only impact is that the
developing region is able to imitate at a reduced rate. The result, as is to be expected
intuitively, is an improvement in the terms of trade of the northern country because the
fraction of goods produced in the north increases. Presumably, this implies that with perfect
"' Grossman and Helpman (1991a, Ch.8) also rule out southern innovation and argue that this can
be done in a number of ways: firstly by assuming that southern producers require more labour to invent
the same product as the north, they would have endowed the north with comparative advantage in
innovation; secondly they could have assumed that n^»n^ , (as in this chapter), ensuring that the
knowledge gap would enable the north to maintain its lead in the long run; and finally, by assuming
that the north has skilled labour while southern labour is unskilled, would again ensure that the south
would produce low quality goods.
18Senforcement of intellectual property protection, the rate of imitation would be close to zero.
However, the possibility of licensing is not addressed, should this be the case.
Within the framework of the models we discussed earlier however, such as the
Grossman and Helpman (1991a and b) models, which use a sectoral analysis to discuss
innovation and imitation, patents are in general ruled out when discussing trade, and the south
always imitates products from the north rather than licensing them. Thus these models tend
to ignore the enforcement of intellectual property rights across national boundaries in order
to emphasise imitation. In our approach instead, both intellectual property rights are
recognized across national borders and we allow for licensing where licensing becomes a fixed
cost in the producer's production function.
Licensing across countries is however discussed briefly in Grossman and Helpman
(1991a, Ch 7), in terms of a lump sum payment for a patent from the innovating firm to the
licensee. In the case of horizontally differentiated products, the licensing firm in these
circumstances will only license if its costs of paying for the license equals the present value
of profits from entering into duopolistic competition with the innovator. In their case this only
occurs if there is a manufacturing cost difference between the two countries, which ensures
that the licensee could make monopoly profits which are higher than the profits it could make
on its own. This would ensure that the licensor would not compete with the licensee and
therefore the latter would divert all monopoly profits from the former, because factor prices
would be equalized as a result of the transfer of technology.
In the case of vertically differentiated products, because innovations are no longer
imperfect substitutes for older products such as is the case with horizontally differentiated
innovations, there is no longer competition with like goods. The innovator is now competing
with manufacturers of older products. There are two trade equilibria which emerge in this
case: in the first, there is no enforcement of non-competition clauses, such that if the patent
is licensed but the innovator also continues to produce the product, there is no licensing in
equilibrium. This is because if the new product is more costly to produce and the innovating
country has comparative advantage in the production of the innovation, then if there is
competition between the two countries, the innovating country would earn all the profits in
the Bertrand equilibrium. In the the second case where the innovating country agrees to make
the licensor the exclusive producer of the innovation, as in the model presented in this chapter,
there is an equilibrium which allows licensing to be profitable. However, in contrast to the
model presented below, licencing in the Grossman and Helpman case only takes place if the
cost of production in both countries is the same. Innovators will license their innovations
because competition to improve products targets only the newest generation of products. Thus
competition is most intense among innovators in the technologically advanced region. The
rationale for granting a license to a producer in the non-innovating region is to ensure that a
longer period of monopoly profits can be sustained for that innovation. This would not be
possible, if the innovation was produced by the innovating firm because of competition to
develop the new generation of innovations'™.
'1;
'" Grossman and Helpman (1991a, pp 200-205). This point is also made with reference to the
result they get in many of their papers, that once innovation takes place, the race to develop the next
generation of products begins and the innovated product becomes the new target for quality
improvements (see also Grossman and Helpman 1991b and c).
186In this chapter imitation by the south is completely ruled out and the south can only
produce goods by licensing the technology from the northern innovator. Unlike Grossman and
Helpman (1991a, Ch 7), we do not rule out licensing by northern firms of new innovations.
However, we do rule out any competition with regards to the same innovation, i.e. the
innovation is only licensed out to one producer. Thus each patent is licensed to only one
producer and the product to which that patent belongs is only produced by that licensor.
9.1. The Integrated Equilibrium
«-• "• r v; v; - _" . „•?. '•'.. . ...
The structure of production and resource endowment is assumed to be the same as in the
previous chapter, except now the countries are indexed N and S (for north and south
respectively). We assume that while only the north can do R&D (i.e. it has a comparative
advantage in R&D), both regions produce and export the differentiated good, z. The structure
followed in this chapter is the same as in Chapter 8 above, beginning with demand and then
moving on to describe the differentiated and R&D sectors.
Consumer preferences and utility are described in the same manner as in the closed
economy, i.e. intertemporal utility is denoted by :
_,.
-O [log «] (9-1)
where rho is the subjective discount rate and the subutility function u is
M =
z e [z~,n]




where ^ is the quantity of quality z demanded, while z" is the lowest and n is the highest
quality demanded by consumers. The parameter 6 represents society's constant demand
elasticity for quantity. Utility is maximized with respect to the budget constraint by
consumers in the north and in the south, where /? (x) is the rate of cumulative interest from
time f to time T, p is price of quality z, £ is consumer income in each period and wealth
is assumed to be zero because its impact has been discussed in the previous chapter.
Thus the budget constraint for each region can be written ., • ;<,-;>: >;. ;•.•;••. ; i,
rfc (93)
187and similarly for the south
- E, rfx < 0 (9.4)
where subscripts denote regions north and south and £^, and £j is national income for the
north and south respectively. The Lagrangean can now be written
(9.5)
and similarly for the south
L = Je "?<'-*> log K[.] d
_»
from which the first order conditions arc equation (9.3) and
-«('-*) £. - rfc (9.6)
, -p(r-t)
< 0 (9.7)
for the north and equation (9.4) and
(9.8)
for the south, and if (9.7) and (9.8) above hold with equality, we can calculate the price




As relative prices, 0 and quality weights are the same in both countries, relative quantities
demanded must also be the same. From (9.9) and (9.10) we can calculate northern and
southern elasticity of demand respectively
_,_,
and
3p, 9, (9 "
';,/^ 1^_1 = 0-1 (9.12)
Thus because we assume that preferences are the same in both regions and that the
structure of the utility function is the same, we obtain the same result for elasticity of demand
for z goods. The solution to the intertemporal utility maximization problem can be calculated
by multiplying <^ to equation (9.7) and (9.8) and integrating over z
and
-lH-lpt.]"'' 6 ff? «*)" = X(f)e-*<*-'> fp 9 dz
Expenditures in both countries grow at the rate of interest minus the rate of time preference.
In the case of no capital markets that rate is zero if incomes are constant.
We now move to the differentiated sector, where it is assumed that both regions have
the ability to produce differentiated products. We assume only one factor of production,
labour N, which is allocated between the two sectors, and has human capital of //. As
before, we assume that producers of differentiated products license innovations from the R&D
sector, and become monopolists by virtue of being the sole users of the new patent.
International patents are enforced, ensuring that southern producers cannot imitate or pirate
189an innovation, but have to license it from the northern innovator just as northern producers
of the differentiated good do. Thus both north and south license innovations and produce
differentiated goods. We also impose the condition that once the innovation is licensed to one
producer, it cannot be licensed to another. Thus each differentiated producer, produces
different differentiated products.
The production function in both countries is the same as before
i = JV.S (9.15)
and because we assume linear technologies in production as before, this can be written:
(9-16)
The monopolist minimizes production costs
(9.17)
where w. is wage per efficient labour unit and C (.) is total variable cost
The producers' first order condition for cost minimization with respect to #,-* is
• „'••.. w.ff. -Vz.//. =0 " (9.18)
which can be rewritten




which is the marginal cost of the monopolist.
Because we have assumed that differentiated producers become monopolists by licensing z,
from the R&D sector, the profit function of the monopolist can be written
p^(^) - C^(^) - & 1 (9.21)
190Optimization with respect to <^ yields the following first order condition
(9.22)
which means that marginal revenue equals marginal cost which is the monopolist's optimal
pricing condition. From the first order conditions for consumer demand we have determined
the price elasticity of demand and from (9.22), we can calculate the marginal
revenue of the monopolist
(9.23)
implying that
and from equation (9.20)
(9.24)
w. (9.25)




The assumption is again that profits have to be zero because free entry into this sector enables
each potential producer to offer all profits when a blueprint is auctioned off (see Romer,
1990). Equation (9.26) can be written as ,, ... „
i =
(9.27)
Cancellation of z^ and integration over northern and southern ranges of z yields
191e
(9.28)
R&D, we assume can only be done by the northern region, i.e. as in Grossman and
Helpman (1991a, Ch 8), we assume that the north has comparative advantage in R&D and
innovation activities. The R&D sector therefore has the same structure and allocation of
resources and the price structure of each new innovation is therefore the same as before.
Since R&D is only done by the north, we drop all country subscripts, except to indicate
northern and southern wages and incomes, in this section. As before, the production function
of the research sector is
(9.29)
where rt is the flow of innovations and n is a measure of learning from each innovation.
Delta measures the elasticity of these spillovers where if delta = 1, we have perfect learning
as in Shell (1967) and if delta = 0, there is no learning as in Phelps (1966). The assumption
of linear technologies in labour means that equation (9.29) can be rewritten
(9.30)
Each innovation is patented by its innovator and licensed out to the producer of a
differentiated good. We assume free entry in this sector and the producer maximizes the sum
of profits over time from zero to infinity
L = Max
where w^ is wage and ^ is the licensing charge for innovation z, subject to the production
function (9.30)
From the current value Hamiltonian for the R&D sector
H = (9.32)
we obtain
152_^_ = -w^ + Xn'tf, £ 0 , _Z2jV* = 0 (9.33)






X S ^^ (9.36)
Inserting equation (9.36) in (9.34), and using w^ as the numeraire, this yields
X = A - ft - ^"** , (9-37)
-•• •":. •? .'•••••. «• " « '•• ^ ! .••:••••••
From equation (9.36) we can calculate the derivative of lambda with respect to time and take
growth rates
X = -Jl-li or X = -H5 (9.38)
Combining this with equation (9.35) we get
* «i- -• (9-39)
J
which after multiplying by « can be written .^
' fi8 = fe.n**' -J«« +//<6V (9.40)
and inserting from the production function (9.30) we solve
193(9.41)
Thus the fixed cost (or the cost of licensing the innovation from the innovator) depends
positively upon the rate of interest but negatively upon the learning parameter and n.
9.7.7. Labour A/Zocarion
Another major change from the previous chapter is the presence of a larger labour force in
the integrated equilibrium, and although the south devotes all its labour force to the production
of differentiated products, specialization is not necessarily the case with the north. The next
step therefore is to calculate the allocation of labour in the two sectors in the north. For this
we take the new zero profit condition in the R&D sector, which can now be written
= 0 (9.42)
where the two extremes of each integral denote the range of products produced in the north
(N) and in the south (S) (which can be assumed to be continuous in an integrated




which can be rewritten
(9.44)
where £j is southern income since the south does no R&D and therefore allocates all its
labour to the production of the differentiated good. From the labour market equilibrium in
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0
from which we obtain
,„,„ J ^ (9.47)
0
'„#„-(1-6)2, (9-48)
Once again, from the labour market equilibrium in the north, we can replace the LHS of this
equation to write
W^(A^-A^) = 0w/^A^ - (1 -0)£j (9.49)
which can be written
=> (1 -
Taking northern and southern income together as £^, we obtain the allocation of total labour
in the integrated equilibrium to northern R&D.
and if w^ and H^, are set equal to one, then equation (9.52) can be written
=< (9-53)
Thus a constant rate (1 -0), of world labour is allocated to the R&D sector in the north in
the integrated equilibrium. From this allocation, we can now calculate the trade equilibrium.
Taking the two extremes of factor price equalization, i.e.
195and if all labour in the north were allocated only to R&D, i.e. perfect specialization:
we can draw
Figure 9.1. Labour and Income Constraints
1
NN N'
and inserting the labour allocation from the integrated equilibrium gives the three equilibria
shown in figure 9.2. below which can be derived from equation (9.51)
where £^=w^A^ and £j=wyVj
(9.54)




(9.56) is the positively sloped equation drawn in figure 9.2 below. Putting N * =A^ equation
(9.56) can be written
*>„ (1 -
(9.57)
Figure 9.2. The Trade and Integrated Equilibria
There are four equilibria in this case, A, B, C and D. At point A and D, there is factor
price equalization in an integrated equilibrium. In A, north does both R&D and production.
In D, north hires labour from the south to do only R&D. Without labour migration, there are
only trading equilibria at points B and C. At point B there is complete specialization, with
north doing all the R&D and the south producing all the differentiated products. The
equilibrium at point B will be discussed in more detail in the next section.
Equilibrium C is a special situation, where by looking at the graph one sees that at
point C W^/H'^> 1 , implying that southern income is higher than northern. In this case, the
197south is becoming richer by producing the differentiated good, rather than through innovation,
which is an interesting result because it is contrary to all growth theoretic and policy
arguments in favour of investment in R&D to enable a country to encourage innovation and
welfare.
Equilibrium C may be of interest when considering a narrow wage gap. It is rather
implausible, intuitively, that in the north-south context that has been discussed in this model,
that the south will have higher wages relative to the north. However, in the case of north-
north trade, i.e. where there is comparatively less of an income difference between the two
regions, this may be a possible conclusion. For example, a country may become more rich
by allocating resources to a sector where it has strong demand than in a sector such as R&D.
Within the framework of this model then, the north would invest in R&D whereas, the sector
in the country with higher relative wages may become richer by investing in production rather
than in R&D. Thus the equilibrium wage levels in this case may be demand determined in
Q
the sense that may be higher than relative labour supply, A^/T^/A^//^ in (9.57).
1 —9
The integrated equilibria at A and D are analogous to the closed economy case, since
labour migration is allowed in these cases. Thus, the most interesting case is the equilibrium
at point B where migration does not occur and there is perfect specialization with the north
doing only R&D and the south producing all the differentiated products. We discuss this in
the next section.
9.2. Equilibrium with Perfect Specialization j
i
Thus, as we have established above, at points B and C, when migration is not allowed, the
north perfectly specializes in R&D while the south produces all the consumer goods. This is
not an unlikely situation if one relates this back to biotechnology. For example, advanced
genetic engineering techniques are being used in the industrialized world to develop new
products or genetic material, which then can be sent to developing countries to produce or
reproduce, which in turn is sold back to consumers in the industrialized world. This is the
case for instance in agriculture, where genetic engineering or non-molecular engineering
techniques are being used to develop new varieties, which are sent to developing countries for
reproduction and mass regeneration. The reproduction, once completed, results in a great
many plants or plantlets with the same or similar characteristics, which are then sold back to
consumers in industrialized countries'". ** "?
To take this one step further, and to bring it in line with the model described here,
southern producers would be able to license new products which are patented in the north to
produce and export these products back. This would be the case if the protection of
'" The reason for this particular pattern of trade which is taking place between a number of
countries (this particular example is from an Indian firm which specializes primarily in tissue culture,
but whose techniques increasingly revolve around these activities), appears to be primarily related to
lower wages and lower marginal costs of production. The scientific knowledge and capability required
for such activities however are also important and this has important policy considerations for
capability building which we will expand upon below.
198 iintellectual property rights is complete and enforced, as is assumed in the model. However,
though this is not at present the case, there is considerable evidence which points to a
strengthening of intellectual property rights and this may become reality in the near future.
Here a word of caution is perhaps appropriate, since it is not clear from the evidence we have,
that the innovations are only licensed to a producer in the south, and not to other competitors
in the north as well.
As in the case of the closed model, we calculate the fixed cost and its growth rate.
The first order conditions from consumer optimization (9.13) and (9.14), can be written as
(9.58)
which after cancellation can be written
(9.59)
In growth rates this yields the rate of change in expenditures (which in this case, under the
assumption of no capital markets, is also income), which is zero, and equals the difference
between the rates of interest and of time preference:
F -w + /v -n-/?-r> ''^te.- >ys"
^\ - *V * "N - " - * P (9.60)
4 = #, + w, = 0 = /? - p
We insert these in (9.41) to solve for fc^_ which in the steady state is *,
To calculate the growth rate of fc^, from equation (9.9) or (9.10) and the zero profit
condition of the firm (9.26), we calculate the relationship between fe. and 6 where i and/'
are variants selected by the household. From equation (9.9) and (9.10) above, the relationship
between relative quantities of the two variants which are consumed in both countries, is the
same for both regions. Thus inserting relative quantities from (9.26) and relative prices from




Hence, we conclude that fc. and 6 grow at equal rates because of (9.26) and at the same rate







This result is similar to that obtained in the closed economy model under the
assumption of no capital markets and strong learning effects. The major difference between
the closed and open economy models is in the amount of labour allocated to production. In
the case of the closed economy model, (1 -8)N was allocated to the R&D sector, whereas
in the open economy case, this is A^. The absolute size of labour allocated to R&D is
therefore greater in the trade equilibrium with complete specialization, than in the closed
economy case. This implies that the rate of innovation will be faster but lower (higher) than
in the integrated equilibrium, if the economy is in equilibrium B (C) because the
corresponding integrated equilibria is D (A) with M^/W^<(>)0 .
What remains now, is to describe the two differential equations which determine




and since labour allocation in the south is
200(9.68)
From prices and the zero profit condition in the differentiated sector (9.28) we calculate
(9.69)
Inserting equation (9.67) into (9.68) and differentiating with respect to time yields
(9.70)
Dividing both sides by _ H»
6 *
H>, + Af- (9.71)
Dividing and multiplying by ^
0£™
w. + jy, - —H =
(9.72)
because of (9.63), t^ is constant and can therefore be taken before the integral. From
equations (9.28) above, we insert for ]£jd!z and write
e 'i (9.73)
Since the growth rates of southern wages and labour are assumed to be zero, we can now
solve for z"
201_ J^ <,„,
In equation (9.75), we insert values for fe^ = -/J8 = -8n'~A^ from (9.65) and we usei
equal to z' and,/ equal to n in (9.62) to replace ft^. and we insert 6^=p/n* from (9.61)
above and use (9.57):
Z - — - "MM-" »"»/I—^ v" <• / i C976^
This is the general equation for z". As in the case of the closed economy, we now have two
differential equations, one in n which describes the change in new products and the other in z"
which describes the change in old products:
n = n*A^
' r« lA (9.77)
z" =A^(p-5n)U!-e"<"-<•> F*
U" J
A comparison of these two differential equations shows that learning has a positive
influence on both. However, the size of northern labour also has an influence on the
differential equation for older varieties.
If the net effect on j" is stronger in the negative term i.e., p<8n , then, as in the
closed economy case, the movement of the differential equation will be negative, implying that
old products are reselected and variety is growing. This is because the fixed cost is falling
(and its level rho, is small), and since ^ =^, this implies that the quantity of goods produced
in equilibrium is also declining and consumers can spend more of their budgets on consuming
variety. The opposite will hold in the case of p>8/t and if rho is large with the result that
variety will decline or may remain constant for some period, as in the last Chapter, before
declining. Thus the net result is the same as in the closed economy case except that the rate
of innovation and of older varieties dropping out or being added, is faster because A^ in
(9.77) was (1 -6)Ntf in the closed economy case.
In previous trade models such as Grossman and Helpman (1991c), an increase in the
resource base results in an increase in innovation, as more resources can be devoted to R&D.
Since the size of the resource base in the north determines the rate of innovation in this case,
202the model here also has the same result. However, the impact on total variety depends upon
the rate of time preference and the growth rate of new varieties.
We can now look at the impact of greater innovation on the terms of trade. We
describe the terms of trade in terms of relative prices, i.e.,
which implies that an increase in innovation in the case of learning, would drive the terms of
trade of the north down and an increase in the size of the south will drive the terms of trade
of the north up. If we set A/^ equal to 1, then an increase in the rate of time preference p,
will also imply an improvement in northern terms of trade. A rise in 8, i.e. the constant
elasticity of demand for quantity, will result in a decline in the northern terms of trade. In
the case of learning, an increase in the parameter delta, will result in a decline in northern
terms of trade for any given n.
The movement of the z" curve can therefore be either negative if p -A^,<0 , and
positive if p -A^,>0 as in the case of the simulation results obtained from the case of no
capital markets and spillovers in the closed economy model. Thus variety can either increase,
remain constant or decrease, depending upon the size of the rate of time preference.
In the case of p -5n>0 where the total amount of variety first increases, and
eventually declines after some time, the implications for southern products, especially
traditional products (here represented by the differential equation in z"), is that their share
is increasing or remains constant for a period of time, before these products are completely
driven out of the market by new varieties. This would therefore lend support to the earlier
observation made in Chapter 5 above, that developing countries are losing market share as a
result of their traditional products being driven out of the market by biotechnology R&D in
industrialized countries, which targets traditional products. The examples used included sugar,
vanilla and cocoa among others.
In the case of no learning also, the size of the north drives both differential equations.
As in the case of the closed economy model in Chapter 8 above, here too, both equations will
move positively. However, it is unclear from the information contained in these equations,
what the speed of the movement will be. Thus, it is difficult to say whether the number of
varieties will increase, remain constant or decline. On the basis of experience from the
previous chapter, we would guess that the exponential term will drive z' quickly towards n.
The implications once again for developing countries would be negative, especially for
producers of traditional products. If innovation completely drives out traditional products, as
appears to be the case with no learning in innovation, the share of developing country
traditional products in international trade would again decline. Thus the dynamics of the
model lend strong support to the idea put forth by empirical studies, that the developing
country share of international trade is declining.
To summarize then, there are four equilibria, two integrated and two perfect
specialization possibilities without migration. In the equilibrium discussed above, there is
complete specialization with the north doing all the R&D and the south producing the entire
range of differentiated products. Innovation in this case is higher (nA/^ in the case of
203learning), than in the closed economy case, because all labour is now devoted to innovation
in the north rather than a percentage ((1 -0)), of it. The relationship between the innovation
rate and the rate of rejection or rcselection of old varieties is therefore similar to the closed
economy model.
However, referring back to figure 9.2 above, the integrated equilibrium D, appears to
have large gains from trade. From this equilibrium it is evident that if resources could be
moved between countries, the resources devoted to innovation would be greater than A^,
( (1 -6)£^ from equation 9.53 above), and the rate of innovation would be even higher in
an integrated equilibrium than in the trade equilibrium, implying also that consumers would
be able to buy higher qualities and the southern wage would equal the northern wage, even
though the south is technologically backward.
Conclusions
In the last two chapters, we have developed a closed economy model of endogenous growth
and an open economy growth model in this Chapter, based largely on the sectoral framework
developed in the new growth models, which show interesting similarities and dissimilarities
with previous models of the same genre.
Thus the closed economy growth model is characterised by regulated monopoly in
innovation, and monopolistic competition in the production sector due to producers licensing
innovations from the R&D sector. Innovation takes place in the form of higher quality
products. Products are patented indefinitely by innovators and then licensed out. The
assumption of free entry in the initial periods, together with a legal framework or regulation
in the R&D sector ensures that there are no monopoly profits. However, each product is only
licensed to one producer, giving that producer monopoly rights over its production.
The main contribution of this model is in the use of a utility function which combines
both quality improvements as well as consumer preferences for variety in a very simple
manner. This is perhaps a more realistic approach, given what is observed from industrial and
agricultural biotechnology sectors; secondly, the model also produces a variety of results,
ranging from the case of perfect or creative destruction, seen in the quality ladders models of
Grossman and Helpman (1991a Ch4, and 1991b and c) and Aghion and Howitt (1992), and
the result obtained by Flam and Helpman (1987) and by Young (1993) of a constant range,
to that of an increasing range as discussed by Young (1991).
In the trade model, we extend this analysis further to explain international trade
between two regions, one less technologically advanced than the other. We rule out imitation
by the less technologically advanced region (called south), because of strict enforcement of
intellectual property rights, arguing that this appears to be the general trend in the real world
at present. Extending the closed economy model in this manner, results in complete
specialization, with the north, which has a comparative advantage in R&D because it is
technologically more advanced, doing all the R&D, while the south licenses innovations from
the north and supplies both national and international markets with the differentiated product.
Although the dynamics with respect to quality and variety remain the same as in the
closed economy case under the assumption of no capital markets, the trade model shows
interesting results from interactions between north and south in terms of rates of innovation.
• .'•-•:'.• .-.•'.'•.;•/..•••••;•••,.•«. . ."•.r; ".••.. "-,For example, an increase in the rate of innovation, increases the range of new patents
transferred to the south. An increase in the rate of innovation however, will lower northern
terms of trade. A decline in the north's terms of trade however, will also imply a lower fixed
cost of production for southern producers. If learning effects are present, and if p<-8n ,
then variety will increase, while if p> —8n , then variety can temporarily either increase,
decrease or stay constant
Another important conclusion we drew relates to the share of developing country
exports in international trade. Although in the model, developing countries are the only
producers of differentiated products, we found that both under conditions of learning
( p-8/i>0 ), and no learning in innovation, developing countries will lose market share in
traditional products. This supports the earlier observation made that R&D by biotechnology
companies in industrialized countries appears to be targeting and displacing traditional
products which are produced in developing countries, resulting in a decline in their market
share.
Thus the model in general demonstrates a number of possible outcomes for quality and
variety and has interesting implications with regard to the impact of innovation on economic
welfare in an integrated equilibrium.
In the next chapter which is also the concluding chapter, we draw some policy
conclusions and summarise the results as they relate to economic growth and development
especially with respect to biotechnology. The framework chosen of quantity, quality and
variety will serve as a background as with the rest of the thesis until now.
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Introduction
This thesis was presented in three broad Parts to examine the nature of innovation and
industrial and agricultural production in biotechnology and to formally present some of these
observations in an endogenous growth and trade model, which was developed within the
differentiated product framework of the new growth and trade literature.
Part I examined patterns of innovation, institutional structures and production in
biotechnology based industries, both in industrialized and in developing countries. In Part II,
we examined the basic characteristics of the new growth and trade literature and its relation
to innovation, and economic growth, culminating in the development of a growth and trade
model in Part in. The common theme within which context each section was placed, was that
of the impact of quality and productivity improving product innovations through
biotechnology, on the total variety of products available in the economy. In this final chapter,
we continue to work within this framework to summarise and draw some policy conclusions
from the observations made above.
The main objective of the thesis was to examine the patterns of innovation, production
and economic growth which are characterised by biotechnology, and to draw some parallels
and contrasts between the experiences of industrialized and developing countries. In section
1 below, an attempt is made to synthesize some of the observations as they relate to
technological and organisational structures, and how the direction and intensity of innovation
relates to these in turn. The identification of patterns of innovation is crucial to describing
the interactions between different agents in the economy, and how those interactions contribute
to technological change.
The second section examines the structure of recent models of growth and trade which
together with observations about patterns of innovation in biotechnology, provided the
framework within which to develop the economic model presented in chapters 8 and 9.
Finally, we return to the three themes of quantity, quality and variety and draw some tentative
policy conclusions with respect to the future development of biotechnology, both in
industrialized and in developing countries.
10.1. Some Stylised Facts about the Nature of Biotechnology R&D
In Part I, the question of patterns of innovation and the general institutional and organisational
structure of biotechnology was addressed. Although specialisation across countries tends tobe different, with biotechnology playing an important role in the pharmaceutical sector in
many industrialized countries whereas it is more predominant in agriculture in developing
countries, there are a number of similarities in research and production structures and
frameworks.
The R&D structure in general appears to be dominated by two types of institutions or
firms: (i) Firstly, basic research tends to be carried out largely in the public domain, by public
sector institutions and universities, and although this is changing in many industrialized
countries, modern biotechnology in the 1960s and especially 1970s owes its origins to basic
research breakthroughs made at universities in Europe and in the USA.
These institutions however, tend to be weak at performing more applied R&D of a
downstream nature, for a number of reasons, the most important of which are perhaps a lack
of knowledge about market structures and marketing techniques and the incentive structure
which is different in academic institutions and in private sector firms.
Downstream research and development, for these reasons then tends to be dominated
by the private sector, both in industrialized and increasingly in developing countries, although
the absence of capital markets in the latter has made downstream development all the more
difficult, even for the private sector.
(ii) The second sector therefore tends to be mostly dominated by private companies,
although again, in developing countries this is less the case. The applied research done by
these private agents is more suited to particular market needs and niches than the broad
framework within which generic research is done by universities. The proximity to the market
and the presence of marketing and management skills is another reason for the greater success
of the private sector in developing products for commercialization. The problems of small
biotechnology companies demonstrated very well the need for these techniques. These
companies have now tried to overcome these constraints by forming marketing and distribution
alliances with a number of suppliers in different countries. There is also increasing evidence
that there may be a tendency toward concentration as biotechnology, especially industrial
biotechnology, tends to become better established. Although the evidence is relatively sketchy
thus far"* (and more research on this subject may reveal more definite trends), if this were
indeed the case, it would point toward a structure dominated by imperfectly competitive
markets.
"* The entry of a large number of multinationals along with a decline in the number of small
firms in the 1980s and early 1990s for example led many to conclude that this was a general trend
toward concentration. Evidence of this however, is mixed, especially since by 1994, more and more
small companies had become emerging and raising money through the stock market. In a number of
cases also where there have been mergers or takeovers between large and small companies, the degree
of control has been limited. For example, the most famous takeover, that of Genentech by Hoffman
LaRoche has not led to Genentech being subsumed by LaRoche. Instead, Genentech remains relatively
autonomous and has continued to be one of the more successful and competitive biotechnology
companies. On the other hand, it is also clear that there is a rising degree of multinational investment
in biotechnology and as product approval becomes more rapid by the government, investment in
biotechnology by these companies is likely to increase. The initial cost of investing in biotechnology
is also prohibitively high, and except for those countries where venture capital is available, most
notably the US, (in Europe for example, the absence of a venture capital market has resulted in
domination by the large companies), the biotechnology industry will tend to be dominated by
multinationals who can afford the investment
- ••.'••-•j- -" • • • •"
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is also strong. The dependence of the second sector on the first is evident in that without the
initial innovations made through basic research, such as the discovery of the double helix
structure of DNA by Watson and Crick in 1963 or the discovery of Monoclonal Antibodies
and the gene splicing technique developed by Cohen and Boyer in the 1970s, applied research
leading to commercial biotechnology would not be possible. The first sector however has also
become dependant upon the second to provide research grants and in the American
environment, to develop the new biotechnology firms.
The high initial costs for investing in biotechnology have been emphasized in the
presence of imperfect capital markets. In many countries the lack of funding through the
capital market infrastructure has been a barrier to the entry of small investors. Yet, it was the
small investors who initially formed a bridge between basic and applied research. This is
most evident in the case of the USA, where commercial biotechnology appears to have had
a head start because of the presence of a venture capital market which was willing to fund the
small biotechnology companies. A number of other countries in Europe, most notably the UK,
have also tried to develop their venture capital markets to encourage the development of
specialised companies, but with relatively less success than in the USA.
Evidence of bridging activities by these small companies can also be found in their
links to the publicly funded research sector. The founding members of the first biotechnology
firm, Genentech for example, were Robert Swanson, a venture capitalist and Herbert Boyer,
a University of California Professor, who had along with Stanley Cohen demonstrated the
rDNA splicing technique a few years earlier. Despite forming the company however, Boyer
continued to maintain his position at the University and especially during the early years,
when patents were not being granted to genetic engineering, Genentech's research team and
facilities consisted of Boyer and two researchers, who used the facilities of the University'".
Thus, even after the venture capital company had been formed, the linkages with the
University remained strong.
Thus the structure of innovation in biotechnology in both industrialized and also to an
increasing degree in developing countries, tends to exhibit a structure in which the public
sector tends to dominate the early stages of R&D, but increasingly innovation through
patenting is taking place in the private domain. The formation of small biotechnology
companies and the growing evidence of strategic marketing and research alliances,
demonstrates the dominance of the private sector in production.
10.2. Quantity, Quality and Variety: The Evidence Thus Far
The framework used throughout the thesis was that of the impact of quality and quantity on
variety. The framework was developed as a result of observations from modem
biotechnology, where productivity improvements, i.e. an increase in quantity, vertical and
horizontal improvements have had a direct impact on the total variety of products available
in the economy. A number of examples have been used to demonstrate this, and because of
the pervasive nature of biotechnology, it appears that it can both increase as well as decrease
See McKelvey (1994), Chapter 5.
209total variety either through productivity or quality improvements or through the production of
an alternative product or process which adds to the total amount of variety in the economy.
The treatment of quantity, quality and variety in new growth and trade models which
was examined in Part II above, showed also a number of alternative approaches and structures.
In contrast to orthodox growth theory, "new" growth and trade models, especially since the
1980s differ in that they treat innovation in the form of the production of new differentiated
products, rather than an increase in the quantity of existing products. One group of models
looked at horizontal product innovation, i.e. the production of new goods which are simply
substitutes for already existing products. Variety is usually modelled in the utility function,
with the love of variety approach emphasizing consumer preferences for variety. In these
models, because the new goods are imperfect substitutes for the old goods, it is implied by
the specification of utility, that they do not displace the old goods at all. Thus the result often
is an infinitely increasing variety of goods (given the budget constraint), all of which are
imperfect substitutes for each other.
The second group of models, look specifically at quality improvements. In these
models it is argued that innovation is not only horizontal, i.e. adding to the variety of
products, but much of the world's innovations come in the form of quality improvements upon
older products. Thus innovation is often vertical and this is modelled specifically in the utility
or the production functions. Consumer preferences in turn are often modelled as desiring the
highest quality adjusted for price. In these models, the result almost always is creative
destruction, with the highest quality improvement always driving out any older variety because
each innovation gives the innovator a nationwide or worldwide monopoly over that product.
At the same time, each new innovation, because of its monopoly, drives out any previous
monopolist by destroying his/her monopoly. Thus creative destruction always results in just
one variety, usually the newest quality in the market.
There are however, a number of exceptions to these models and we have looked at a
number of relevant examples. Here innovation is the result either of learning by doing or of
human capital used as an input. They are distinct from the other quality models described
above, because instead of just one variety present at all times, these models present a number
of products of different qualities present in the economy at all times. The models by Young
are especially interesting because the results show an increasing range of variety (1991) and
a constant range of varieties in the 1993 paper.
The drawback of all these models is that they provide only single selection profiles
with respect to the impact of innovation through increasing quality on older products and
therefore the total amount of variety in the economy. Instead, what was needed from the
viewpoint of biotechnology, was a formulation which would be able to express many of these
options, depending upon cost dynamics and consumer preferences for quality and variety. The
model described in chapters 8 and 9 provides an example of how this can be achieved.
Instead of just one variety being present in the economy at each time, or instead of a constant
or increasing range of varieties being present, alternatively, the model developed above
provides a number of scenarios in which each of these situations is a special result, at least
for some time periods. Through simulations we found conditions under which variety can
either remain constant for a long period of time, or increase over time, or eventually collapse
to just one variety as in the models of Aghion and Howitt and Grossman and Helpman
described above. Thus, the model provides rich dynamics and a number of implications for
the future development of industrial or agricultural biotechnology.
21010.3. Policy Implications and Suggestions for Future Research
An additional interesting feature of the model, especially for future research, is that of
perfectly exploited learning opportunities over time. Thus each generation of producers
benefits from sufficiently strong learning as in the case of (delta = 1). The perfectly
intertemporal exploitation implies that there is no underinvestment in R&D and that a
government subsidy to R&D should not encourage innovators to invest more because the rate
of innovation is already at an optimal level, in the presence of such imperfections. The
assumption of perfect learning mimics the fact that private knowledge of this nature has most
likely also been an important source of technical change in modern biotechnology. In
industrialized countries, this is most evident from the pharmaceutical sector where the most
modern techniques are being used and evolving most rapidly. The presence of learning by
doing would imply that those firms which are innovators today, would continue to innovate
in the following periods, because of an accumulation of private knowledge. However, policy
conclusions may change with every imperfection or sector added to the model. Allowing for
monopoly profits in the R&D sector may lead to underinvestment in this sector. This will be
explored in future research.
Although patent data at present is insufficient to really measure the extent of such
cumulative learning and innovation, figures 10.1 and 10.2 below, show some preliminary data
for the five largest innovators among the specialized biotechnology companies. Despite a
considerable amount of fluctuation, especially for patent applications (figure 10.1), the trend
appears to be non-decreasing. Tables 10.1 and 10.2 in the text below give a numerical idea
of this increasing trend. The figures on total patents granted to this group of biotechnology
innovators is even more clear, as table 10.2 and figure 10.2 show. Thus, although incomplete,
the figures and graphs below, give a rough confirmation of the important role played by
learning for successive innovations.
Table 10.1. Patent Applications by NBTFs














































































































































Source: Compiled from European Patent Statistics (EPO, Munich, 1993)
A calculation of growth rates of patenting activities by these firms was also somewhat
enlightening with regard to learning. The equation estimated was of the log linear form:
Inn = (5-l)lnn + lnN** where N*" is constant Thus if delta is 1 there is perfect learning,
the first term on the RHS should be zero, implying a constant slope equal to zero. If delta
less than 1, i.e., there is weak learning, this slope should be declining, since the first term on
the RHS is negative.
The results (tables 10.3 and 10.4 below) show that for all the companies, the slope for
patents granted is negative, whereas for patent applications is positive, implying weak learning
from the former set of statistics, and strong learning from the latter set.
The second set of statistics, that is, patent applications, may in fact be a better measure
of learning, since they imply private knowledge gained from previous innovations, which is
being used to generate the next set of innovations which are deemed patentable. The second
reason is that of the lag associated with screening and granting of patents. The knowledge
gained by the innovation when it is applied for may therefore be more useful for the
company's future research activities, rather than when the patent is granted or rejected two
years later. The low R squares obtained from the data on patents granted also indicates that
these may not be good at explaining growth rates. This is also evident from the graphs
presented in ^g«rej 70.6 to 70.70, characterised by strong fluctuations in contrast to the
figures on applications, which with the exception of Amgen (/igMre 70.5), show generally
steady trends. Given the restrictive nature of the data set, it may be useful not only to obtain
a longer time series but also to include employment statistics in the regressions. This may add
to the explanatory value of the equations, since the value of TV*' has been assumed to be
constant thus far. In the case of patents granted, including employment statistics may not only
raise the R squared, but also may change the constants, which are negative, another indication
of the weakness of the data on patents granted.






























































The relationship between Inn and Inn is also summarized in/igMrey 70.7 to 70.5 for patent
applications (relating to the figures in tables 10.1 and 10.3 above), and in/jgwrej 70.6 to 70.70
for patents granted (relating to tables 10.2 and 10.4 above).
The figures show that especially in the case of applications for patents, (/j^wrej 70.7
to 70.5 above), the trend toward stability is much higher than in the case of patents granted.
In the case of patents granted, the relationship between Inn and Inn shows a more mixed
record. Here the fluctuations are quite large, showing periods of no change followed by
periods of rapid decline or rapid increases. As mentioned above, with respect to the
regressions, these figures are probably less reliable than those on patent applications. This
may also be due to the relatively small number of data points, presenting large fluctuations
in the graphs.
Thus, as mentioned earlier, it would be instructive to obtain a larger time series, along
with data on employment, in order to obtain anything conclusive about patterns of innovation










Figure 10.1. Applications: Genentech
(1981-1991)
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Figure 10.2. Applications: Chiron
(1981-1991)
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In developing countries similarly, many of the simpler techniques which are being
used for agriculture, are based on green revolution technologies from the 1970s. Many of
these products and techniques were developed in institutions in developing countries, such as
the National Agricultural Research Centres which were established during this period in many
countries.
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Figure 10.4. Applications: Celltech
(1981-1991)
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Today's biotechnologies are being developed largely through the use of knowledge gained
during the period of the green revolution, as is evident from dependence upon the R&D
infrastructure developed during this period, as well as the relationship between the simpler
technologies in use in many developing countries today and their precursors from the green
revolution.
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Figure 10.6. Patents Granted: Genentech
(1983-1991)
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Thus, learning has also contributed to the development of some of the breeding
techniques present today in many developing countries and providing R&D subsidies to firms
would encourage them to invest in these activities and to increase the rate of innovation.
Whether or not this is optimal depends of course, on the precise way of modelling.
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Knowledge accumulation therefore is an area that the government can play a major role
in to encourage rates of innovation and economic growth. This is a conclusion reached also
from Chapters 3 and 4 where biotechnology policies in industrialized and developing countries
were examined, at least with respect to efficient public institutions. The survey, although
brief, on developing countries in chapter 3 above, has identified a number of constraints and
also a number of examples of success.
217Figure 10.9. Patents Granted: Celttech
(1983-1991)
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Needless to say, the situation is different from country to country, and depends greatly on
economic environments and institutional structures. Nevertheless, a number of broad
requirements can be identified based on some of these observations. Firstly, the need for a
strong science base is fairly obvious due to the scientific nature of biotechnology. A trained
group of skilled scientists and researchers to contribute to the basic as well as applied research
218sectors also appears to be a basic requirement. Although this was not addressed explicitly in
the model, technology gaps between north and south could have been attributed to differences
in human capital skills between the two regions as this affects only absolute advantages. The
results, in terms of specialization would then have been the same.
Many developing countries have recognized both these as being severe constraints to
the development of biotechnology, and a large percentage of public resources have been
devoted to these tasks. In other words, capability building is a major goal of most national
programmes on biotechnology in developing countries. Perhaps the next step would therefore
be to try and explicitly include capability development within the model and examine the
implications for the south as well as for the north.
Similarly, in industrialized countries, the problem is not as acute as it is in developing
countries, education in science and technology, is still regarded as an important target of
government funding and for the future development of biotechnology. Basic education and
the knowledge base have played an important role in the early development of biotechnology
in a number of countries such as Britain, the USA and Germany (Sharp, 1985). Britain in
fact, may now be at a disadvantage with respect to the other countries as government funding
for scientific training and research has fallen sharply during the last two decades.
Having identified the characteristics of biotechnology and its impact on quality and
variety and therefore on consumer welfare, the next question to examine is that of any policy
recommendations that can be made to address some of the distortions caused by market
failures.
With respect to trade, the result of complete specialization implies that the north
devotes all its resources to R&D research and the south similarly, to the production of
differentiated products. Thus neither country can move its resources into another sector
efficiently. Indeed there would be a more efficient solution if resources could be moved
between countries, as was the result in the integrated equilibrium. However, since migration
is not allowed, this is not possible, and the allocation of labour in both sectors cannot be
changed without labour migration. A movement from the specialization in equilibrium B to
D where there is higher welfare because of labour movement, would increase international
efficiency. In the specialization equilibrium however because resources are fully employed
in each sector, any form of intervention by the government, except for allowing for migration,
cannot therefore change the allocation of resources. Thus specialization appears to be an
exaggeration. A much better explanation of wage differences across countries is from the
ratio #,/#s.
The economic models of chapters 8 and 9 formalised some of the structural
characteristics of innovation and technological change in biotechnology. However, as with
other models of its type, this model is also characterised by market distortions due to the
presence of externalities and monopolistic features. The result of these distortions is usually
that the optimal rate of innovation, economic growth and welfare is not the same as that
provided in the market equilibrium. Policy measures are therefore recommended to try and
offset these market failures and to try and internalise externalities. In this section, we look
at any policy conclusions that can be drawn from the implications of the model for economic
growth and trade.
With respect to the closed economy model, the presence of two distortions in the
model may contribute to non-optimality and therefore could merit policy interventions. The
219differentiated sector, as modelled above, is characterised by imperfect competition with
monopoly profits providing the incentive to producers. Similarly, in the R&D sector, the
presence of externalities which accrue to consumers from increasing variety are not reflected
in pricing. Thus, governments which wish to encourage innovation, may be inclined to
subsidize research, inducing greater investment in R&D. However, Judd (1985) and Grossman
and Helpman (1991a, Ch.8) have shown that the symmetric nature of the CES utility function
ensures that the rate of innovation in this case, is optimal, regardless of the presence of
monopolistic structures. Grossman and Helpman (1991a Ch.8) show that this is because the
opposing distortions caused by monopoly in production and externalities from innovation, are
equal to each other and therefore cancel each other out. Thus in this case, the ideal policy
would be no policy intervention.
The use of a non-CES utility function however, as Judd (1985) has shown, can indeed
lead to under or over production of innovations, and perhaps may be useful for further
research on models which examine the impact on variety of increasing quality innovations.
Finally, while the new growth and trade models with differentiated goods, tend to
break down innovation and production into different sectors, there is no public investment, a
notable and influential factor we see in the development of biotechnology. The literature
treating public investment, notably Shell (1967), Barro (1990), Sorenson (1993), Ziesemer
(1990 and 93) '", doesn't extend to differentiated goods. A possible area of further research
may therefore be to extend the analysis in the models described in Chapters 8 and 9 above,
to public investment and imperfect capital markets. This may also result in more conclusive
policy implications than can be inferred from this model.
10.4. Conclusions and Linkages to Future Research
The research in this thesis has focused on identifying the basic structure and interactions in
biotechnology based industries in developing and industrialized countries, and the manner in
which innovation occurs in both.
Although a relatively young technology modern biotechnology has made rapid strides
in the last two decades. The thesis has attempted to identify the major players and to measure
rates of technological change which can be attributed to biotechnological innovations. The
underlying economic and institutional structure has also played an important role in
encouraging or discouraging biotechnology research in various countries. The survey in
Chapters 3 and 4 found that although patterns of technological change and areas of
specialisation have varied quite greatly between countries, there are a number of basic
similarities in terms of financial and institutional requirements and linkages. The model which
followed in Chapters 8 and 9 was based on these non-financial and private linkages and
demonstrated a number of important relationships between the accumulation of knowledge
through learning and innovation and of consumer choice and impacts on changing quality and
variety.
An interesting conclusion which has important implications for the changing role of
developing countries in international trade, is that product selection in this model may have
"' See Ziesemer (1993) for a survey of public factors in endogenous growth models.
220an impact on their share of international trade. Empirical evidence from recent trade related
impacts of new biotechnology on traditional products shows that developing country exports,
especially of traditional products such as sugar and cocoa are being increasingly eroded by
the development of biotechnology based substitutes. In so far as these traditional products are
agricultural, as is the case with a large number of products exported by developing countries,
this also has an impact on land value. If the case is that older varieties are rejected by
consumers, this will imply a lower share of developing country products in international trade,
and also a lower value of land as the price of those products fall. In the case of a reselection
of older varieties, the value of land will increase as will the share of developing country
exports in international trade. The introduction of land into the model as well as a more in
depth analysis of trade related impacts of biotechnology, especially on developing countries,
would perhaps yield interesting results as to the interplay between these variables.
The policy recommendations which arose from empirical observations relate largely
to financing and encouraging investment in public knowledge accumulation. When allowing
for profit, they may turn out to be also relevant in the private sector as viewed from the
perspective of the model. The need for this is perhaps most evident in developing countries
where the research base which was so crucial to the development of modern biotechnology
in industrialized countries, is often missing altogether or deficient. The need for a strong
research base to support downstream product development is also evident. For example,
without the important innovations of the 1970s and 1980s, it is unlikely that modem
biotechnology would have developed as rapidly. Linkages between generic or basic research
which is often publicly funded and carried out at public facilities, and applied research which
is most often dominated by the private sector and strongly biased toward product development
and commercialization, are also crucial. All these are basic requirements of perhaps any
modern technology, and more so for biotechnology which is strongly science based and
therefore dependant upon a strong research sector.
Rapid changes in the nature of the technology and also of the structure within which
it operates, make the need for in-depth examinations of these changes imperative if one is to
understand the nature of innovation in biotechnology. A related area of research which is
exciting is that of the changing market structure in industrial biotechnology. The importance
of strategic alliances and the rise and fall of the small biotechnology firm are hotly debated
topics in the industry today. It is not as yet clear whether there is an increase in one or the
other, nor if one is more important at different stages than the other. The model allows for
constant or decreasing firm size. Moreover, when variety (in)decreases, the number of firms
(in)decreases as well. The market share of the top firms then (de)increases.
Many small companies are also involved in strategic alliances (see the work done by
Hagedoora here), whereas others prefer to merge with larger companies. This area of research
was briefly alluded to in Chapters 3 and 4 above, when discussing the development of
biotechnology in industrialized countries. However, it was difficult to go into further detail
given data constraints. A future area of research, especially as the data become available,
could therefore be an examination of innovation under different market structures and
especially the resurgence of the small firm after a period of emphasis on the large company.
A second area of research which may lead to some insights on capability building,
especially in developing countries, would be to study the phenomena of science parks and
regions of scientific capability, perhaps an emulation of Silicon Valley in California during
the development of microelectronics. The regions offer scientific expertise and a number of
221examples exist, especially in industrializing countries (such as Korea where a large science
park has just been completed in Taejon, and India, where Bangalore has become a scientific
centre in recent years), where the capabilities exist, which are flourishing because of their
relatively lower labour costs and scientific expertise. The phenomena would be interesting
to study because of its possible parallels with the development of similar areas of
technological and scientific capability in other parts of the world. It would also have
interesting implications for capability building and learning, especially the role of the latter
in developing technological and scientific capability.Appendices
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227Appendix II Calculating the initial value of z:
The Case of No Capital Markets
In order to carry out the simulations for the growth rates of n and z ~, the initial value ofz"
had to be calculated, given the initial value of n. We look here only at the no capital market
case, for which simulations were carried out.









In the case of no capital markets, income equals expenditure in each period. From equation
(8.24) and from the zero profit condition in the differentiated sector (8.25) for /^ and ^ into
the budget constraint to obtain
* •
(A2.3)
as in equation (8.84).
Substituting for £^ from equation (A2.2) into equation (A2.3) we write
E-JLV
i -e J "-
(A2.4)
which can be rewritten
228£ = —Lfe (/ue""»)*=r fz^/"^\fc (A2.5)




From which the two extremes of the integral can be defined accordingly:
"(0) =
(A2.7)
From (A2.6) we can write
ae J A L ae
and
Inserting (A2.8) into equation (A2.4) yields
£ = _!_& (n «""»W f F? ,T?^ «e K (A2.9)
i _e %\«» / j [ ae J ^ i -e j
fl-6^ Taking the constant term before the integral equation (A2.9) can be rewritten as:
229We define p as any integer value. Inserting p = into equation (A2.10) we write
1 -6
The initial value for z~ was then calculated from equation (A2.ll) using the
mathematical computer programme, A/af/zemaftca. This was calculated in three steps. Fist,
the integral was calculated using the rule of partial integration. Mathematica's calculations
yield a series as the solution to the partial integration. The second step was to express this
series in terms of the two extremes of the integral, where according to equation (A2.7) above,
the values of n^ and z" were reconverted into n^ and z" respectively. The final step was
to calculate the term before the integral and multiply it to the expanded series. The value of fc^_
was calculated in terms of values for p and w * depending upon the two cases of Shellian
learning or of Phelpsian learning; alpha was initially varied between 0.1 and 0.5, but later
only 0.1 and 0.2 were used, as the use of higher values of alpha tends to make the simulations
go out of bounds; the initial values of n used were 2, 4, and 8; and finally, p was varied
between 5 and 19 (implying values of theta between 0.83 and 0.94). The initial value of £
was normalized to be equal to one.
Given all the values in this manner, mathematica then solves for the only missing
value, z".
t )
230Appendix III Simulations from No Capital
Market Case
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233Figure A3.6. No Learning (delta = 0)
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Figure A3.9. Learning (delta = 1)
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Figure A3.10. Learning (delta = 1)
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Figure A3.18. Learning (delta = 1)
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Figure A3.28. Learning (delta = 1)
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Figure A3.33. Learning (delta = 1)
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266Samenvatting (Summary in Dutch)
Dit proefschrift gaat over de invloed van innovatie in de biotechnologie op economische groei
in industrie- en ontwikkelingslanden, en de gevolgen daarvan voor de handels- en technolo-
giekloof tussen deze twee groepen landen.
In hoofdstuk 1 en 2 worden de huidige ontwikkelingspatronen van nieuwe biotechno-
logie besproken; in hoofdstuk 3 en 4 wordt dieper ingegaan op de veranderingen in de
biotechnologie in respecnevelijk industrie- en ontwikkelingslanden. Bij de behandeling van
biotechnologische innovatie in industrielanden in hoofdstuk 3 wordt een empirische analyse
uitgevoerd die is gebaseerd op patenten voor biotechnologische uitvindingen die zijn
geregistreerd bij het Europese Octrooi Bureau en het Octrooibureau van de Verenigde Staten.
Er is sprake van een toename in het aantal biotechnologische patenten van ongeveer 10% per
jaar, wat tamelijk hoog is voor vindingen in nieuwe technologieen. Het gebrek aan grote
aantallen gepatenteerde vindingen door ontwikkelingslanden in deze technologie vraagt echter
om een andere methode om biotechnologische innovatie in deze landen te bestuderen. De
empirische analyse in hoofdstuk 4 gaat dan ook uit van proeftoepassingen in India waarmee
de toekomstige invloed van biotechnologie op de landbouwproductiviteit kan worden bepaald.
Dit proefschrift houdt zich vooraamelijk bezig met de invloed van verbeteringen in
kwaliteit danlczij biotechnologie op het totale aanbod aan (oude en nieuwe) produkten die con-
sumenten kunnen verkrijgen en kiezen. In hoofdstuk 5 worden dergelijke kwaliteitsverbeterin-
gen bestudeerd, met name in de landbouw en farmaceutica. De resultaten hiervan zijn dat, in
tegenstelling tot de nieuwe groei- en handelstheorieen die in hoofdstuk 6 en 7 aan de orde ko-
men, hoogwaardige produkten die dankzij biotechnologie tot stand zijn gekomen een verschil-
lende invloed hebben op het produktaanbod in de economie. In een aantal gevallen leiden
verbeteringen in kwaliteit ertoe dat consumenten uitsluitend de hoogste kwaliteit willen,
terwijl in andere gevallen de consumenten de voorkeur geven aan diversiteit boven kwaliteit.
In hoofdstuk 8 worden deze observaties in een nieuw model gepresenteerd. In het
gesloten economie-model wordt gebruik gemaakt van observaties over kwaliteit en diversiteit
vanuit de biotechnologie; de consumentenpreferentiefunctie die daarin wordt gebruikt lijkt op
de 'love of variety' functie zoals die in de nieuwe groeimodellen wordt gebruikt, behalve dat
de specificatie een kwaliteitsweging inhoudt die consumenten in staat stelt te kiezen tussen
kwaliteit en diversiteit. In de nieuwe groei- en handelstheorieen zijn tot nu toe drie soorten
resultaten naar voren gekomen: (i) de 'love of variety' nutsfunctie leidt tot een steeds
groeiend produktaanbod omdat nieuwe produkten oude produkten nooit overbodig maken; (ii)
de voorkeuren voor het ideale aanbod leiden tot nieuwe produkten die een oud produkt altijd
overbodig maken; en (iii) een aantal van de nieuwere modellen duiden op resultaten die
tussen deze twee extremen in liggen, dat wil zeggen het produktaanbod in de economie blijft
constant of wordt groter terwijl elke nieuwe innovatie ertoe leidt dat een of meer oudere
produkten worden vervangen, afhankelijk van de modelspecificaties. Uit formele analyse en
simulaties met het model dat in hoofdstuk 8 wordt beschreven, blijkt echter dat deze drie
typen resultaten speciale gevallen zijn. Het model dat in dit proefschrift wordt gepresenteerd
is dus een veel breder model dat veel van de observaties omvat zoals we die in de
biotechnologie tegenkomen, omdat deze betrekking hebben op de relatie tussen innovatie en
consumentenvoorkeuren en tegelijkertijd kunnen worden uitgebreid naar een aantal andere,
267meer algemene, technologieen.
Hoofdstuk 9 is een uitbreiding van hoofdstuk 8 in een open economie-situatie. Hierbij
wordt uitgegaan van twee economieen, noord en zuid. De noord-economie heeft een voor-
sprong in R&D omdat verondersteld wordt dat het technologisch verder gevorderd is. De
resultaten van de open economie tonen aan dat een toename van innovaties het aanbod aan
nieuwe patenten die naar het zuiden worden overgedragen vergroot maar dat daardoor de
handelstermen in het noorden verslechteren. Het laatste leidt bovendien tot lagere vaste
produktiekosten voor producenten in het zuiden. De algemene conclusie is dat, in het geval
van leereffecten en lage tijdsvoorkeur, het aanbod groter zal worden; indien de tijdsvoorkeur
hoger is dan het groeitempo, kan het aanbod tijdelijk groter worden, kleiner worden of gelijk
blijven.
Een andere belangrijke conclusie heeft betrekking op het aandeel in de export van ont-
wikkelingslanden in de internationale handel. Hoewel uit het model blijkt dat
ontwikkelingslanden de enige producenten zijn van gedifferentieerde produkten en dus
nieuwere soorten produkten maken die vanuit het noorden worden gepatenteerd, is het gevolg
dat het totale produktaanbod in alle gevallen kleiner wordt. Omdat nieuwere soorten
produkten de oudere verdringen, zullen producenten van nieuwere soorten produkten ook
steeds vaker de plaats innemen van producenten van oudere of traditionele produkten.
Hiermee wordt in grote mate de observatie ondersteund die vooral in hoofdstuk 5 aan de orde
was: R&D uitgevoerd door biotechnologische bedrijven in industrielanden, zal door de
introductie van nieuwere produkten oudere produkten en met name van producenten van de
oudere produkten verdringen. In hoofdstuk 10 worden tenslotte beleidsconclusies en
implicaties voor verder onderzoek gepresenteerd.
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growth is studied by using the example of modern biotechnology which is
making radical changes in methods of production across a wide range of sec-
tors. R&D activities and policy efforts that have been undertaken in indus-
trialized and developing countries are discussed. The measures of innovation
used, included patent statistics from the European Patent Office and the US
Patent Office and because in most developing countries patents for this tech-
nology are not recognized, statistics from agricultural field trials in India
were used instead. Observable trends in technological change in these coun-
tries show that in biotechnology, the production of high quality products
does not appear to replace older products immediately. Instead, variety
tends in some cases to increase in the short run, although as genetically engi-
neered products become more widely available to consumers, it is likely that
variety will decrease in the long run.
A growth and trade model is developed based on these observations about
quality and variety. The model builds on recent new growth and trade mod-
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new growth models present separate cases of variety increasing infinitely,
decreasing instantly to one, or remaining constant, in the model developed
here, all three are presented as special cases. Thus the model presented here,
is in fact, much broader and can be extended to a number of different tech-
nologies and sectors. Finally, policy implications and issues for further re-
search are examined.
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